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Introduction: Biomarkers of tuberculosis (TB) diagnosis and treatment response in patients co-infected 
with human immunodeficiency virus (HIV) are a necessity to ensure early diagnosis and adequate 
monitoring of TB treatment response. We conducted 3 sub-studies: study 1 was a bioavailability study; 
study 2 was a PK study in HIV-TB co-infected persons, and study 3 evaluated a WHO-recommended 
treatment algorithm in TB-HIV co-infected persons. Study 1 and 2 contributed to the study of 2 (NAT2) 
polymorphisms. Study 1 was leveraged to evaluate Quantiferon Gold in tube (QFT-GIT) and a quality of 
life instrument as a longitudinal biomarker in smear and culture positive TB-HIV co-infected patients. 
Study 3 was leveraged to study urine lipoarabinomannan (LAM) as a diagnostic adjunct in  smear-negative 
HIV-infected patients treated for TB. 
Methods: Blood was collected from participants with HIV-infection only and TB-HIV co-infection for 
NAT2 polymorphisms at baseline, and for QFT-GIT at baseline, month 3, 6 and 12; a health-related 
quality-of-life (HRQOL) instrument was applied at the same timepoints to monitor treatment response in  
Study 1. An additional 40 TB-HIV co-infected participants (Study 2) were included in the analysis for the 
assessment of NAT2 polymorphisms and its effect on isoniazid plasma levels and hepatotoxicity.   Urine 
was collected from seriously ill HIV-infected patients with confirmed smear-negative presumptive-TB 
(Study 3) prior to anti-TB treatment and tested using a commercially available LAM-ELISA. Blood and 
sputum were collected and processed for TB culture.  
Results: One hundred and twenty participants (100 TB-HIV co-infected and 20 non-TB but HIV-infected) 
from Study 1 and Study 2 with genotype results and were evaluated. Percentage of metabolisers in each 
category were: slow 52.5% (63/120),  (NAT2*5/*5); intermediate 35.8% (43/120), (NAT2*4/*5 and 
NAT2*5/12); and rapid 11.7% (14/120), (NAT2*4/*11, NAT2*11/12 and NAT2*12/12). In general, 
isoniazid area under the concentration curve (AUC)0-∞ and maximum concentration (Cmax) were lower 
amongst the study 1 compared to study 2 participants. INH and AcINH PK parameters across genotypes 
were not statistically significantly different within each study. The log AcINH: log INH ratio, calculated 
as a measure of acetylation at two and four hours post-dose, showed no statistically significant difference 
between genotypes.  
Baseline, month-3, and month-6 interferon gamma (IFN-γ) responses, irrespective of antiretroviral 
therapy, did not differ between TB patients who culture-converted and those who did not (1.25 vs. 1.05 
IU/ml, p=0.5; 3.76 vs. 1.15 IU/ml, p=0.2; 0.06 vs. 0.7, p=0.3 respectively). IFN-γ levels did not correlate 
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with markers of sputum bacillary load (p=0.50 and 0.30 for smear status and liquid culture time-to-
positivity, respectively).  
Baseline HRQOL scores were analysed in 76 participants. Those with CD4 count <200 had lower HRQOL 
when compared to those with CD4 count >200 [99.65 (29.68) versus 124.46 (29.02); p<0.001]. There was 
a significant improvement in total score between baseline, month 3, 6 and 12 (all p-values<0.0001) for all 
groups. There was a significant increase in the total score over time (Slope: 3.45 (2.77,   4.1) p-value 
<0.001).  
 Data from 156 patients (Study 3) with complete data were analysed for LAM. Mean age was 37 years, 
and median CD4-count was 75 cells/mm3 (IQR [34–169]). 54/156 (34.6%) were sputum culture-positive, 
12/54 (22%) blood-culture positive, and 53/156 (34.0%) LAM-positive. Thus, LAM sensitivity was 55.6% 
(30/54). The study design did not allow for calculation of specificity. Urine-LAM positivity was 
associated with low CD4 count (p=0.002). Ninety percent (48/53) of LAM-positive patients received 
antibiotics [15/48 (31.2%), 23/48 (47.9%) and 10/48 (20.8%) received one, two or three different 
antibiotics respectively], while the duration of antibiotic therapy was more than 5 days in 26 of 46 (56.9%) 
patients. 
Conclusion: 1) Although there was a high prevalence of slow acetylation compared to results of other 
studies in South Africa, this did not translate to significantly higher rate of hepatic adverse events in this 
group. There was no direct concordance between genotype and phenotype. NAT2 genotyping is therefore 
not a useful tool in individualised treatment allocation among this group. More work is needed to 
investigate NAT2 as a biomarker for hepatotoxicity in patients receiving isoniazid, and to explore 
polymorphisms and other factors better describing acetylator phenotype in this population. 
2) QFT-GIT is not a useful biomarker for monitoring TB treatment as reversion does not always occur 
during and at the end of TB treatment.  
3) HRQOL is a useful instrument for evaluating TB-HIV treatment response. Further studies are needed 
with more frequent evaluations and using more specific HRQOL instruments.  
4)) Urine LAM is a useful biomarker for diagnosis of smear-negative TB in patients with low CD4 
counts. Early diagnosis with urine LAM could potentially reduce excessive use of antimycobacterial 




Diagnostic and therapeutic biomarker responses in HIV and 
tuberculosis co-infected patients. 
Chapter 1 
1. Introduction 
Tuberculosis (TB) remains a leading cause of global morbidity and mortality, with approximately 10 
million cases and 1.5 million deaths in 2018 (1). South Africa is a high TB burden country with an 
estimated 301,000 cases in 2018,  and is counted among the eight countries accounting for two thirds of 
the global total of tuberculosis (TB) (1). In addition, South Africa is one of the fourteen countries with 
overlap in high burden of drug susceptible TB, Multi-drug resistant (MDR) TB, and TB/ human 
immunodeficiency virus (HIV). There is country commitment to work towards ending TB by 2035 (2), 
however this combination makes it difficult to achieve the targets to end TB by 2035 (3). KwaZulu Natal 
is one of the provinces in South Africa with the highest TB prevalence, including drug resistant TB (4). 
 
To achieve the targets to end TB, early diagnosis of TB and proper monitoring of treatment to ensure cure 
are necessary. Diagnosis of TB in HIV-infected patients and monitoring of treatment is difficult. 
Researchers have found that HIV-infected individuals tend to have smear-negative TB, depending on the 
level of immunosuppression (5). Chest X-rays are not conclusive for diagnosis of TB, more so in HIV-
infected patients, as chest X-rays are atypical. Biomarkers of TB-HIV diagnosis and treatment monitoring 
are needed to ensure early diagnosis and treatment, as well as adequate monitoring of treatment responses. 
 
Besides early diagnosis and treatment, monitoring of patients on combined TB and HIV therapy is one of 
the most important aspects of management of these two co-morbidities. TB treatment on its own presents 
with multiple problems, as the drugs used for its cure have multiple side effects affecting different organs 
(6). In addition, HIV therapy has overlapping side effects with TB treatment (7), and a combination of 
these therapies require strict monitoring to ensure patient safety. Some patients default treatment because 
they cannot handle the side effects they experience with the treatment (8-10), whilst some patients find 
the treatment completely tolerable, without experiencing any side effects (11). In sputum smear-negative 
individuals with HIV infection, TB is even more difficult to diagnose. This has often led to giving these 
patients antimicrobial antibiotics while waiting for sputum culture results. This, in spite of the WHO 
recommended algorithm to reduce mortality in seriously-ill patients with HIV infection and smear-
negative pulmonary TB, recommending the start of anti-TB treatment (ATT) within three days of 
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admission (12). When patients are given these treatment regimens there should be proper monitoring of 
treatment response and side effects. There are different biomarkers and tools of monitoring TB treatment 
responses and evaluating the side effects of TB and HIV treatment or predicting which patients are more 
likely to experience these side effects. These may include genetic tests, quality of life tools, other tests on 
different body fluids and self-reporting by patients.  
 
In this Chapter the following points will be addressed, 1.1 Thesis rationale, 1.2 Problem statement, 1.3 
Research question, 1.4 Aims and objectives, 1.5 Studies and methods reported in this thesis, 1.6 Definition 
of terms and 1.7 Justification and outline of the thesis. 
 
1.1 Thesis rationale 
TB is one of the commonest opportunistic infections in people living with HIV, and is known to be the 
leading cause of morbidity and mortality (13, 14). In South Africa, more than 70% of patients with TB 
are also HIV-infected (15), and about 50% of them receive antiretroviral therapy (ART) (1). Guidelines 
for TB and HIV treatment have been changed to allow all HIV-infected TB patients to be started on ART 
irrespective of their CD4 count, in line with the latest World Health Organization (WHO) and country 
guidelines. These guidelines require all TB patients to receive ART with their TB treatment, as ART 
reduces opportunistic infections as well as morbidity and mortality (16, 17). TB programmes in South 
Africa and elsewhere use defined clinical outcomes such as cure (smear-negative at treatment completion 
and on at least one previous occasion), plus treatment completion without confirmation by smear-
microscopy, loss to follow up, treatment relapse and chest radiography to assess TB treatment effect.  
 
Diagnosis of TB and monitoring of TB treatment response using sputum smear and culture may be ideal 
but poses many problems as HIV-infected patients are frequently smear-negative (18), or may fail to 
produce sputum (19), and these tests themselves are suboptimal predictors of outcome (20). Gene Xpert 
MTB/RIF, while useful for diagnosis of TB, is not as beneficial in patients previously treated for TB as it 
detects both live and dead bacilli (21, 22). Urine lipoarabinomannan (LAM) has also been investigated as 
a biomarker for the diagnosis of TB and has been found to work best in HIV-infected patients with severe 
immunosuppression (23, 24). We chose to investigate the usefulness of urine LAM and its benefits in 




Failure to respond to treatment has serious consequences, such as infectiousness and increased morbidity 
and mortality (25). Genetic factors have a role to play in how individuals respond to treatment (26). Much 
has been done to assess the extent to which genetics and environmental factors affect patients’ response 
to treatment. Genomic variation or single nucleotide polymorphisms (SNPs) are responsible for diversity 
in human subjects (27). Isoniazid (INH) is one of the backbones of the combination regimen for treatment 
of TB. The bacterial activity of INH has been studied extensively (28-32), and is highly efficient, 
especially during the first few days of TB treatment. The rate of acetylation of INH by NAT2, an important 
enzyme responsible for the metabolism of certain antibiotics, (28, 33-37) and inter-individual variation in 
plasma concentration has been studied extensively over the years. NAT2 is one of the three NAT genes 
involved in drug metabolism and the most important for INH metabolism; the other two are NAT1 and 
NAT pseudogene (NATP) (38). As reported by Parkin et al., there is a trimodal distribution of metabolic 
phenotype for isoniazid reported in different populations consisting of rapid, intermediate and slow 
acetylator status (39).  
 
The consequences of pharmacogenetic variation in acetylation enzymes include (i) altered drug levels of 
INH; (ii) altered drug interactions due to changes in the concentration of the perpetrator drug (and NAT 
substrate); and (iii) adverse drug reactions (40). The speed of acetylation largely determines which 
individuals develop serious adverse effects of drugs (slow acetylators) or poor response to treatment (rapid 
acetylators). Of note are the INH induced hepatotoxicity and peripheral neuropathy experienced by slow 
acetylators that have been reported (41-51). Drug-induced hepatotoxicity is one of the main adverse events 
that has been reported to be a result of the individual’s acetylator status (41, 52-55). The clinical 
significance of these variations leads to the prediction of exposure, with certain individuals being more 
prone to adverse events or certain diseases. The functional importance of NAT2 genotype has been well-
investigated in Caucasian and Asian populations (27, 41, 56-62), while information on black South 
Africans is scanty (63-66). We therefore decided to investigate the effects of NAT2 on the metabolism of 
INH in the Black, Zulu-speaking population. 
 
Use of TB treatment monitoring tools that give results in a short time, allowing access of results within 
the same day, and that are more specific, is ideal. More recently interferon-gamma release assays (IGRAs) 
have become available and have been investigated for use as diagnostics and biomarkers of TB treatment 
response and prognosis (67-87). Reports that IGRAs may be useful in monitoring TB treatment response 
have been mentioned in some studies (84, 88). While in other studies, most patients remain IGRA-positive 
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after completion of ATT, despite sputum smear and culture conversion (73). These studies have examined 
the utility of measuring longitudinal interferon-gamma (IFN-γ) responses during TB treatment. They have 
mostly been conducted in pre-dominantly HIV-uninfected individuals (73, 82, 89-91) and mainly in 
countries with low TB and HIV burdens (72, 92-94). Only a few studies have used the commercially 
available standardised QuantiFERON®-TB Gold in Tube (QFT-GIT) assay in settings with high burden 
of TB and HIV (85, 95). However, to our knowledge, no study has hitherto reported effects of ART and 
or ATT on quantitative IFN-ᵧ responses in TB-HIV co-infected patients. There are also hardly any data 
about the effect of ART alone on such responses. A further limitation of these studies is that several 
published studies, even from Africa, have used non-standardised in-house IGRAs in an enzyme-linked 
immunosorbent assay format (77, 96). Although there have been reports that IGRAs may correlate with 
TB bacterial load in low burden settings (97, 98), this was not the case in the only published report in 
patients from a high burden setting (85). Therefore, there was a need for more data from high burden 
settings, such as South Africa, where TB prevalence was estimated to be between 0.4 million and 0.6 
million cases in 2012 (13).  
 
These monitoring tools may satisfy the biomedical model but not the biopsychosocial model of TB 
treatment. A comprehensive assessment of the health status of patients is essential, including routine 
clinical, radiological, bacteriological and psychosocial assessments, in considering the impact TB has on 
health and patients’ perception of their wellbeing (99). The possibility of side effects when receiving TB 
treatment (100, 101), may be worsened by concomitant HIV treatment, thereby further affecting patients’ 
quality of life (QOL). Health-related quality of life (HRQOL) in patients receiving treatment for TB or 
those receiving treatment for HIV have been investigated in different studies (102-108). However, studies 
investigating the HRQOL of patients co-infected with TB and HIV and receiving concomitant therapy are 
few and far between (109-111).  
 
Decision-making by clinicians whether to alter treatment may result from reported and or observed 
adverse effects of treatment or based on the extent to which the patient’s QOL has been modified by the 
disease. HRQOL may be included, which has the potential to give a fuller picture of the patients’ state of 
health, from the beginning to beyond the end of TB treatment. According to Dhuria et al., this can be 
performed by measuring the HRQOL that has several dimensions (112). HRQOL has been defined as how 




The purpose of this thesis is to report on the studies conducted to assess biomarkers of TB diagnosis and 
responses to ATT alone, and combined ATT and ART. The aims of these sub-studies were 1) to study the 
relationship between polymorphisms in drug metabolising enzymes and drug pharmacokinetics and 
hepatotoxicity; 2) to investigate the use of an INF-γ release assay to determine the response to TB therapy 
and 3) to assess the HRQOL of TB and HIV on dual therapy. 4) to investigate the usefulness of urine 
LAM to diagnose TB in smear-negative seriously-ill patients with HIV-infection and investigated the use 
of mycobacterial antibiotics in these patients. 
 
1.2 Problem statement 
TB is one of the world’s diseases with high morbidity and mortality. In 2016, 6.3 million new cases of TB 
were reported (an increase from 6.1 million in 2015), equivalent to 61% of the estimated incidence of 10.4 
million, and 10.1 million in 2018 (1). In 2018, according to the WHO Global TB report, Africa had an 
estimated 24% of the global TB incidence, with South Africa having 3%. Among these, 64% were HIV-
infected, confirming that TB is still the most common opportunistic infections associated with HIV. 
Globally, it is estimated that the largest number of adults having both TB and HIV-infection – 
approximately 1 million persons – reside in South Africa (15). Between 1997 and 2004, TB was the 
leading cause of death among all persons (HIV-infected and HIV-uninfected persons) in South Africa 
(114), which was despite the availability of treatment for TB and later HIV therapy. A study by Osman et 
al characterised the general morbidity and mortality among adults who had successfully completed TB 
treatment during the past five years in a high incidence setting in South Africa, and found that among the 
51 patients interviewed, almost half reported persistent respiratory symptoms (115). There are many 
factors contributing to the morbidity and mortality of patients with TB and HIV (116, 117). These factors 
include side effects of treatment and known adverse events experienced during HIV infection, with 
anaemia being one of the problems experienced by TB and HIV-infected people. These may negatively 
affect the quality of life of patients taking these drug combinations.  
 
Apart from side effects, combining HIV and TB therapy may lead to interactions between these therapies. 
Drug/drug interactions between HIV and TB therapy arise through shared routes of metabolism and are 
often due to enzyme induction or inhibition (118). The hepatic cytochrome (CYP) P450 system is one 
important family of enzymes, which is involved in the metabolism of many drugs including the protease 
inhibitors (PI) and non-nucleoside reverse transcriptase inhibitors (NNRTI), which form part of most 
ARTs. The NNRTI and PI have proven clinically important drug interactions with the rifamycins, as the 
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latter are known to be potent inducers of CYP3A4 (119). There are reports that INH inhibits CYP3A4 
activity and may therefore its coadministration with  drugs that are metabolised by this isoform may result 
in significant drug interactions (120). Polymorphisms in CYP 2B6 are known to affect the bioavailability 
of efavirenz, and similarly, NAT2 also affect the bioavailability of isoniazid (121). Numerous 
polymorphisms are associated with CYP2B6; the G516T SNP is associated with loss of function leading 
to high blood concentrations of efavirenz, which may lead to adverse events of the central nervous system 
(CNS). INH has been reported to mediate the CYP2B6*6 genotype drug-drug interaction between 
efavirenz and anti-TB therapy through mechanism-based inactivation of CYP2A6 (122, 123), Betrand et 
al. found that patients carrying the CYP2B6 516TT genotype and N-acetyltransferase 2 (NAT2) slow 
acetylation phenotype had the lowest efavirenz apparent clearance (124).  
 
There is a relatively high risk of drug-induced hepatoxicity in patients on combined treatment with ARVs 
and TB drugs, several of which are known to be hepatotoxic. The rate of acetylation of isoniazid, 
influenced by polymorphisms of the NAT2 gene, is associated with the risk of hepatoxicity. (60). Slow 
acetylators having a higher risk of developing side effects like peripheral neuropathy and hepatotoxicity 
than fast acetylators (35, 125). On the other hand, fast acetylators have a higher risk of developing drug 
resistance. Genetic differences among individuals can affect ways in which the body responds to drug 
metabolism, distribution to cells and tissues and elimination from the body (126).  
 
Diagnosis of TB and monitoring of drug adverse reactions is challenging in patients taking both anti-TB 
and antiretroviral drugs. It is difficult to decide which drug caused the event, since similar metabolism 
routes are found in some TB and HIV therapies or whether it is because of the illness. Baseline assessments 
and screening tests are very important to record the status of the patient before starting treatment as this 
will assist in effective monitoring. A better understanding of the side effects of combining ATT and ART 
would assist with monitoring of patients. Incorporating HRQOL measurements as part of assessing the 
treatment response would elicit evidence on treatment outcomes providing better post-treatment 
information on patients’ wellbeing. Different levels of response to treatment may have serious 
consequences such as infectiousness, increased morbidity, and even mortality.  
 
There is a constant search for appropriate biomarkers for diagnosis and monitoring of TB and HIV 
treatment. Very few of the thousands of biomarker discovery research yields final products. Gene Xpert 
MTB/RIF and urine LAM are the two recent products of the research and both are now being used for 
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diagnosis of TB. At the time of the studies, urine LAM ELISA was one of the biomarkers newly released 
for the diagnosis of TB, while there was very limited information about QFT-GIT in active TB-HIV-
infected persons. We chose to evaluate these biomarkers in two different cohorts; one in smear-negative 
patients for LAM and the other in smear positive patients for QFT-GIT. We also realised that there was 
limited information about the NAT2 genotype in the black population of South Africa, especially among 
the Zulus where there was high prevalence of all forms of TB, including drug resistant forms. We chose 
to evaluate NAT2 in a PK study being conducted.  We added the longitudinal QOL instrument as an 
additional marker for the same cohort. 
 
1.3 Research question – study hypotheses 
How can we best diagnose TB and monitor treatment in patients taking combined TB and HIV therapy?  
The study hypotheses are: 
1) Polymorphisms in drug metabolising enzymes, specifically NAT2, may explain the variations in the 
experience of adverse events and response to treatment.  
2) QFT-GIT is useful to monitor treatment response in TB and HIV co-infected patients receiving combined 
treatment  
3) HRQOL can be a useful tool in assessing the effectiveness of combined TB and HIV therapy.  
4) Urine LAM is a useful biomarker for diagnosis of TB in smear-negative individuals and can potentially 
reduce antibiotic overuse. 
 
1.4 Thesis aim and objectives 
The aim of the thesis is to report on the use of a combination of markers for TB diagnosis and treatment 
monitoring using urine LAM, NAT2 genotype, QFT-GIT, and HRQOL in TB and HIV co-infected 
patients. 
 
Objective 1 – To assess polymorphisms of NAT2 in participants receiving combined TB-HIV therapy. 
Sub-objective 1.1- To determine genetic polymorphism frequency in the TB-HIV co-infected 
isiZulu-speaking black patients. 
Sub-objective 1.2 - To evaluate the relationship of genetic polymorphisms with drug levels and 
inter-individual variability of INH. 
Objective 2 - To determine the kinetics of mycobacterial cellular immune responses in TB-HIV patients 
on combined treatment using an INF-γ release assay. 
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Objective 3 – To evaluate HRQOL in TB-HIV co-infected patients receiving combined treatment.  
Sub-objective 3.1 - To examine changes in the HRQOL of patients receiving TB-HIV co-
treatment.  
Sub-objective 3.2 - To evaluate whether HRQOL differs in patients receiving TB treatment alone 
or together with ARV therapy. 
Sub-objective 3.3 - To compare changes in the HRQOL of co-infected patients receiving TB-HIV 
co-treatment with those receiving TB treatment alone. 
Objective 4 - To determine the utility of urine LAM in diagnosis of TB in seriously-ill HIV-infected 
patients with TB. 
Sub-objective 4.1- To determine the utility of urine LAM for the diagnosis of smear-negative TB.  





1.5 Studies reported in this thesis  
In this thesis we report findings of three studies as shown in the Flow chart below. 
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Three studies are reported in this thesis: 
Study 1 was a prospective, longitudinal sub-study to evaluate “Bioavailability of the fixed dose 
formulation Rifafour containing isoniazid, rifampicin pyrazinamide, ethambutol and the WHO 
recommended first line anti-retroviral drugs zidovudine, lamivudine, efavirenz administered to new TB 
patients at different levels of immunosuppression.” that assessed HRQOL and QFT-GIT kinetics from 
baseline to months three, six and 12 in TB-HIV co-infected patients with receiving TB treatment and HIV 
therapy, and HIV patients without TB, as well as assessment of NAT2 polymorphisms to determine 
patients’ INH acetylation profiles and effect on treatment.  
 
Study 2, “Pharmacokinetics of Rifabutin Combined with Antiretroviral Therapy in the Treatment of 
Tuberculosis Patients with HIV Infection in South Africa”, was a randomised controlled trial of two 
different rifabutin doses co-administered with lopinavir/ritonavir-based antiretroviral therapy. We used 
the data collected to investigate isoniazid pharmacokinetics and NAT2 polymorphisms were determined. 
The writer of this thesis was not involved in the design and conduct of this study, the isoniazid 
PK data are analysed and reported in this thesis. 
 
Study 3 was a sub-study conducted as part of a prospective cohort study evaluating the use of a WHO-
recommended algorithm to reduce mortality in seriously-ill HIV-infected patients with sputum smear-
negative PTB in South Africa. 
 
1.6 Definition of terms 
1.6.1 Pharmacogenetics 
Pharmacogenetics involves pharmacokinetic and pharmacodynamic studies. Pharmacokinetics describes 
drug concentration over time, allowing for estimation of clearance, to which drug metabolism contributes. 
Drug metabolizing enzymes can broadly be classified into two types, phase I (e.g. mixed-function oxidase 
system, and phase II (e.g. conjugating enzymes ) and are located primarily in the liver. NAT2 is a phase 
II enzyme, wide variation in its expression is associated with highly variable exposures to certain drugs 
such as isoniazid (127). NAT2 acetylation polymorphism results in segregation of humans into slow, 
intermediate and rapid acetylator phenotypes. INH is metabolised in the liver and gut mucosa, catalysed 





1.6.2 Interferon-gamma release assays (IGRAs) 
IGRAs are tests that can be used as surrogate markers of disease, in this case, TB. These tests are based 
on antibody recognition of Mycobacterium tuberculosis (Mtb) antigen by the body’s immune response. 
T-lymphocytes release IFN-γ when exposed to specific antigens. Specifically for TB, ESAT-6 and CFP-
10 are encoded by regions of the Mtb genome which are absent from M. bovis BCG, M. avium and most 
of the non-tuberculous mycobacteria (129). These antigens have been shown to elicit strong IFN-γ 
responses from the T-cells of persons infected with Mtb but not from the T-cells of those at low risk of 
infection or those solely BCG-vaccinated (130-132). Berthet et al. found that ESAT-6 and CFP-10 are 
both secreted and may interact with one another or have a common function in Mtb (132). For this reason, 
the IGRAs have been suggested as being useful for the monitoring of treatment. 
 
1.6.3 Health-related quality of life 
The WHO’s definition of health is, “a state of complete physical, mental and social well-being and not 
merely the absence of disease or infirmity” (133, 134). The QOL concept includes multiple factors 
affecting a person and may include physical well-being, financial, and social functioning. Physical well-
being may include mobility and ambulation, ability to do usual activities and experience of pain. Mental 
health may include cognitive function, emotional health and its limits on functioning. Social well-being 
may involve abilities to interact with friends and family, intimacy, spirituality, and aspects of the social 
and physical environment in which the person lives (135). In a clinical setting, Cleary et al. defined QOL 
as condition-specific symptoms, body discomfort, social and role functioning, the overall perception of 
health, cognitive status, and general well-being (136). HRQOL has also been defined as how well people 
are able to perform activities of daily living and their well-being (113).  
 
1.6.4 Urine LAM for TB diagnosis   
Currently, it is only through sputum microbiological culture where Mycobacterium tuberculosis is 
recovered that the diagnosis of active TB is definitively made. Diagnosis of and assessment of treatment 
response of TB in human immunodeficiency virus (HIV) infected patients is difficult and often present 
with sputum smear-negative results, (smear microscopy detects less than half of TB-HIV co-infected 
patients)(18), atypical radiographic findings and resemblance to other opportunistic pulmonary infections 
(137). Thus, the treatment of smear-negative TB patients is often delayed and clinicians may have to resort 
to other invasive procedures which lead to further delays in diagnosis and treatment. Delays in treatment 
would increase the morbidity and mortality which is already rated too high. There are few new tests that 
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have been approved for diagnosis of active TB, these include tests like Gene Xpert MTB/RIF, which has 
been used in different body fluids such as blood, sputum and urine.  Gene Xpert MTB/RIF is approved by 
WHO for use to diagnose active TB in sputum. Urine LAM has recently been approved in diagnosis of 
active TB in HIV-infected patients with severe immunosuppression (CD4 count <100 cells/mm3 (138). 
 
1.7 Justification of the study and outline 
Numerous reports indicate the difficulty in diagnosing TB in HIV-infected individuals, especially when 
they are seriously-ill as often they present with smear-negative disease (18, 139).  There is a constant need 
to test biomarkers for diagnosis and treatment monitoring of TB and HIV co-infected patients (140-143). 
When an HIV-infected patient is diagnosed with TB, and in most TB programmes, HIV-infected patients 
need to be started on ART if not already on it. In South Africa, at the time of the study, patients were 
started on ART only when their CD4 counts had decreased to below 200 cells/mm3 from 2004 (144). 
There were questions on the appropriate time to start ART in patients with TB co-infection. The Starting 
Antiretroviral Therapy at Three Points in Tuberculosis (SAPIT) trial was a pivotal with strong indications 
that patients could safely take ART with TB treatment (145, 146). In 2010, new guidelines were published, 
requiring ART to be given to TB patients when their CD4 count was below 350 cells/mm3 (147). These 
guidelines were followed by ones increasing the CD4 cut-off point requiring that all TB-HIV co-infected 
patients must be started on Highly Active Antiretroviral Therapy (HAART) irrespective of CD4 count in 
2012 (148). Although the latest guidelines require all patients with active TB should be started on ART, 
we still find some patients starting ART at very low CD4 count levels and others who stop taking ART 
for different reasons (149, 150). Accordingly, this raises issues of adverse drug events for each individual 
drug along with drug-drug interaction between TB and HIV therapy.  
 
Pharmacogenetics deals with some of the issues related to the genetic aspects of drug metabolism and the 
influence of genetic predisposition on individual drug levels. The influence of NAT2 on isoniazid 
metabolism and adverse effects is known in different populations. Knowledge of genetic polymorphisms 
of a population may be useful in determining whether the drug regimen doses are appropriate for the 
population in question. Adjustment of regimens may be possible, in line with the findings of the genetic 
results. In the population of choice for the study of NAT2, there is a high relapse rate and investigation of 
the influence of NAT2 in this population may help understand if there is a relationship. Diagnosis and 
assessment of TB therapy responses need to be improved as the present methods are sometimes not 
possible. Most often pulmonary TB patients are unable to produce sputum, especially after a few months 
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of treatment. Patients with extra-pulmonary TB may need more invasive methods of sputum collection to 
confirm their diagnosis. There is a need for tests that are non-invasive and tests that give results within a 
short space of time, possibly within the same day. IGRAs may be useful in this aspect, although they are 
not recommended in active TB in high prevalence countries. 
 
Since South Africa has one of the highest rates of TB and HIV patients, it is important to have a good and 
useful system for evaluating patients on combined therapies. The use of quality of life assessments before, 
during and after treatment may be one of the useful methods. This method is not expensive and can be 
used as an addition to existing methods (smear and culture).  
 
1.7.1 Sample size and power justification 
The sub-studies were conducted from projects with sample size calculated for those objectives.  For the 
study investigating LAM as a diagnostic, assuming a test sensitivity of 50% with at least 50% of probable 
TB  patients meeting the final TB diagnosis, a level of significance of 0.05% and to achieve a margin of 
error of 10%, we would need a sample size of 96. See table below for the estimates. 
Confidence level % Proportion % Error margin % Sample 
95 50 10 96 
95 60 10 92 
95 70 10 81 
95 80 10 61 
 
The PK study used for the NAT2, QFT-GIT and QOL evaluations: assuming a difference of 20%, 95% 
confidence interval and 80% proportion, a sample size of 15 per arm was adequate. We, however, used 
the existing samples calculated for the original studies without reducing or increasing the sample size 
because of limited funding. 
The next section, Chapter two, deals with the review of the literature, which looks at each concept in the 
hypothesis, biomarkers of TB diagnosis and monitoring, pharmacogenetics, IGRAs, quality of life and 
urine LAM. Chapter three covers the NAT2 polymorphisms , and in Chapter four the results of IGRA are 
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presented, Chapter five the results of the QOL are presented, in Chapter six covers urine LAM for 







1. WHO. Global Tuberculosis Report. 2019. 
2. Africa NGoS. South Africa's National Strategic Plan for HIV, TB and STIs 2017-2022. 2017. 
3. Organization WH. The End TB strategy. WHO. 2014. 
4. Africa SS. National TB statistics for South Africa. 2018/2019. 
5. Raviglione MC, Narain JP, Kochi A. HIV-associated tuberculosis in developing countries: 
clinical features, diagnosis, and treatment. Bulletin of the World Health Organization. 1992;70(4):515. 
6. Sharma SK. Antituberculosis drugs and hepatotoxicity. Infect Genet Evol. 2004;4(2):167-70. 
7. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective 
antiretroviral therapy. American journal of respiratory and critical care medicine. 2001;164(1):7-12. 
8. Vijay S, Kumar P, Chauhan LS, Vollepore BH, Kizhakkethil UP, Rao SG. Risk factors 
associated with default among new smear positive TB patients treated under DOTS in India. PloS one. 
2010;5(4):e10043. 
9. Muture BN, Keraka MN, Kimuu PK, Kabiru EW, Ombeka VO, Oguya F. Factors associated 
with default from treatment among tuberculosis patients in Nairobi province, Kenya: a case control 
study. BMC public health. 2011;11(1):696. 
10. Elbireer S, Guwatudde D, Mudiope P, Nabbuye‐Sekandi J, Manabe YC. Tuberculosis treatment 
default among HIV‐TB co‐infected patients in urban Uganda. Tropical Medicine & International Health. 
2011;16(8):981-7. 
11. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et al. Adverse events and 
treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 
2006;61(9):791-4. 
12. Holtz TH, Rustomjee R, Mthiyane T. Diagnosis and treatment of pulmonary tuberculosis in 
patients with HIV ? Author's reply. Lancet Infect Dis. 2012;12(4):268-9. 
13. WHO. Global tuberculosis report 2012. World Health Organization 2012. 
2012(WHO/HTM/TB/2012.6). 
14. UNAIDS. 2012 UNAIDS Report on the Global AIDS Epidemic UNAIDS corporate publications 
2012. 
15. Bekker LG, Wood R. The changing natural history of tuberculosis and HIV coinfection in an 
urban area of hyperendemicity. Clin Infect Dis. 2010;50 Suppl 3(Supplement 3):S208-14. 
16. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of 
tuberculosis in South Africa: a cohort study. Lancet. 2002;359(9323):2059-64. 
17. Kingkaew N, Sangtong B, Amnuaiphon W, Jongpaibulpatana J, Mankatittham W, Akksilp S, et 
al. HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death. Int 
J Infect Dis. 2009;13(6):722-9. 
18. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary 
tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent 
policy changes. Lancet. 2007;369(9578):2042-9. 
19. Theron G, Peter J, Meldau R, Khalfey H, Gina P, Matinyena B, et al. Accuracy and impact of 
Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using 
bronchoalveolar lavage fluid. Thorax. 2013;68(11):1043-51. 
20. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, et al. Sputum monitoring 
during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet 
Infect Dis. 2010;10(6):387-94. 
30 
 
21. Miotto P, Bigoni S, Migliori GB, Matteelli A, Cirillo DM. Early tuberculosis treatment 
monitoring by Xpert® MTB/RIF. European Respiratory Journal. 2012;39(5):1269-71. 
22. Organization WH. Xpert MTB/RIF implementation manual: technical and operational ‘how-to’; 
practical considerations. World Health Organization; 2014. Report No.: 9241506709. 
23. Peter J, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, Kraus S, et al. Diagnostic accuracy 
of a urine LAM strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J. 2012. 
24. Dheda K, Davids V, Lenders L, Roberts T, Meldau R, Ling D, et al. Clinical utility of a 
commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum 
samples. PLoS ONE. 2010;5:e9848. 
25. Donald PR, Schaaf HS. Old and new drugs for the treatment of tuberculosis in children. 
Paediatric respiratory reviews. 2007;8(2):134-41. 
26. Ramachandran G, Swaminathan S. Role of pharmacogenomics in the treatment of tuberculosis: a 
review. Pharmgenomics Pers Med. 2012;5:89-98. 
27. Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the 
arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet. 
1997;34(9):758-60. 
28. Ellard GA, Gammon PT. Acetylator phenotyping of tuberculosis patients using matrix isoniazid 
or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-
containing regimens. Br J Clin Pharmacol. 1977;4(1):5-14. 
29. Evans DA. Enzymes and Drug Sensitivity. Acetylation Polymorphisms. Proc R Soc Med. 
1964;57:508-11. 
30. Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rustomjee R, Levin J, et al. The early 
bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care 
Med. 2005;172(1):128-35. 
31. Donald PR, Sirgel FA, Botha FJ, Seifart HI, Parkin DP, Vandenplas ML, et al. The early 
bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit 
Care Med. 1997;156(3 Pt 1):895-900. 
32. Donald PR, Parkin DP, Seifart HI, Schaaf HS, van Helden PD, Werely CJ, et al. The influence of 
dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and 
pharmacodynamics of isoniazid. Eur J Clin Pharmacol. 2007;63(7):633-9. 
33. Fuselli S, Gilman RH, Chanock SJ, Bonatto SL, De Stefano G, Evans CA, et al. Analysis of 
nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations 
and high intra-population diversity. Pharmacogenomics J. 2007;7(2):144-52. 
34. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, et al. 
Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents 
Chemother. 2005;49(5):1733-8. 
35. Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its 
significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther. 1976;19(5 Pt 2):610-25. 
36. Eidus L, Hodgkin MM. Screening of isoniazid inactivators. Antimicrob Agents Chemother. 
1973;3(1):130-3. 
37. Evans DA, Manley KA, Mc KV. Genetic control of isoniazid metabolism in man. Br Med J. 
1960;2(5197):485-91. 
38. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic 
N-acetyltransferase. Proc Natl Acad Sci U S A. 1991;88(14):6333-7. 
39. Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, et al. 
Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir 
Crit Care Med. 1997;155(5):1717-22. 
31 
 
40. Spielberg SP. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic 
drug metabolism. J Pharmacokinet Biopharm. 1996;24(5):509-19. 
41. Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. NAT2 polymorphisms and susceptibility to anti-
tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis. 2012;16(5):589-95. 
42. Drayer DE, Reidenberg MM. Clinical consequences of polymorphic acetylation of basic drugs. 
Clin Pharmacol Ther. 1977;22(3):251-8. 
43. Mitchell JR, Long MW, Thorgeirsson UP, Jollow DJ. Acetylation rates and monthly liver 
function tests during one year of isoniazid preventive therapy. Chest. 1975;68(2):181-90. 
44. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis. Report of an 
outbreak. Am Rev Respir Dis. 1972;106(3):357-65. 
45. Gordin FM, Cohn DL, Matts JP, Chaisson RE, O'Brien RJ. Hepatotoxicity of rifampin and 
pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than 
in HIV-uninfected persons? Clin Infect Dis. 2004;39(4):561-5. 
46. Gronhagen-Riska C, Hellstrom PE, Froseth B. Predisposing factors in hepatitis induced by 
isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis. 1978;118(3):461-6. 
47. Kopanoff DE, Snider DE, Jr., Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service 
cooperative surveillance study. Am Rev Respir Dis. 1978;117(6):991-1001. 
48. Maddrey WC, Boitnott JK. Isoniazid hepatitis. Ann Intern Med. 1973;79(1):1-12. 
49. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, et al. 
Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. 
Clin Pharmacol Ther. 1975;18(1):70-9. 
50. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, et al. 
Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med. 
1976;84(2):181-92. 
51. Warrington RJ, Tse KS, Gorski BA, Schwenk R, Sehon AH. Evaluation of isoniazid-associated 
hepatitis by immunological tests. Clin Exp Immunol. 1978;32(1):97-104. 
52. Teixeira HC, Abramo C, Munk ME. Immunological diagnosis of tuberculosis: problems and 
strategies for success. J Bras Pneumol. 2007;33(3):323-34. 
53. Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, Lindquist L, et al. Anti-tuberculosis 
therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. PLoS One. 
2008;3(3):e1809. 
54. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, et al. Polymorphism of the N-
acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. 
Hepatology. 2002;35(4):883-9. 
55. Kiser JJ, Zhu R, D'Argenio DZ, Cotton MF, Bobat R, McSherry GD, et al. Isoniazid 
pharmacokinetics, pharmacodynamics, and dosing in South African infants. Ther Drug Monit. 
2012;34(4):446-51. 
56. Singh N, Dubey S, Chinnaraj S, Golani A, Maitra A. Study of NAT2 gene polymorphisms in an 
Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients. 
Mol Diagn Ther. 2009;13(1):49-58. 
57. Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, et al. NAT2 genotype guided 
regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug 
standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. 
Eur J Clin Pharmacol. 2013;69(5):1091-101. 
58. Djordjevic N, Carrillo JA, Ueda N, Gervasini G, Fukasawa T, Suda A, et al. N-
Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high 
prevalence of rapid acetylators in a White population. J Clin Pharmacol. 2011;51(7):994-1003. 
32 
 
59. Ohkura K, Fukino K, Shinohara Y, Hori H. N-acetyl transferase 2 polymorphisms associated 
with isoniazid pharmacodynamics: molecular features for ligand interaction. Anticancer Res. 
2010;30(8):3177-80. 
60. Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K. Molecular genetics of human 
polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric 
NAT2 allozymes. Hum Mol Genet. 1994;3(5):729-34. 
61. Garcia-Martin E. Interethnic and intraethnic variability of NAT2 single nucleotide 
polymorphisms. Curr Drug Metab. 2008;9(6):487-97. 
62. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) 
genetic diversity and traditional subsistence: a worldwide population survey. PLoS One. 
2011;6(4):e18507. 
63. Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES. Worldwide 
distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 
2008;9(21):21. 
64. Bach PH, Higgins-Opitz SB, Bima B, Leary WP. Isoniazid acetylator status of Black South 
African tuberculosis patients. S Afr Med J. 1976;50(29):1132-4. 
65. Loktionov A, Moore W, Spencer SP, Vorster H, Nell T, O'Neill IK, et al. Differences in N-
acetylation genotypes between Caucasians and Black South Africans: implications for cancer 
prevention. Cancer Detect Prev. 2002;26(1):15-22. 
66. Werely CJ. Pharmacogenetics of Arylamine N-acetyltransferase genes in South African 
populations: Stellenbosch: Stellenbosch University; 2012. 
67. Adetifa IM, Lugos MD, Hammond A, Jeffries D, Donkor S, Adegbola RA, et al. Comparison of 
two interferon gamma release assays in the diagnosis of Mycobacterium tuberculosis infection and 
disease in The Gambia. BMC Infect Dis. 2007;7:122. 
68. Adetifa IM, Ota MO, Jeffries DJ, Hammond A, Lugos MD, Donkor S, et al. Commercial 
interferon gamma release assays compared to the tuberculin skin test for diagnosis of latent 
Mycobacterium tuberculosis infection in childhood contacts in the Gambia. Pediatr Infect Dis J. 
2010;29(5):439-43. 
69. Adetifa IM, Ota MO, Walther B, Hammond AS, Lugos MD, Jeffries DJ, et al. Decay kinetics of 
an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases. 
PLoS One. 2010;5(9):e12502. 
70. Ak O, Dabak G, Ozer S, Saygi A, Dabak R. The evaluation of the Quantiferon-TB Gold test in 
pulmonary and extrapulmonary tuberculosis. Jpn J Infect Dis. 2009;62(2):149-51. 
71. Barth RE, Mudrikova T, Hoepelman AI. Interferon-gamma release assays (IGRAs) in high-
endemic settings: could they play a role in optimizing global TB diagnostics? Evaluating the 
possibilities of using IGRAs to diagnose active TB in a rural African setting. Int J Infect Dis. 
2008;12(6):e1-6. 
72. Bocchino M, Chairadonna P, Matarese A, Bruzzese D, Salvatores M, Tronci M, et al. Limited 
usefulness of QuantiFERON-TB Gold In-Tube® for monitoring anti-tuberculosis therapy. Respiratory 
Medicine. 2010;104(10):1551-6. 
73. Chee CB, KhinMar KW, Gan SH, Barkham TM, Koh CK, Shen L, et al. Tuberculosis treatment 
effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur 
Respir J. 2010;36(2):355-61. 
74. Connell TG, Davies MA, Johannisen C, Wood K, Pienaar S, Wilkinson KA, et al. Reversion and 
conversion of Mycobacterium tuberculosis IFN-gamma ELISpot results during anti-tuberculous 
treatment in HIV-infected children. BMC Infect Dis. 2010;10:138. 
33 
 
75. Dheda K, van Zyl Smit R, Badri M, Pai M. T-cell interferon-gamma release assays for the rapid 
immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Curr Opin 
Pulm Med. 2009;15(3):188-200. 
76. Dheda K, van Zyl-Smit RN, Sechi LA, Badri M, Meldau R, Meldau S, et al. Utility of 
quantitative T-cell responses versus unstimulated interferon-{gamma} for the diagnosis of pleural 
tuberculosis. Eur Respir J. 2009;34(5):1118-26. 
77. Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, Lugos MD, et al. Longitudinal 
assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med. 2007;4(6):e192. 
78. Kabeer BSA, Perumal V, Paramasivam P, Raja A. Yield of QuantiFERON-TB gold in tube assay 
and tuberculin skin test in healthy persons from a tuberculosis endemic population. Journal of Pediatric 
Infectious Diseases. 2010;5(2):125-9. 
79. Katiyar SK, Sampath A, Bihari S, Mamtani M, Kulkarni H. Use of the QuantiFERON-TB Gold 
In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis. Int J Tuberc Lung Dis. 
2008;12(10):1146-52. 
80. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Oka M. Transitional changes in T-cell 
responses to Mycobacterium tuberculosis-specific antigens during treatment. J Infect. 2009;58(3):197-
204. 
81. Kobashi Y, Sugiu T, Ohue Y, Mouri K, Obase Y, Miyashita N, et al. Long-term follow-up of the 
QuantiFERON TB-2G test for active tuberculosis disease. Intern Med. 2008;47(22):1957-61. 
82. Lee SH, Lew WJ, Kim HJ, Lee HK, Lee YM, Cho CH, et al. Serial interferon-gamma release 
assays after rifampicin prophylaxis in a tuberculosis outbreak. Respir Med. 2010;104(3):448-53. 
83. Pai M, Joshi R, Bandyopadhyay M, Narang P, Dogra S, Taksande B, et al. Sensitivity of a 
whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-
cell responses during anti-tuberculosis treatment. Infection. 2007;35(2):98-103. 
84. Sauzullo I, Mengoni F, Lichtner M, Massetti AP, Rossi R, Iannetta M, et al. In vivo and in vitro 
effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response. PLoS One. 
2009;4(4):e5187. 
85. Theron G, Peter J, Lenders L, van Zyl-Smit R, Meldau R, Govender U, et al. Correlation of 
mycobacterium tuberculosis specific and non-specific quantitative Th1 T-cell responses with bacillary 
load in a high burden setting. PLoS One. 2012;7(5):e37436. 
86. Kabeer BS, Raja A, Raman B, Thangaraj S, Leportier M, Ippolito G, et al. IP-10 response to 
RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis. 
2011;11(135):1471-2334. 
87. Bugiani M, Bonora S, Carosso A, Piccioni P, Cavallero M, Mondo A, et al. The effect of 
antituberculosis treatment on interferon-gamma release assay results. Monaldi Arch Chest Dis. 
2011;75(4):215-9. 
88. Markova R DR, Todorova Y, Terzieva V, Stefanova D. Monitoring the efficacy of anti-TB 
therapy by using the QuantiFERON-TB Gold In tube test. European Respiratory Review. 2008;17:74-5. 
89. Dyrhol-Riise AM, Gran G, Wentzel-Larsen T, Blomberg B, Haanshuus CG, Morkve O. 
Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold 
In-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis. 2010;10:57. 
90. M. Bugiani SB, A. Carosso, P. Piccioni, M. Cavallero, A. Mondo, V. Ghisetti. The effect of 
antituberculosis treatment on interferon-γ release assay results. Monaldi Arch Chest Dis. 
2011;75(4):215-9. 
91. Kabeer B, Raja A, Raman B, Thangaraj S, Leportier M, Ippolito G, et al. IP-10 response to RD1 




92. Markova R, Drenska R, Todorova Y, Terzieva V, Stefanova D. Monitoring the efficacy of anti-
TB therapy by using the QuantiFERON-TB Gold In tube test. European Respiratory Review. 
2008;17(108):74-5. 
93. Herrmann J-L, Belloy M, Porcher R, Simonney N, Aboutaam R, Lebourgeois M, et al. Temporal 
Dynamics of Interferon Gamma Responses in Children Evaluated for Tuberculosis. PLoS ONE. 
2009;4(1):e4130. 
94. Chiappini E, Bonsignori F, Mangone G, Galli L, Mazzantini R, Azzari C, et al. Serial T-
SPOT.TB and Quantiferon-TB-Gold in Tube Assays to Monitor Response to Anti-Tubercular Treatment 
in Italian Children with Active or Latent Tuberculosis Infection. Pediatr Infect Dis J. 2012;8:8. 
95. Connell TG, Ritz N, Paxton GA, Buttery JP, Curtis N, Ranganathan SC. A three-way 
comparison of tuberculin skin testing, QuantiFERON-TB gold and T-SPOT.TB in children. PLoS One. 
2008;3(7):e2624. 
96. Aiken AM, Hill PC, Fox A, McAdam KP, Jackson-Sillah D, Lugos MD, et al. Reversion of the 
ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis. 2006;6:66. 
97. Ribeiro-Rodrigues R, Resende Co T, Johnson JL, Ribeiro F, Palaci M, Sa RT, et al. Sputum 
Cytokine Levels in Patients with Pulmonary Tuberculosis as Early Markers of Mycobacterial Clearance. 
Clinical and Vaccine Immunology. 2002;9(4):818-23. 
98. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G, et al. Direct Ex 
Vivo Analysis of Antigen-Specific IFN-γ-Secreting CD4 T Cells in Mycobacterium tuberculosis-
Infected Individuals: Associations with Clinical Disease State and Effect of Treatment. The Journal of 
Immunology. 2001;167(9):5217-25. 
99. Dhingra V, Aggarwal N, Rajpal S, Aggarwal J, Gaur S. Validity and Reliability of Sputum 
Smear Examination as Diagnostic and Screening Test for Tuberculosis. Indian J Allergy Asthma 
Immunol. 2003;17:67 - 9. 
100. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. American Thoracic 
Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment 
of tuberculosis 
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active 
tuberculosis. Am J Respir Crit Care Med. 2003;167:603 - 62. 
101. Aggarwal AN. Health-related quality of life: A neglected aspect of pulmonary tuberculosis. Lung 
India. 2010;27(1):1-3. 
102. Mannheimer S, Matts J, Telzak E, Chesney M, Child C, Wu AW, et al. Quality of life in HIV 
infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005;7:10-2. 
103. Kohli RM, Sane S, Kumar K, Paranjape RS, Mehendale SM. Assessment of quality of life 
among HIV-infected persons in Pune, India. Qual Life Res. 2005;14(6):1641-7. 
104. Naveet W, Raja L, Hemraj P, Vivek A, Chander M, Sunil A. The impact of HIV/AIDS on the 
quality of life: A cross sectional study in north India. Indian Jour Med Sciences. 2006;60(1):3-12. 
105. Monde D. The assessment of patients' health-related quality of life during tuberculosis treatment 
in Wuhan, China. Int J Tuberc Lung Dis. 2004;8(9):1100-6. 
106. Guo N, Marra F, Marra C. Measuring health-related quality of life in tuberculosis: a systemic 
review. Health and Quality of Life Outcomes. 2009;7:14. 
107. Mekasha T, Woldemichael K. Assessment of patients' health related quality of life during 
tuberculosis treatment as compared to their neighbours in Hawassa town, Ethiopia. Master's thesis in 
public health. 2009. 
108. Marra CA, Marra F, Cox VC, Palepu A, Fitzgerald JM. Factors influencing quality of life in 
patients with active tuberculosis. Health Qual Life Outcomes. 2004;2:58. 
109. Deribew A, Tesfaye M, Hailmichael Y, Negussu N, Daba S, Wogi A, et al. Tuberculosis and 
HIV co-infection: its impact on quality of life. Health and Quality of Life Outcomes. 2009;7(1):105. 
35 
 
110. Maguire GP, Anstey NM, Ardian M, Waramori G, Tjitra E, Kenangalem E, et al. Pulmonary 
tuberculosis, impaired lung function, disability and quality of life in a high-burden setting. Int J Tuberc 
Lung Dis. 2009;13(12):1500-6. 
111. Muniyandi M, Rajeswari R, Balasubramanian R. Evaluation of post-treatment health-related 
quality life (HRQoL) among tuberculosis patients. Int J Tuberc Lung Dis. 2007;11:887-92. 
112. Dhuria M, Sharma N, Ingle GK. Impact of tuberculosis on the quality of life. Indian Journal of 
Community Medicine. 2008;33(1):58–9. 
113. Lorenz KA, Cunningham WE, Spritzer KL, Hays RD. Changes in symptoms and health-related 
quality of life in a nationally representative sample of adults in treatment for HIV. Qual Life Res. 
2006;15(6):951-8. 
114. Africa SS. Mortality and Causes of Death in South Africa, 2003 and 2004: Findings from Death 
Notification, Statistical Release P0309.3. http://wwwstatssagovza. 
115. Osman M, Welte A, Dunbar R, Brown R, Hoddinott G, Hesseling AC, et al. Morbidity and 
mortality up to 5 years post tuberculosis treatment in South Africa: A pilot study. International Journal 
of Infectious Diseases. 2019;85:57-63. 
116. da Silva Escada RO, Velasque L, Ribeiro SR, Cardoso SW, Marins LMS, Grinsztejn E, et al. 
Mortality in patients with HIV-1 and tuberculosis co-infection in Rio de Janeiro, Brazil-associated 
factors and causes of death. BMC infectious diseases. 2017;17(1):373. 
117. Isanaka S, Mugusi F, Urassa W, Willett WC, Bosch RJ, Villamor E, et al. Iron deficiency and 
anemia predict mortality in patients with tuberculosis. The Journal of nutrition. 2012;142(2):350-7. 
118. Pozniak A, Miller R, Lipman M, Freedman A, Ormerod L, Johnson M, et al. BHIVA treatment 
guidelines for tuberculosis (TB)/HIV infection 2005. HIV medicine. 2005;6(S2):62-83. 
119. Robinson. Pharmacokinetic interactions between nevirapine and rifampin. World AIDs 
conference Geneva Switzerland. 1998. 
120. Wen X, Wang J-S, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based inhibitor of 
cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. European Journal of 
Clinical Pharmacology. 2002;57(11):799-804. 
121. Ma MK, Woo MH, McLeod HL. Genetic basis of drug metabolism. Am J Health Syst Pharm. 
2002;59(21):2061-9. 
122. Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 genetic 
polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS. 
2009;23(16):2101-6. 
123. Court MH, Almutairi FE, Greenblatt DJ, Hazarika S, Sheng H, Klein K, et al. Isoniazid Mediates 
the <em>CYP2B6*6</em> Genotype-Dependent Interaction between Efavirenz and Antituberculosis 
Drug Therapy through Mechanism-Based Inactivation of CYP2A6. Antimicrobial Agents and 
Chemotherapy. 2014;58(7):4145-52. 
124. Bertrand J, Verstuyft C, Chou M, Borand L, Chea P, Nay KH, et al. Dependence of Efavirenz- 
and Rifampicin-Isoniazid–Based Antituberculosis Treatment Drug-Drug Interaction on CYP2B6 and 
NAT2 Genetic Polymorphisms: ANRS 12154 Study in Cambodia. The Journal of Infectious Diseases. 
2013;209(3):399-408. 
125. Evans DA. Genetic variations in the acetylation of isoniazid and other drugs. Ann N Y Acad Sci. 
1968;151(2):723-33. 
126. Kwara A, Flanigan TP, Carter EJ. Highly active antiretroviral therapy (HAART) in adults with 
tuberculosis: current status. Int J Tuberc Lung Dis. 2005;9(3):248-57. 
127. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine 
metabolism and carcinogenesis. Mutat Res. 2002;506-507:65-77. 
128. Ramachandran G, Swaminathan S. Role of pharmacogenomics in the treatment of tuberculosis: a 
review. Pharmacogenomics and personalized medicine. 2012;5:89-98. 
36 
 
129. Sorensen AL, Nagai S, Houen G, Andersen P, Andersen AB. Purification and characterization of 
a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun. 
1995;63(5):1710-7. 
130. Lewinsohn DA, Zalwango S, Stein CM, Mayanja-Kizza H, Okwera A, Boom WH, et al. Whole 
blood interferon-gamma responses to mycobacterium tuberculosis antigens in young household contacts 
of persons with tuberculosis in Uganda. PLoS One. 2008;3(10):e3407. 
131. Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P. Evidence for occurrence of the 
ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in 
Mycobacterium bovis BCG. Infection and immunity. 1996;64(1):16-22. 
132. Berthet FX, Rasmussen PB, Rosenkrands I, Andersen P, Gicquel B. A Mycobacterium 
tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). 
Microbiology. 1998;144 ( Pt 11)(11):3195-203. 
133. WHO. CONSTITUTION OF THE WORLD HEALTH ORGANIZATION. 2006. 
134. Health WHOPoM. WHOQOL: measuring quality of life. 1997. 
135. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis. 
1987;40(6):593-603. 
136. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in 
Khayelitsha, South Africa--a primary data analysis. Cost Eff Resour Alloc. 2006;4:20. 
137. Sharma SK, Mohan A, Kadhiravan T. HIV-TB co-infection: epidemiology, diagnosis & 
management. Indian J Med Res. 2005;121(4):550-67. 
138. Organization WH. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the 
diagnosis and screening of active tuberculosis in people living with HIV: policy guidance. World Health 
Organization; 2015. Report No.: 9241509635. 
139. Colebunders RL, Ryder RW, Nzilambi N, Dikilu K, Willame JC, Kaboto M, et al. HIV infection 
in patients with tuberculosis in Kinshasa, Zaire. Am Rev Respir Dis. 1989;139(5):1082-5. 
140. McNerney R, Daley P. Towards a point-of-care test for active tuberculosis: obstacles and 
opportunities. Nat Rev Microbiol. 2011;9(3):204-13. 
141. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, et al. Advances in tuberculosis 
diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 
2013;13(4):349-61. 
142. McNerney R, Maeurer M, Abubakar I, Marais B, Mchugh TD, Ford N, et al. Tuberculosis 
diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. Journal of Infectious 
Diseases. 2012;205(suppl_2):S147-S58. 
143. Walzl G, McNerney R, du Plessis N, Bates M, McHugh TD, Chegou NN, et al. Tuberculosis: 
advances and challenges in development of new diagnostics and biomarkers. The Lancet Infectious 
Diseases. 2018;18(7):e199-e210. 
144. Africa NDoHS. National Antiretroviral Treatment Guidelines. 2004. 
145. Boulle A, Clayden P, Cohen K, Cohen T, Conradie F, Dong K, et al. Prolonged deferral of 
antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase 
mortality? SAMJ: South African Medical Journal. 2010;100(9):566-71. 
146. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of 
initiation of antiretroviral drugs during tuberculosis therapy. New England Journal of Medicine. 
2010;362(8):697-706. 
147. Africa NDoHS. Clinical Guidelines for the Management of HIV &  AIDS in Adults and 
Adolescents. 2010. 
148. Africa NDoHo. National Strategic Plan on HIV, STIs and TB 2012-2016. 2012. 
149. Miller CM, Ketlhapile M, Rybasack-Smith H, Rosen S. Why are antiretroviral treatment patients 
lost to follow-up? A qualitative study from South Africa. Trop Med Int Health. 2010;15 Suppl 1:48-54. 
37 
 
150. MORATIOA GU. PSYCHOSOCIAL FACTORS THAT AFFECT ADHERENCE TO ANTI 
RETROVIRAL THERAPY AMONGST HIV/AIDS PATIENTS AT KALAFONG HOSPITAL: 








Literature review  
2.1 Introduction 
This review covers the four areas that are subjects of this thesis; NAT2 polymorphisms for prediction of 
isoniazid pharmacokinetics variability and adverse events; IGRAs for monitoring of combined TB and 
HIV therapies in co-infected patients, monitoring treatment response using a QOL instrument in TB and 
HIV co-infected patients, and finally, urine LAM for smear-negative TB diagnosis. 
 
Early diagnosis and treatment of TB are the necessary components for curbing the spread of the disease. 
In TB surveys it has been determined that 40 – 79% of the prevalent cases do not report any signs and 
symptoms of TB (1). By the time an individual experiences signs and symptoms of TB, he/she has possibly 
infected a number of individuals around him/her (2). HIV is another player in this area, as TB is one of 
the most common opportunistic infections in people living with HIV (3).  Any new diagnostic, to be 
effective, must be able to diagnose TB in HIV-infected individuals, including those with severe 
immunosuppression. These individuals are often sputum-scarce, too sick to cough out sputum, or present 
with smear-negative TB disease, making it difficult to diagnose (4). An ideal diagnostic should also be 
performed at the point of care. New biomarkers for detection and treatment monitoring are urgently needed 
to ensure early diagnosis and treatment of active TB, especially in high TB and HIV endemic countries 
(5, 6). Xpert MTB/RIF is a recent biomarker that effectively diagnoses TB in both HIV-infected and 
uninfected. Unfortunately, although very sensitive, there are still people that are not diagnosed by this test, 
and it has not replaced smear and culture, especially in relapse and reinfection TB.  
 
Studies investigating different biomarkers in detecting latent and active disease have been ongoing for 
some time. Different types of biomarkers include host-derived (immunological) and pathogen-derived 
biomarkers (7-10). Among these biomarkers are IGRAs, that seemed to be promising for the diagnosis of 
TB but were found not to be specific for active TB, leading to the WHO cautioning against their use in 
high endemic  countries (11). While IGRAs have been ruled out as a diagnostic for active TB diagnosis, 
studies have been conducted to investigate their use in TB treatment monitoring (12-14). There are 
conflicting results in this regard, although it is generally accepted that these should not be used for 
treatment monitoring. Urine LAM has been investigated for diagnosis of TB, and for a long time, it seemed 
that urine LAM would not be useful because of its low sensitivity (15-18) but studies investigating its 
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usefulness in diagnosis of TB in HIV-infected individuals have found its usefulness in severely 
immunocompromised individuals (19-21). 
 
NAT2 polymorphisms involved in drug metabolisms, IGRAs, QOL and urine LAM, are the key terms for 
discussion in this chapter. QOL or HRQOL has been studied in HIV-infected individuals and there are 
few studies reporting the usefulness of QOL as a biomarker for treatment monitoring. 
 
2.2 Definition of key concepts 
The biomarker working group defined a biomarker as a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention(22). Using the term widely, we have included the HRQOL in our 
definition of biomarker as it has been used as predictive marker of worsening of certain conditions (23). 
Boxwala et al. defined an adverse event as, “An undesirable event occurring in the course of medical care 
that produces a measurable change in patient status” (24). The adverse events may be clinical or laboratory 
parameters and may or may not be related to the treatment. Safety means the level to which side effects 
to treatment are experienced by patients taking the drugs for TB or HIV therapy or the combined treatment. 
Furthermore, it may include known or unknown side effects of TB treatment and ART involving different 
body systems. These may include worsening of the condition, in this instance, TB and HIV. Side effects 
are any unintended effect of a pharmaceutical product occurring at doses usually used in humans, which 
are related to the pharmacological properties of the product (25).  
TB treatment outcomes, according to the WHO and International Union against TB and Lung Disease 
(IUATLD) (26) are: 
• Cure: a patient who was initially smear-positive and has completed treatment and has two negative 
smears, one on completion of treatment. 
• Treatment completion: an initially sputum smear-positive patient who has completed treatment, 
has a negative smear at the end of the initial phase and no sputum smear at the end of treatment. 
• Treatment loss to follow up: a patient who at any time after registration has not taken treatment 
for at least two or more consecutive months. 
• Failure: an initially smear-positive patient who is smear-positive at five months or more after 
starting treatment. 
• Death: a patient who died while on treatment, regardless of the cause. 
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• Treatment relapse: TB relapse is defined as a patient who has become (and remained) culture 
negative while receiving therapy but after completion of therapy becomes: 
1. Culture positive again, or 
2. Has clinical or radiographic deterioration that is consistent with active tuberculosis. 
Monitoring involves the perception of the individuals’ subjective experiences on how treatment is 
affecting them. Monitoring clinical characteristics involve laboratory tests, adverse events and serious 
adverse events reporting. LAM, pharmacogenetics or genetic factors involved in drug metabolisms, 
IGRAs as well as QOL or HRQOL are the key terms for review in this chapter.  
 
2.3 Literature review 
The review of literature will cover the four biomarkers discussed in this study; TB diagnostics, 2.3.1; 
NAT2 polymorphisms; 2.3.2, interferon-gamma release assays; 2.3.3 quality of life; and 2.3.4. Urine for 
diagnosis of smear-negative TB. 
 
Biomarkers 
Strimbu and Tavel defined the biomarker as objective indications of medical state observed from outside 
the patient – which can be measured accurately and reproducibly (27). The National Institute of Health 
(NIH) biomarker working group defines a biomarker as a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention (22)   and have created a glossary of terms relating to biomarkers. 
They have defined different biomarkers including diagnostic, monitoring, pharmacodynamic/response, 
predictive, prognostic, safety, susceptibility/risk biomarkers. A diagnostic biomarker is used to detect or 
confirm the presence of a disease or condition of interest or to identify individuals with a subtype of the 
disease. There are different definitions of a biomarker in the literature. A biomarker can be defined as a 
characteristic that is objectively measured and assessed as an indicator of normal biological processes, 
pathogenic processes, or pharmacological responses to  a therapeutic intervention.  
 
According to Selleck, Senthil and Wall, to be truly valuable, “a biomarker must contribute clinically 
relevant information beyond what is available or provide the same information at a lower cost, either 
financially or in measurable patient risk” (28). This is true for urine LAM, studies have shown that it 
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diagnoses hard to diagnose patients with smear-negative and extra-pulmonary TB. It is also cheaper than 
currently available tests and is a point of care test.  
 
A monitoring biomarker is defined as a characteristic measured serially for assessing status of a disease 
or medical condition or for evidence of exposure to (or effect of) a medical product or an environment 
agent. According to Ptolemy and Rifai, in addition to identifying illnesses, biomarkers can be useful as an 
indicator for clinical or therapeutic intervention efficacy (29), but notes the lengthy process of clinical 
validation. Califf clarifies that biomarkers should be distinct from direct measures of how a person feels, 
functions, or survives – a category of measure known as a clinical outcome assessment (COA) (30). COAs 
can be used to meet standards for regulatory approval of therapeutics, whereas, according to Califf, 
biomarkers serve a variety of purposes, including linking a measurement to a prediction of COAs. Certain 
diagnostic biomarkers may be used as monitoring biomarkers as well. It is noted that a diagnostic 
biomarker may be useful in one set of clinical circumstances while misleading in another context. We note 
in the case of urine LAM that a negative test is common in HIV-uninfected or in HIV-infected with low 
levels of immunosuppression.  
 
Pathogen derived biomarkers 
Tucci, Gonzalez-Sapienza and Marin conducted a short review on biomarkers derived from M. 
tuberculosis and their usage in active TB diagnosis  (8). They report that diagnostic tests based on detection 
of LAM in urine were among the first to move from research to commercial stage due to their promising 
initial results. LAM is one of the successes of a diagnostic biomarker that is derived from M. tuberculosis.  
 
2.3.1 Pharmacogenetics and NAT2 polymorphisms 
Pharmacogenetics  
The concept of genetic predisposition began over 140 years ago through the pharmacogenetics work of 
Francis Galton and Archibald E. Garrod (31, 32). Pharmacogenetic research emerged as a discipline 
attempting to understand the hereditary basis for variability in response to therapeutic agents among 
individuals. The variability in drug response ranges from small to large differences in response among 
individuals. Variations in the hepatic phase II system cause a wide variation in expression by drugs such 
as isoniazid and hydralazine (33). 
 
 Genetic polymorphism  
42 
 
The term, “genetic polymorphism”, means a difference in deoxyribonucleic acid (DNA) sequence among 
individuals, groups or populations (34), encompassing monogenic traits that exist in the normal population 
in at least two phenotypes, neither of which is rare (35). Phenotypes are the visible properties of an 
organism, which are produced by the interaction between the genotype, or the genetic constitution of an 
individual, and the environment. Many factors contribute to inter-patient variations in expression of 
pharmacokinetic and of pharmacodynamic-type polymorphisms. SNP is a source variance in a genome, a 
single base mutation in DNA (34). SNPs are the most simple forms and most common source of genetic 
polymorphisms (34). SNPs in a coding region can have two different effects, synonymous, which causes 
no amino acid change, or non-synonymous, which results in an alteration of the encoded amino acid. The 
effects of a pharmacogenetic variant on an individual depends on the metabolic pathway of the medication. 
A loss-of-function polymorphism of the main metabolic pathway of medication, may result in extremely 
high concentrations of the medication—even into the toxic range. If, on the other hand, the polymorphism 
affects a minor enzymatic pathway, there may only a negligible  change in drug concentrations.  
 
Drug-metabolising enzymes 
Genetic polymorphisms in drug metabolism are quite common among the population because of 
differences  intrinsic (physiologic) and extrinsic (cultural, behavioral and environmental characteristics of 
people (36). These factors may cause mutations in the genes for drug-metabolising enzymes (DMEs) (37). 
The mutation can cause higher or lower enzyme activity or lead to the partial or total absence of an enzyme 
protein. Polymorphisms have been defined for numerous DMEs, and many of these were identified after 
an adverse drug reaction occurred from a standard dose of medication. These adverse reactions then led 
to the evaluation of the association between decreased drug clearance and decreased activity of DMEs.  
For certain DMEs, a constant percentage of the population lacks or has greatly reduced enzyme activity. 
Based on these differences, the population can be subdivided into poor metabolisers and extensive 
metabolisers (38). Genetic polymorphism exists when an inherited trait is maintained in the population 
because the gene controlling the trait is present with a frequency greater than 1% (39). Genetic variants of 
NAT2 are amongst the better-studied polymorphisms (40, 41). NAT2 polymorphism was discovered more 
than 50 years ago using INH as the substrate probe. INH is bactericidal against actively growing Mtb and 
is bacteriostatic against non-replicating organisms (42, 43). It acts through inhibition of oxygen-dependent 
synthetic pathways of mycolic acid, an important constituent of mycobacterial cell walls. Significant 
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interpatient variability in serum concentrations of INH was recognised early, generally occurring hours 
after an oral dose (44, 45).  
 
NAT2 polymorphisms 
NAT2 activity is reported to be highest in the liver and gastrointestinal tract (46). According to available 
literature, drugs such as isoniazid and sulfamethazine were termed polymorphic substrates for N-
acetylation as a result of the observation that they divided the population into rapid and slow acetylator 
phenotypes, while other drugs yielded normal distribution (35, 47, 48). Parkin et al. found that isoniazid 
presented a trimodal distribution in the population, rapid, intermediate and slow acetylation (49). Whether 
the distribution is bimodal or trimodal, its relationship to treatment effect would not change.  
 
The reference NAT2*4 gene is associated with rapid acetylator phenotype activity and is referred to as the 
“wild type” (35, 40). The most commonly investigated SNPs are 191, 282, 341, 411, 590, 803 and 857. 
Two are synonymous or silent (C282T and C481T), the substitution causing no amino acid change to the 
protein it produces, whereas the remaining four variants are non-synonymous, the substitution resulting 
in an alteration of the encoded amino acid (34) (T341C, G590A, A803G and G857A). G191A was not 
investigated in this study. 
 
NAT2 genotype and phenotype inference  
Different methods are used to infer NAT2 genotype and phenotype of individuals. Determination of NAT2 
SNPs has been done using polymerase chain reaction (PCR) restriction fragment length polymorphism 
and sequencing techniques (50-52). Methods using gel electrophoresis and microarray systems (53), SNP 
specific PCR primers and fluorogenic probes as detailed by Doll et al. have also been used (54). More 
possibilities become available with technological advances (55, 56), especially with new sequencing 
techniques. A decision on which method to use is based on the cost and numbers. Genotype scoring often 
used, is according to the nomenclature by Vatsis and co-workers (57) but recently computational methods 
are being used (58-61). Different methods come with differences in data quality (62), and investigators 
have to make choices on which methods would work best for their study. The use of  Tag SNP (A SNP in 
strong linkage disequilibrium with a set or a copy number variant)  has been described as a good 




Caffeine is most commonly used probe drug  for NAT2 phenotyping by measurement of urinary molar 
ratio of the caffeine metabolites (65). Phenotype inference from isoniazid pharmacokinetic sampling has 
been conducted using different methods. Investigators have used any one or a combination of elimination 
half-life of INH (66, 67), INH plasma levels at six hours after drug intake, inactivation index (I3) (68), and 
molar acetylation ratio (69). Hitchings et al. found that using the 3-hour isoniazid AcINH/INH was better 
than the elimination half-life method (70). There is no gold standard for the classification of phenotype. 
Investigators use different criteria to classify INH phenotype, although the inactivation index (metabolic 
ratio) is the most commonly used (71-73).  Different studies have used different SNP combinations to 
infer phenotype. Because of the high rate of admixture in South Africa, using either a 2 or 4 genotype 
panel to infer phenotype may not be adequate. The accuracy of the SNP panels differ from population to 
population, where a 3-SNP panel of 481>T, 590>A and 857>A was 100% sensitive in inferring phenotype 
for Guarani and Japanese, 79.4% for Mozambicans (79). 
 
Adverse events of anti-TB treatment and antiretroviral therapy 
The achievement of therapeutic drug levels of ATT and ART is necessary to decrease the morbidity and 
mortality related to TB and HIV. For the absorption, distribution, metabolism, elimination and action of 
these drugs to be understood, the influence of pharmacogenetics needs understanding (74). Most patients 
will tolerate ATT well, experiencing only minimal adverse events, as shown in studies although, some 
patients may experience severe incapacities because of adverse events of either ATT, ARV therapy or 
combined therapy (75, 76). Their results showed that the risk of adverse reactions is significantly higher 
in HIV-infected patients. Multidrug therapy of any kind can be complicated by overlapping toxicity 
profiles, such that it may be difficult to determine which of several agents being used caused a specific 
adverse effect (77). 
Guidelines issued by various agencies provide different initiation recommendations according to resource 
availability (78-80). Consequently, the decision to initiate ART in co-infected patients has always been 
made on clinical grounds and a case-by-case basis, while until recently, all patients in resource-poor 
settings received treatment only when their CD4 count dropped to below 200. A decision on when to start 
ART in an HIV-infected, asymptomatic patient has been controversial for a long time. There is enough 
data from observational and randomised clinical studies that support the idea that most, if not all, 
individuals with HIV would benefit from treatment (81-83). The most benefits of ART in TB patients 
results from a gradual restoration of Mtb-specific CD4 cell immune responses (84).  
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NAT2 acetylation and isoniazid side effects have been investigated extensively (85-90), and early studies 
reported peripheral neuropathy and hepatoxicity and its relation to slow isoniazid acetylation. Since not 
only INH but pyrazinamide (PZA) and rifampicin have been responsible for hepatotoxicity, patients on 
ATT are more prone to hepatic side effects (91-93). Also, certain ARVs have similar side effects, making 
concomitant therapy of ATT and ARV leading to increased side effects (88, 91, 94). 
 
2.3.2 Interferon-gamma release assays 
There have been suggestions that IGRAs can be used as biomarkers to monitor TB treatment responses 
(95, 96). Studies conducted to examine the effect of active TB treatment on INF-γ responses have had 
inconsistent results. Some studies have shown declining responses (97) while others have shown 
unchanging, fluctuating or increasing responses post-treatment (98-101). This variation may be because 
of differences in methodology and types of tests used.  
 
Mtb initially infects macrophages, and cellular immunity plays a vital role in the healing process of TB 
(102). Macrophages produce toxic radicals and hydrolytic enzymes to defend the body against Mtb. 
However, the Mtb has a rich lipid outer capsule which protects it from the body’s defences. Macrophages, 
after activation, possess potent antimicrobial activity which can kill bacilli and arrest TB infection, which 
is not entirely eliminated easily. Cytolytic T lymphocytes may be used as well in the destruction of the 
infected cells (103, 104). Helper T-cells (Th) are needed to recruit and activate new monocytes and 
macrophages to the tubercle. CD4+ T-cells are divided into Th1 and Th2 subsets, depending on the type 
of cytokines produced. Th1 cells produce the cytokines IFN-γ and interleukin (IL), which are important 
for the activation of any antimicrobial activities and essential for delayed type hypersensitivity (DTH) 
response. IFN-γ specifically activates macrophages and stimulate them to ingest and kill mycobacteria 
more effectively. 
 
The induction of INF-γ has been shown to be essential for individual protection against TB (79, 105). 
Surcel et al. investigated Th1/Th2-like cell profiles in patients with active TB (106). They studied T-
lymphocyte activation by analysing IL-4 and INF-γ production at single-cell level using Enzyme-linked 
Immunosorbent Spot (ELISPOT) assays in peripheral blood mononuclear cells (PBMC) stimulated with 
individual mycobacterial antigens. They found that the average numbers of cytokine secreting cells were 
generally elevated in TB patients following stimulation with murine tracheal surface epithelial (MTSE) 
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containing a wide range of antigens. The numbers of IL-4-producing cells were significantly elevated in 
PBMC from TB patients compared with controls in response to 38,000 MW antigen, while the 19,000 
molecular weight (MW) antigen-induced more prominent activation of INF-γ-producing cells in TB 
patients compared to controls. They found that the number of INF-γ secreting cells did not differ 
significantly between patients and controls. Increased INF-γ secretion was found slightly more frequently 
in patients than in controls after three days of antigen stimulation. 
 
The use of surrogate endpoints has been widely examined in HIV and acquired immunodeficiency 
syndrome (AIDS) compared to in any other disease (10). Surrogate markers for TB and HIV/AIDS are 
essential for the clinical evaluation of the extent of the disease as well as response to treatment and 
vaccines. According to Lawn et al., findings that patients are still prone to TB while on antiretroviral 
treatment, is an indication that complete restoration of cellular immunity against TB may not be possible 
(107). Of interest is, what the effect on the immunity of starting antiretroviral treatment together with ATT 
would be in co-infected patients. 
 
A study by Schluger et al. was conducted to assess the restoration of immune responses to TB, as 
manifested by secretion of T-helper type 1 cytokines (IFN-γ, IL-12, and IL-2) and T helper type 2 
cytokines (IL-10), in HIV-infected patients on ART (108). Included in the study were ten antiretroviral 
treatment naïve HIV-infected patients, who were about to start ART for clinical indications and 11 HIV-
negative healthy participants. They assessed the T-cell proliferation and cytokine production after 
administration of ART to patients with HIV infection. All patients had a baseline negative tuberculin skin 
test (TST) and were anergic. Blood was drawn at two-monthly intervals for 12 months after the start of 
treatment. This study demonstrated that mycobacterial immune responses are restored to some degree, 
although delayed compared to HIV viral load suppression and CD4+ T-cell increase. Also, the restoration 
was found to be submaximal when compared with responses seen in peripheral mononuclear cells 
(PBMC) obtained from healthy volunteers. IFN-γ production reached levels seen in healthy volunteers 
only after several months of ART. 
 
Subramanyan et al. conducted a study to test the hypothesis that HIV infection brings about an alteration 
in the host immune response to TB (109). Levels of the proinflammatory cytokine IFN-γ and its regulatory 
cytokines (IL-12, IL-18 and IL-10) in plasma were measured in TB (HIV-uninfected and -infected) 
patients and their controls. Then stimulation of PBMC by mycobacterial antigens followed. They found 
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that TB patients had higher IFN-γ than non-TB patients, with TB/HIV co-infected patients having less 
than TB non-HIV patients. Plasma levels of IFN-γ were found to be significantly higher in HIV-infected 
TB patients with low CD4 counts (<200 cells/mm3) than in HIV-uninfected TB patients as well as in HIV-
infected TB patients with higher CD4 counts. The presence of significantly higher levels of IFN-γ in 
individuals with low CD4 counts suggested a greater degree of immune activation. 
 
In another study, Wu et al. compared the INF-γ response between TB patients and non-tubercular 
pneumonia patients (110). INF-γ responses were measured using an enzyme-linked immunosorbent assay 
(ELISA) test. Results showed that patients with TB had less INF-γ expression than those with pneumonia. 
They also looked at other co-morbidities and how these affected INF-γ production. In vitro INF-γ response 
did not differ between patients with and without other co-morbidities, such as liver cirrhosis, 
bronchiectasis and diabetes mellitus, although in other studies, lower INF-γ responses were found in 
patients with diabetes mellitus. The researchers concluded that TB was the only independent factor 
associated with INF-γ response in patients with lung infection indicating that INF-γ response was 
principally affected by Mtb infection and not by other co-morbidities.  
 
Pai et al., in a study to evaluate the INF-γ responses in health care workers diagnosed and treated for latent 
TB, found no significant changes in the responses to treatment in subjects who took medication. The study 
was limited by a small sample of ten subjects who took treatment. Another explanation of the persistent 
INF-γ levels would be a persistent infection and or re-infection (unproven). Authors recommended a 
follow up longer than six months (111). A similar study in Japan showed a decline of INF-γ levels soon 
after treatment (112, 113). Chee et al. studied the effect of TB treatment on IGRA responses measured by 
QFT-GIT and T-SPOT.TB (97). There were significant declines in the positivity rates and qualitative 
results of both IGRAs with treatment. They reported significant test reversion rates for both tests, a 
substantial proportion of patients, however, remained positive after TB treatment. 
 
To evaluate the feasibility of ELISA assay for INF-γ during HIV infection, Goletti et al. enrolled 16 
patients with active TB disease (smear- and culture-positive): ten HIV-infected and six HIV-uninfected 
patients (114, 115). They included six HIV-infected patients with opportunistic infections other than TB 
and four HIV-negative individuals as controls. ELISPOT or ELISA for IFN-γ was performed in cells 
stimulated with ESAT-6 peptides and correlated with response to HIV-uninfected and recall antigens. At 
the time of TB diagnosis, seven HIV-infected individuals showed an in vitro response to purified protein 
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derivative (PPD) all of whom responded to ESAT-6 peptides. This response decreased over time and 
became negative after three months of therapy when patients were sputum TB-Ribonucleic acid (RNA) 
and culture-negative. At baseline no response to antigens tested was observed in five of HIV-TB patients 
analysed; although at follow-up four out of five showed induction of response of at least two of the recall 
antigens tested. Within TB-HIV-negative patients, five responded to PPD, and four out of five responded 
to ESAT-6 peptides. The response to stimulation decreased over time. None of the TB-negative controls, 
either HIV-infected or non-infected healthy controls responded to ESAT-6 although some were PPD 
positive. It was concluded that it is possible to perform an immune diagnosis of TB based on the detection 
of ESAT-6 peptide-specific IFN-γ secreting CD4 T-cells in HIV-infected individuals, even in patients 
with low CD4 cell counts. Since this response decreases over time and correlates with successful ATT 
and to a restored induction of recall antigen response, it is possible that this test may be used to monitor 
TB treatment response. Although findings from these studies vary greatly, they show that it might be 
worthwhile to investigate the role of IFN-γ in monitoring TB-HIV treatment. 
 
A recent study evaluated the diagnostic performance of QFT-Plus and compared it with the QFT-GIT test 
in Korean patients with active TB and healthy controls including subjects with latent TB infection. This 
test includes a TB2 antigen tube with peptides that may stimulate CD8+ T cells. They found that both tests 
had the same sensitivity of 93.9%, but the specificity was higher in the QFT-GIT test. The QFT-Plus test 
did not clearly discriminate between active and latent TB although IFN-γ concentrations were lower in 
those with latent TB (116). This study concluded that the tests had excellent agreement and further surveys 
are needed to evaluate the role of QFT-Plus to determine patients with different stages of TB infection or 
to monitor treatment effect. In addition, this study did not include HIV-infected patients; therefore, it 
would be beneficial to evaluate this test in such patients. Another study evaluated the effect of HIV on 
QFT-Plus test in HIV-infected patients with active and latent TB infection in Zambia (117). They found 
that the test had similar sensitivity in both HIV-infected and uninfected patients, and that CD4 count did 




2.3.3 Quality of life  
The definition of health by the WHO in their Constitution of the WHO, states, “Health is a state of 
complete physical, mental and social well-being and not merely the absence of disease or infirmity” (118), 
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this is consistent with other definitions. There are multiple definitions for the quality of life, each one 
depending on the discipline or disease for which the QOL is being measured. The WHO’s definition of 
Quality of Life is, “individuals’ perception of their position in life in the context of the culture and value 
systems in which they live and in relation to their goals, expectations, standards and concerns. It is a broad-
ranging concept affected in a complex way by the person's physical health, psychological state, level of 
independence, social relationships, personal beliefs and their relationship to salient features of their 
environment” (119). However, there is a general agreement that QOL, especially HRQOL, includes the 
physical, emotional, cultural/social, and emotional aspects of a person, among other things. 
 
The term, Health-related quality of life, was proposed by Kaplan and Bush to distinguish between health 
effects and other factors influencing a subject’s perception of his/her health (120). Different studies have 
investigated QOL in participants receiving treatment for TB or those receiving treatment for HIV (121-
127), but studies investigating the QOL of patients co-infected with TB and HIV and receiving 
concomitant therapy are few and far between (128-130).  
 
QOL and tuberculosis 
The possibility of problems related to side effects when receiving TB treatment (131, 132), may be 
worsened by concomitant HIV therapy, thereby affecting QOL. A comprehensive assessment of patients’ 
health status is essential to consider the overall impact of TB on health and what perception the patient 
has of his/her wellbeing, as well as routine clinical, radiological and bacteriological assessments (133). 
According to Dhuria et al., this can be performed by measuring the QOL that has several dimensions 
(134). Carr et al. discuss the determination of QOL through expectations or experience (135) relating to 
HQOL as the “gap between our expectations of health and our experience of it”. Because of different 
expectations, people may adapt to the change in their health by altering expectations. This may reduce the 
minimal important difference (MID), defined by Jaeschke et al. as, the smallest difference in score in the 
domain of interest that patients perceive as a change in score that mandate a change in the patient’s 
management (136). The individual is deemed the main person reporting his/her subjective experience. 
They concluded that it was likely that patients have different standards about the changes in symptoms 
that they view as important or trivial. When conducting research on HRQOL, it would be important to 




There are several reviews of the literature on QOL in patients with TB. The review by Kastien-Hilka et al 
found that TB and HIV therapy affected the QOL of patients negatively, including adherence to 
treatment(137). Another review by Bauer et al reported on the QOL of active TB and latent TB infection 
(LTBI) using different QOL instruments and found that patients with active TB had poorer QOL than 
those with LTBI(138).   
 
There are two different types of QOL instruments, disease-specific and generic instruments. The generic 
instruments are general and may miss disease traits in measuring HRQOL, while disease-specific 
instruments are more focused on the specific disease symptoms and effects. Among the generic 
instruments are the self-administered instruments such as the sickness impact profile (SIP, and the Medical 
Outcomes Study Short Torm-36 (MOS). The SIP, with 136 questions, was developed in 1976, and the 
MOS, developed in 1990, has different versions including the SF-36 which is the most widely used and 
well known. These instruments have demonstrated reliability and validity in HIV-infected patients. Table 
1 gives 12 different instruments, what they measure and advantages and disadvantages in co-infected HIV 
and TB patients. In a review by Guo et al., SF-36 was the most used HRQOL instrument among TB 
patients (126). In addition, the Linear Analogue Self-Assessment (LASA) QOL; the Nottingham Health 
Profile (NHP); the McMaster Health Index Questionnaire (MHIQ); the Cooperative Information Project 
(COOP); the WHO Quality of Life (WHO-QOL); the Health Utility Index (HUI); and the Reintegration 
to Normal Living Index (RNLI), are some of the available generic QOL instruments. 
 
Disease-specific instruments for TB are not easily available. Only the St George’s Respiratory 
Questionnaire, a specific questionnaire for respiratory diseases is more widely known. As a standardised, 
self-administered questionnaire, it is used to measure impaired health and perceived HRQOL in lung 
disease (139). This instrument consists of 76 items, with a symptom, activity, impact and a total score. 
The ‘symptoms score’ assesses the patients’ perception of their recent (four weeks) respiratory problems; 
the ‘activity’ score measures the individuals’ current (in)ability to perform daily physical activity; the 
‘impacts’ score evaluates the whole range of (in)abilities the individuals’ currently experience in their life 
because of respiratory problems, and the ‘total’ score sums and weighs all the former components. 
 
Dhingra and Rajpal measured HRQL with the DR-12, a new TB-specific instrument, which was developed 
in India and first published in 2003 (133, 140). Composed of 12 items, seven cover TB symptoms (i.e., 
cough and sputum, haemoptysis, fever, breathlessness, chest pain, anorexia, and weight loss) and five 
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relate to socio-psychological and exercise adaptation (i.e., emotional symptoms/depression, interest in 
work, household activities, exercise activities, and social activities). All 12 response options are presented 
on a scale of three points with equal weights given to each item when calculating scores.  
 
























SIP  1976 Physical: ambulation, mobility, body 
care Psychosocial: social interaction, 
communication, alertness, emotional 
behaviour 
Other: sleep/rest, eating, work, home 
management, recreation and pastimes. 
















Not HIV or TB-




QWB 1980+ Self-care, mobility, 
institutionalisation, social activities, 
reports of symptoms and problems 
(physical and mental) 
(Formerly Index of Well-being scale). 










usal and HIV 
Can be used 
to calculate 
cost-utility 
Not HIV or TB-
specific; takes longer 




1990 Physical functioning, role limitations 
caused by physical problems, social 
functioning, body pain, general 
mental health, role limitations caused 
by emotional problems, vitality, 
general health perceptions. 
36 items; 10 
min Self-
administered 





Not HIV or TB-
specific 
LASA  1980+ Energy level, daily activity, overall 
QOL. 
3 items; 1–2 
min Self-
administered 





time; easy to 
administer 
Not HIV or TB-
specific; not as 
reliable as multi-
item measures; may 
not be truly linear 
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NHP 1970+ 6 domains of experience: pain, 
physical mobility, sleep, emotional 
reactions, energy, social isolation; 7 
domains of daily life: employment, 
household work, relationships, 
personal life, sex, hobbies, vacations. 
45 items; 5–15 
min Self-
administered 










1980+ Activity, daily living, health, support, 
outlook on life. 










sensitivity in HIV 
patients 
MHIQ 1970+ Physical: mobility, self-care, 
communication, global physical 
functioning 
Social: general well-being, 
work/social role performance, social 
support and participation, global 
social functioning. 






Has been used 









1987 Physical condition, emotional 
condition, daily work, social 
activities, overall condition, change in 
condition, pain, general HRQOL. 




















1994 The WHOQOL-100 produces scores 
relating to particular facets of quality 
of life (e.g. positive feelings, social 
support, financial resources), scores 
relating to larger domains (e.g. 
physical, psychological, social 
relationships) and a score relating to 














TB, HIV BREF is easy 
to administer 






A standardised, widely validated and 
tested, instrument that provides a 
simple descriptive 5-dimensional 
profile (EQ-5D), a utility-based index 
of health status, and the EQ-Visual 
Analogue Scale (EQ-VAS). The EQ-
5D descriptive system defines health 
in terms of five domains: mobility, 
self-care, usual activities, pain or 
discomfort and anxiety or depression. 
Self-
administered 
TB, HIV  Not TB specific 
RNLI 1980+ The RNLI contains 11 items, on 
which respondents rate their 
satisfaction of their physical, 
emotional and social lives on 100 mm 
visual analogue scales, where ‘0’ 
means ‘does not describe my 
situation’ and ‘100’ means ‘describes 
my situation’. For the total scores, 
items scores are summed and 






 Not TB specific 
HUI 1980+ The HUI3 system comprises eight 
attributes with five to six levels per 





 Not TB specific 
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are multi-attribute health classification 
systems, for which multi-attribute 
preference functions have been 
developed in Canada. They provide a 
comprehensive instrument for use in 
economic evaluation and population 
health survey studies. 
SIP: sickness impact profile; QWB: quality of well-being scale; MOS SF-36: medical outcomes study short form-36; LASA: linear analogue self-assessment; 
QOL: quality of life; NHP: Nottingham health profile; MHIQ: McMaster health index questionnaire; COOP: cooperative information project; HRQOL: health-
related quality of life. WHO-QOL: World Health Organization, quality of life; HUI: health utility index; RNLI: reintegration to normal living index  
 
HIV/AIDS HRQOL instruments  
The HIV-QOL Questionnaire (HIV-QL31) was designed to assess the effects of clinical interventions in 
the field of clinical and public research in the HIV-infected (141). The HIV-QL31 had 31 items that would 
enable the measurement of the impact of HIV infection on the lives of individuals from their subjective 
view.  
 
Davis and Pathak evaluated four HIV-specific QOL instruments for their psychometric properties (142). 
They chose the HIV/AIDS Quality of Life (HAT-QOL), a 42-item self-administered instrument based on 
patient-reported concerns; the Medical Outcomes Study HIV (MOS-HIV); Functional Assessment of HIV 
Infection (FAHI) and the HIV Overview Problems Evaluation System (HOPES). They used criteria that 
included administration, content, depth, reliability, validity, and responsiveness. They could not decide on 
the best instrument to use for measuring QOL in HIV-infected patients. However, the FAHI instrument 
has been more widely used than the other three. The FAHI was originally developed using the Functional 
Assessment of Cancer Therapy, which measures generic and disease-specific HRQOL for patients with 
such chronic diseases as cancer (143), and later adapted to include HIV/AIDS. This instrument is 
discussed below.  
 
Other disease-specific instruments are, the General Health Self-Assessment (GHSA); the AIDS Health 
Assessment Questionnaire (AIDS-HAQ) and Multidimensional Quality of Life Questionnaire for 
HIV/AIDS (MQOL-HIV). The FAHI questionnaire has already been translated into isiZulu which is the 
language used by most of the study population. This instrument measures HRQOL specifically in HIV-




FAHI instrument  
The FAHI evaluates physical well-being, functional and global well-being, emotional well-being/living 
with HIV, social well-being, and cognitive functioning, yielding a total score and individual subscale 
scores. The FAHI has excellent psychometric properties (144). Although it has not been used extensively, 
it has been used to demonstrate significant improvement in HRQOL following treatment of anaemia with 
recombinant human erythropoietin (epoetin alfa) in HIV-infected patients (145), and effects of etravirine 
versus placebo (146). 
 
The FAHI, an HIV-specific tool, was originally developed using the Functional Assessment of Cancer 
Therapy (FACT), which measures generic and disease-specific HRQOL for patients with chronic diseases 
such as cancer. To better capture aspects important to the HIV-infected population, a revised version 
comprising 27 items from the original core instrument and 17 new items reflecting specific HIV/AIDS 
concerns was developed. Therefore, the FAHI contains 44 items and can be used for self-administration. 
The FAHI evaluates cognitive functioning, social, physical, functional and global well-being and 
emotional well-being/living with HIV. The FAHI is available in ten languages, including isiZulu, the 
language mostly used among the study population in KwaZulu-Natal.  
 
Table 2: Summary of FAHI instrument items 






Physical well-being 13 positive adverse 52 
Emotional well-being 10 positive adverse 40 
Functioning and global 
well-being 
13 adverse positive 52 
Social well-being 8 adverse positive 32 
Cognitive functioning 3 adverse positive 12 
Total 47   182 
 
2.3.3.1 Adverse events and QOL 
Safety of treatment has been defined by the number and severity of adverse events experienced by patients 
taking the treatment concerned. Tolerability has been defined by the patients deciding to discontinue 
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treatment because of not being able to handle the adverse effects of treatment. If adverse events of 
treatment are so serious that the patient should stop treatment, it can be safely assumed that the QOL of 
that patient is affected. Multidrug therapy of any kind can be complicated by overlapping toxicity profiles, 
such that it may be difficult to determine which of several agents being used caused a specific adverse 
effect (77). TB therapy-specific adverse events include gastrointestinal, liver, musculoskeletal and 
dermatological side effects. In a study by Shargie et al. on smear-positive patients, only 6.7% of defaulters 
were related to adverse side effects (147). While in a study by Breen et al. to assess the frequency of 
serious adverse events (SAEs) and treatment interruption, SAEs were recorded in 40% HIV-infected and 
26% HIV-uninfected individuals (76). The most common SAEs were peripheral neuropathy and persistent 
vomiting among the co-infected patients, although ATT interruption was similar in the two groups. In 
most patients, this was because of hepatotoxicity. In a study by Miller et al. on reasons for default in South 
African patients taking ARVs, adverse events had little influence in patients’ decisions to stop treatment, 
while transport costs and time needed for treatment were the most common reasons (148).  
In Table 3, side effects and drugs that potentially cause these are shown.  
 
Table 3: Side effects of anti-tuberculosis treatment and antiretroviral therapy 
Side effect Possible causes 














Nevirapine, HIV-1 protease 
inhibitors, immune   reconstitution 
after starting antiretroviral   therapy 
among patients with chronic viral 
hepatitis 
Leukopenia, anaemia Rifabutin, rifampicin Zidovudine 
 
In studies, it has been shown that most patients will tolerate ATT well, experiencing only minimal adverse 
events, however, some patients may experience severe incapacities as a result of adverse events of either 
ATT, ARV therapy or combined therapy (149, 150). Yee et al. found that the incidence of pyrazinamide-
induced hepatotoxicity and rash during treatment for active TB was substantially higher than with the 




In a prospective study, Lanternier et al. compared the incidence of adverse events related to ATT in HIV-
seropositive and seronegative patients (152). Their results showed that the risk of adverse reactions is 
significantly higher in HIV-infected patients. According to Marra et al., patients mostly complained about 
side effects related to specific symptoms that were thought to be related to taking specific drug regimens 
(127). They found that most common complaints were related to gastrointestinal disturbances (nausea, 
vomiting and diarrhoea) and itchiness caused by INH. Just as side effects of ATT have been reported as 
responsible for non-adherence to therapy, the same has been reported of HIV therapy (153, 154). 
 
Deribew et al. studied the impact on QOL of TB-HIV co-infection (130, 155). They found that co-infected 
patients had significantly lower QOL (WHOQOL-HIV) in all domains than HIV patients without TB. 
However, there was no mention of adverse drug effects. Depression was the main reason for decreased 
QOL. Duyan et al. reported social factors as the most common reason for lower QOL, adverse effects of 
TB were reported to be the greatest in poor people (156). According to Chamla, the associated factors of 
QOL were age, sex, anaemia, white blood cells and the number of symptoms. There was no mention of 
side effects in this study. 
 
2.3.3.2 Hepatotoxicity 
Both anti-TB drugs and ARVs cause hepatic side effects in varying degrees. Besides the gastrointestinal 
side effects, hepatotoxicity seems to be the most common adverse side effect of both therapies. Sharma et 
al. 2004, conducted a study evaluating the clinical and immunogenetic risk factors for the development of 
hepatotoxicity during ATT treatment, and found that the patients that developed hepatotoxicity were 
comparatively older, had lower pre-treatment serum albumin, and a higher frequency of radiographically 
moderately/far advanced disease than the patients who did not (92). 
 
2.3.3.3 Impaired lung function and QOL 
In a study conducted in South Africa by Plit et al., new cases of pulmonary TB were studied prospectively 
over six months to confirm the hypothesis that treatment improves lung function despite the development 
of residual fibrosis (157). These researchers found that over half the patients had residual respiratory 
function abnormalities at the end of treatment. Pulmonary TB (PTB) has been mentioned as one of the 
contributing factors of chronic lung disease which is associated with cardiovascular, respiratory and all-
cause mortality (158, 159). Maguire et al. conducted a study to quantify the extent to which PTB 
58 
 
contributes to permanent lung damage and its influence on exercise tolerance and QOL in a region with a 
high number of cases of PTB and chronic lung dysfunction (160). This study concluded that while QOL 
and exercise tolerance appeared to improve, longer-term clinically significant abnormalities in lung 
function were observed. Moderate reduction in lung function and exercise tolerance attributable to PTB 
in individuals represent a high burden of respiratory morbidity in high-burden areas. The factors discussed 
above indicate that evaluating HRQOL in TB-HIV co-infected patients is important to understand how 
patients view of their condition and may assist the clinical staff in prescribing relevant interventions for 
the patients. 
 
2.3.4 TB diagnosis using urine lipoarabinomannan  
TB diagnosis remains a problem for every clinician, in spite of decades of advances in clinical medicine. 
First there has to be clinical suspicion of disease, usually based on the patient’s report of signs and 
symptoms. Unfortunately, the signs and symptoms are not specific for active TB as they may be present 
in other conditions. The age-old use of chest radiography and sputum examination has its own problems, 
especially where there is co-infection with HIV. According to Shluger and Rom, upon suspicion of TB a 
chest radiography and sputum examination for mycobacteria, but they continue to say that the radiographic 
picture may be atypical for patients co-infected with HIV, with some being normal (161).  The search for 
a TB diagnostic is ongoing and an ideal diagnostic is one that can be used at point of care, is easy to use 
and gives results immediately (162) and is not dependent on sputum production. There have been advances 
since then, leading to newer diagnostics such as Xpert MTB/RIF and urine LAM. The advantage of urine 
LAM over Xpert MTB/RIF is that it is easier to obtain a urine rather than a sputum specimen. Although 
Xpert MTB/RIF has been tested in other body fluids such as urine, blood and cerebrospinal fluids (163-
165), which showed that Xpert MTB/RIF can be useful for the diagnosis of extrapulmonary TB. However, 
some samples are not easy to get as they need invasive procedures. Urine is the easiest to obtain and 
although Xpert can detect TB in urine, the LAM test can do that faster using the strip test (166). 
 
As a result of the difficulty in diagnosis of smear-negative and suspected extra-pulmonary TB, often these 
patients are started on antibiotics and observed for responses. If there is no response, ATT is then started 
while waiting for sputum culture results. In 2007, the WHO released new guidelines on the management 
of smear-negative TB patients. These guidelines allow for start of ATT within 3 days of admission in 
patients who fulfil the criteria for smear-negative pulmonary TB (167).  However, several studies 
reviewing the use of the guidelines have found that they are not followed as they should (168) and there 
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some limitations for low income countries where culture processing is still unsafe (169). In addition, 
culture results can take up to 6 weeks to be available, or may be contaminated. Several studies have been 
conducted to evaluate the use of urine LAM to diagnose TB in seriously-ill individuals with low CD4 
counts. Although the sensitivity varies with the level of immunosuppression, a new test from Fujifilm 
promises to have improved sensitivity while maintaining specificity (170).  
 
Recently, urine diagnosis of TB using LAM has been advocated and WHO guidelines developed for its 
use in HIV-infected individuals with severe immunosuppression (171). Urine LAM is a test based on the 
detection of mycobacterial LAM antigen. LAM is one of the lipopolysaccharide components of the cell 
wall of mycobacterium tuberculosis (172),  some studies have explored the detection of LAM in 
serological fluids and a number of studies have explored the detection of this antigen within blood, sputum, 
pleural fluid and urine as a means for TB diagnosis (15, 163, 173). 
 
The review by Minion et al found that urine LAM sensitivity was 3–53% higher in HIV-positive than 
HIV-negative subgroups; sensitivity was highest with advanced immunosuppression (18). This finding 
has been further confirmed in a review by Lawn, suggesting that the potential utility of LAM ELISAs are 
at point of care, within an outpatient setting or hospital ward (174). A further benefit of the urine LAM 
test is that it can be used by health care workers without any laboratory training nor diagnostic hard-ware 
or electricity. A review by Gupta-Wright found that a positive urine LAM test was associated with 
increased mortality in HIV-TB patients (175). In a study by Peter et al, LAM identified a different subset 
of patients with more advanced immunosuppression and greater disease severity (176). Urine LAM test 
has been research extensively there is consensus in its usefulness in HIV-infected patients with severe 
immunosuppression (21, 166, 176-178).  
 
This chapter has dealt with the literature on a combination of biomarkers, NAT2 genotype, QFT-GIT and 
urine LAM, HRQOL for diagnosis and treatment monitoring of combined ATT and ARV in co-infected 
patients. Much work has been done on each of the subjects and using this information to evaluate whether 
these can be used together is important. The knowledge gap within specific groups in diagnosis of active 
and Latent TB and treatment monitoring of these. Diagnosis of smear-negative TB, sputum scarce groups 
and HIV-infected individuals is still wide and need investigation.  
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N-acetyltransferase 2 genotypes among Zulu-Speaking South Africans and isoniazid and N-acetyl-
isoniazid pharmacokinetics during anti-tuberculosis treatment  
 
The possibility of individualised medicine has been investigated for the treatment of TB. NAT2 
genotyping has the possibility of identifying patients at increased risk of adverse events to isoniazid. 
Knowing the prevalence of these polymorphisms in a population may help determine the best treatment 
dosing to reduce the experience of these adverse events. 
 
Thesis Objective 1 – Assessment of polymorphisms in NAT2 in participants receiving combined TB-HIV 
therapy. 
Sub-objective 1.1- Determine genetic polymorphism frequency in the TB-HIV co-infected 
isiZulu-speaking black patients. 
Sub-objective 1.2 - To evaluate the relationship of genetic polymorphisms to drug levels and inter-
individual variability of INH. 
 
Below, the manuscript responding to this thesis objective and published in Antimicrobial Agents and 
Chemotherapy journal is presented as published. The format has been changed to be consistent with the 
thesis format.   
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Background: Distribution of N-acetyltransferase 2 (NAT2) polymorphisms varies considerably among 
different ethnic groups. There is limited information on NAT2 single nucleotide polymorphisms in the 
South African population. We investigated NAT2 polymorphisms and their effect on isoniazid 
pharmacokinetics in Zulu black HIV-infected South Africans in Durban, South Africa.  
Methods: Participants with culture-confirmed pulmonary tuberculosis (TB) were enrolled from two 
unrelated studies. Participants with culture-confirmed pulmonary tuberculosis (TB) were genotyped for 
NAT2 polymorphisms 282C>T, 341T>C, 481C>T, 857G>A, 590G>A and 803A>G using Life 
Technologies pre-validated Taqman assays (Life Technologies, Paisley, UK). Participants underwent 
sampling for determination of plasma isoniazid and N-acetylisoniazid concentrations.  
Results: Among the 120 patients, 63/120 (52.5%) were slow metabolisers (NAT2*5/*5), 43/120 (35.8%) 
had intermediate (NAT2*5/12), and 12/120 (11.7%) had rapid genotype (NAT2*4/*11, NAT2*11/12 and 
NAT2*12/12). NAT2 alleles in this study were *4, *5C, *5D, *5E, *5J, *5K, *5KA, *5T, *11A, *12A/12C 
and *12M. NAT2*5 was the most frequent allele (70.4%) followed by NAT2*12 (27.9%). Fifty-eight of 
60 participants in study 1 had PK results. The median area under the concentration-time curve from 0 to 
infinity (AUC0-∞) was 5.53 (interquartile range [IQR] 3.63 to 9.12 µg/ml/hr) and maximum concentration 
(Cmax) was 1.47 µg/mL (IQR, 1.14 – 1.89 µg/ml). Thirty-four of 40 participants had both PK results and 
NAT2 genotyping results. The median AUC0-∞ 10.76 µg/ml/hr (IQR, 8.24 – 28.96 µg/ml/hr) and Cmax was 
3.14 µg/ml (IQR, 2.39 – 4.34 µg/ml). Individual polymorphisms were not equally distributed, with some 
represented in small numbers.  Genotype did not correlate with the phenotype, with those with rapid 
genotype showing higher AUC0-∞ than slow but not significant (p=0.43).  
Conclusion: There was a high prevalence of slow acetylator genotypes, followed by intermediate then 
rapid acetylator genotypes. The poor concordance between genotype and phenotype suggests that other 
factors or genetic loci influence INH metabolism, and these warrant further investigation in this 
population.  
 





Tuberculosis (TB) remains a leading cause of global morbidity and mortality, with approximately 10 
million cases and 1.5 million deaths in 2018 (1). South Africa is a high TB burden country with an 
estimated 301,000 cases in 2018. The so-called ‘short-course’ treatment regimen recommended in 
international guidelines; consisting of 6 months of rifampicin and isoniazid, supplemented by 
pyrazinamide and ethambutol in the first 2 months, has remained largely unchanged for several decades. 
Whilst this regimen can achieve high relapse-free cure rates, a range of host and mycobacterial factors can 
influence treatment outcomes. There is increasing evidence that inter-individual variability in the 
pharmacokinetics (PK) of drugs within this regimen lead to heterogeneity in clinical outcomes (2, 3).  
 
Pharmacogenomics (PG) describe one cause of PK variability due to polymorphisms in drug metabolising 
enzymes and transporters. During TB treatment, isoniazid is the paradigmatic case. Isoniazid is acetylated 
to its major metabolite, N-acetyl-isoniazid (AcINH), by the action of hepatic N-acetyltransferase 2 
(NAT2). AcINH is subsequently rapidly hydrolysed to acetyl-hydrazine, which is also acetylated, to 
diacetyl-hydrazine, by the action of NAT2 (4). Accumulated acetyl-hydrazine can be oxidised to form 
other, potentially hepatotoxic metabolites (4-6). Moreover, accumulated isoniazid can be metabolised by 
an alternative pathway where it is first hydrolysed to hydrazine, which has also been implicated in liver 
injury, before acetylation to acetyl-hydrazine, again by NAT2 (4, 7). Hence, the activity of NAT2 both 
dictates metabolism of isoniazid, and determines the availability of potentially hepatoxic hydrazine and 
acetyl-hydrazine metabolites. Within the 870-base pair NAT2 gene a number of low-activity single 
nucleotide polymorphisms (SNPs) have been characterised. The NAT2 genotype has been shown to 
determine the rate of acetylation by NAT2 in several populations (8). Individuals homozygous for the wild-
type alleles are characterised as ‘rapid’ acetylators (RAs), those homozygous for low-activity SNPs as 
‘slow’ acetylators (SAs) and heterozygotes as ‘intermediate’ acetylators (IAs) (9-13). SAs have a higher 
incidence of side-effects, particularly drug-induced hepatitis, during TB therapy, presumably due to higher 
levels of hepatoxic metabolites (14-20). Amongst the first-line TB drugs isoniazid has the greatest early 
bactericidal activity (EBA) and isoniazid PK parameters have been associated with rates of cure, 
sterilisation and acquired drug resistance (3, 21-27). A link between rapid acetylation and increased risk 
of poor treatment outcomes has been reported (28, 29). 
 
NAT2 genotype is known to differ amongst ethnic groups; with approximately 40-70% of Caucasians, 
Indians and African Americans characterised as SAs, versus only around 10% of Asian populations (30-
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42). NAT2 genotype is not well characterised in the communities where TB is most prevalent, particularly 
in sub-Saharan Africa. South Africa has several black ethnic groups and few have been studied (43-45). 
Bach et al. characterised 40% of a Zulu population as phenotypically slow acetylators but these findings 
have not been replicated, or informed by genotypic analysis (44). Moreover, South Africa has a high HIV 
prevalence and discordant relationships between NAT2 genotype and isoniazid acetylator phenotype have 
been described amongst individuals living with HIV in other settings (46, 47).  
 
We therefore characterised the relationship between NAT2 genotype, isoniazid and N-acteyl-isoniazid PK 




Participants, study treatment and sample collection 
Participants from two unrelated PK studies were included (48, 49). Both studies recruited black, Zulu-
speaking adults living with HIV from KwaZulu-Natal, South Africa, between March 2007 and April 2010. 
Study 1 was entitles “Bioavailability of the WHO Formulation Rifafour Containing Isoniazid, Rifampicin, 
Pyrazinamide, Ethambutol and the WHO recommended First Line Anti-Retroviral Drugs Zidovudine, 
Lamivudine, Efavirenz Administered to New TB Patients at Different Levels of 
Immunosuppression.”(50). The results of this study have been previously reported (49). As shown in Table 
9, for the purposes of this analysis, we used samples collected on day 1 of the study after an overnight 
fast, at pre-dose, 1, 2, 4, 5, 6, 8, and 12 hours post dose, with the samples  being analysed for INH and 
AcINH for 60 participants with microbiologically proven pulmonary TB (by a positive sputum culture or 
smear) who received a standard first line TB regimen consisting of an FDC, as described above. The INH 
dose was 150 mg, 225 mg, 300 mg and 375 mg per day for participants with weight 30 -37 kg, 38– 54 kg, 
55 – 70 kg, and 70 kg and above, respectively. Each participant had blood collected NAT2 genotyping. In 
addition, genotyping was performed on a further 20 participants without TB who were initially recruited 
to this study (49).  
 
Study 2, entitled “Pharmacokinetics of Rifabutin Combined with Antiretroviral Therapy in the Treatment 
of Tuberculosis Patients with HIV Infection in South Africa,” was a randomised controlled trial of two 
different rifabutin doses co-administered with lopinavir/ritonavir-based antiretroviral therapy (51, 52). 
The participants initially received 6 weeks of standard intensive-phase treatment, followed by 2 weeks 
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with rifabutin 300mg daily replacing rifampicin. After 2 weeks of the continuation phase, during which 
participants received only isoniazid and rifabutin (both 300mg daily), PK sampling was carried out. 
Individuals were fasted overnight, and a standard hospital breakfast served 2 hours after drug ingestion. 
Sampling was conducted pre-dose and at 2, 3, 4, 5, 6, 8, and 12 and 24 hours after drug intake, with 
samples analysed for INH and AcINH for 40 participants. NAT2 genotyping was performed on 40 
participants with 34 participants having both PK sampling and genotyping.  
 
All participants receiving anti-TB treatment in both studies were given pyridoxine for peripheral 
neuropathy prophylaxis and patients with CD4 counts below 200 cells/mm3 received cotrimoxazole. No 
participants were on antiretrovirals at the time of PK sampling. Both studies were approved by the South 
African Medicines Control Council (SAMCC), Biomedical Research Ethics Committee (BREC) of the 
University of KwaZulu-Natal (Study 1- E294/05; Study 2- BFC011/07) and the South African Medical 
Research Council (SAMRC) ethics committee. Study one was also approved by the WHO Ethics Research 
Ethics Committee. Written informed consent was obtained from all participants. 
 
NAT2 genotype procedures 
Total Genomic DNA was isolated from whole blood using the QIAamp DNA mini kit (Qiagen, Crawly, 
UK) according to manufacturer’s instructions. Participants were genotyped, using the DNA Engine 
Chromo4 system (Bio-Rad Laboratories, Hercules, CA) and Opticon Monitor v.3.1 software (Bio-Rad 
Laboratories), for 6 NAT2 SNPs; 282C>T, 341T>C, 481C>T, 857G>A, 590G>A and 803A>G using Life 
Technologies pre-validated probe-based Taqman assays as per manufactures instructions (Life 
Technologies, Paisley, UK). Each participant sample was analysed in duplicate.  
 
Haplotype assignment and acetylator genotype inference 
Haplotype assignment from probe-based SNP data is poorly described in African populations. We elected 
to employ an unbiased PHASE analysis, which takes the dataset as a whole to assign the most likely 
haplotype for each individual, alongside a probability for this assignment (53, 54). Haplotype for each 
individual and acetylator genotype for each haplotype were defined as per the NAT Gene Nomenclature 
Committee (http://nat.mbg.duth.gr/Human%20NAT2%20alleles_2013.htm) (55). Individuals with two 
rapid alleles were defined as RAs, those with two slow alleles as SAs and those with one fast and one 




Isoniazid and N-acetyl-isoniazid PK and phenotype inference 
Blood samples were collected and placed on ice immediately, before centrifugation within 60 minutes, 
immediate separation and storage of plasma at -70°C until analysis. Concentrations of isoniazid, AcINH 
and the 6-aminonicotinic acid internal control were quantified using validated high-performance liquid 
chromatography and tandem mass spectrometry (HPLC-MS/MS). Sample preparation included a protein 
precipitation with acetonitrile and subsequent dilution with water. Analytes were chromatographically 
separated using a Waters Exterra C18, 3.5µm, 50mm x 2.1mm column and detected using the AB Sciex 
5500 Q-Trap mass spectrometer. All analytes were analysed isocratically with an acetonitrile/water/0.1% 
formic acid mobile phase. isoniazid, AcINH and the internal standard were analysed at mass transitions 
of the precursor ions (m/z) 137.9, 180.1 and 138.7 to the product ions (m/z) 66.0, 78.6 and 50.9, 
respectively. Chromatographic data acquisition, peak integration and quantification of analytes was 
performed using Analyst® software version 1.5.2. We constructed time-concentration curves in the PK 
package in R for windows (version 3.5.1). We characterised the isoniazid and N-acetyl-isoniazid PK 
parameters maximum concentration (Cmax), time to maximum concentration (Tmax), area under the 
concentration curve from zero to infinity (AUC0-∞), apparent oral clearance (CL) and elimination half-life 
and compared Cmax to published efficacy targets (56). AUC0-∞ was calculated using the trapezoid rule, 
apparent oral clearance estimated by dose / AUC0-∞ and elimination half-life was estimated by regression 
analysis of log concentrations of the terminal exponent of elimination. We analysed the ratio of log AcINH 
to log isoniazid at two and four hours to assess acetylation phenotype. 
 
Sample processing and HPLC-MS was initially conducted in 2010 for Study 1. Samples remained in 
storage and were later moved to a new storage facility before they were shipped to a different laboratory 
for determination of isoniazid and AcINH concentrations as above (having previously only had isoniazid 
concentrations determined). To confirm the Integrity of these samples we compared the isoniazid AUC0-
∞ of the current analysis with that previously reported on the same samples analysed in 2010. 
 
Statistical methods 
All data were entered in Epidata and transferred to either Stata (version 14) or R for windows (version 
3.5.1) for statistical analysis. Demographic characteristics were presented as frequencies and percentages 
for categorical variables, and as means with standard deviations for continuous variables. Descriptive PK 
data was described as median and inter-quartile ranges. Cmax and AUC0-∞ were log-transformed prior to 
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comparison between genotypes. PK parameters were compared, by genotype, using the Wilcoxon rank-
sum test or Kruskal–Wallis test. 
 
Hepatic adverse events 
Hepatic adverse events were defined as elevated alanine transaminase (ALT) and aspartate transaminase 
(AST) levels, elevated alkaline phosphatase levels, and elevated total bilirubin levels, graded per the 
Division of AIDS, NIAID, NIH, toxicity table for grading the severity of HIV-positive adult adverse 
events. 





One hundred and twenty-two individuals living with HIV participating in two PK studies were included 
in the study. Eighty participants in study 1 were included in the NAT2 genotyping analysis and 60 in the 
PK analysis while 40 participants in study 2 were included in the PK analysis and 40 participants included 
in NAT2 genotyping analysis (with 34 individuals having both PK and genotype data). Key characteristics 
are outlined in Table 4.  
Table 4: Demographic characteristics 
Characteristic Study 1 (n=80) Study 2 (n=40) Overall (n=120) 
Demographics       
Median (IQR) age (yr) 33 (18-48)  33.6 (24-53) 33.1 (18-53)  
No. (%) male participants 36 (45)  24 (60.0) 60 (50) 
No. (%) participants of Zulu ethnicity   80 (100) 40 (100%)  120 (100) 
        
Mean (SD) weight (kg) 58.7 (11.9)  58.9 (9.7) 58.7 (11.2) 
Mean (SD)BMI  23.0 (5.2)  23.1 (3.9) 23.1 (4.8) 
No. (%) participants with BMI <18.5  13 (16.3)  2 (5.0) 15 (12.5) 
        
Median CD4 (range) 210.5 (10-500)  128 (61 – 199) 161 (10-500) 
CD4 < 200 (%) 40 (50)  40 (100) 80 (66.7) 
 
Participants in study 1 included 60 with pulmonary TB and HIV co-infection; 40 with CD4 count >200 
cells/mm3 and, 20 with CD4 count <200 cells/mm3 as well as 20 participants with HIV and without TB 
(who contributed only genotype data). All 40 participants in study 2 had TB and HIV co-infection, with a 
CD4 count of 200 cells/mm3 or below. In the combined studies, 66.7% of participants had CD4 counts 
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<200 cells/mm3 and 33.3% had CD4 count >200 cells/mm3. The Median age was 33.1 years (IQR 18-53). 
Only 15 (12.5%) of patients had a BMI < 18.86 kg/m2. 
 
NAT2 genotype and deduced phenotype 
One hundred and twenty participants (80 from study 1 and 40 from study 2) were genotyped. Haplotype 
assignment and deduced acetylator phenotype for each individual is shown in Table 6. Allele and 
haplotype frequencies and deduced phenotypes are outlined in Tables 11-13. We identified 12 different 
alleles in the population. The most common allelic group was NAT2*5 (70.4%) followed by NAT2*12 
(27.9%). From the NAT2*5 group NAT2*5C (21.3%), NAT2*5J (17.5%), NAT2*5D (14.6%) and 
NAT2*5K (10.4%) were the most common. The NAT2*12 group was predominantly NAT2*12C. The 
deduced phenotype was 11.7% rapid, 35.8% intermediate and 52.5% slow acetylators (Table 9).  
Table 5 Pharmacokinetic time points and dosing 
Study Schedule of pharmacokinetic 
sampling (day of TB treatment) 
Treatment 
Study 1  
 
Days 1; with sampling pre-dose and at 
1, 2, 4, 6, 8, 12 hours after the dose. 
Four drug FDC formulation (EMB/ RMP/ INH/ PZA 




 Enrolment at week 6 and standard weight- band-based 
treatment with RMP, INH, PZA and EMB (as in study 1) 
 At week 6 and  7: RMP replaced with RFB 300 mg daily 
Day 63 (after 2 weeks on continuation 
phase RBN-INH) with sampling pre-
dose and 2, 3, 4, 5, 6, 8, 12 and 24 
hours after the dose. 
At week 8 and 9, RFB 300 mg and INH 300 mg 
aPK= pharmacokinetics; RMP=rifampicin; PZA=pyrazinamide; EMB=ethambutol; FDC=fixed dose combination; RFB, rifabutin 
(Mycobutin, Pfizer). 
bParticipants weighing 30 to 37 kg received 2 tablets, those weighing 38 to 54 kg received 3 tablets, those weighing 55 to 70 kg received 4 
tablets, and those weighing >70 kg received 5 tablets. 
 
Isoniazid and N-acetyl-isoniazid PK 
As above, to assess sample integrity for sample 1 we compared the AUC0-∞ of the current analysis with 
that previously reported on the same samples analysed in 2010. The median (IQR) AUC0-∞ was 5.53 
(3.63 – 9.12), processed at University of Cape Town (UCT) in 2009 and 5.70 (3.85 – 7.94), processed at 
Africa Health Research Institute (AHRI) laboratory in 2014, suggesting that the integrity of the samples 
was maintained for isoniazid, but cannot be confirmed for N-acetyl-isoniazid.  
 
Participants in study 1 showed rapid absorption, with a isoniazid median time to maximum concentration 
(Tmax) of 1 hr (IQR, 1 -2h). Isoniazid exposure was variable among individuals, with the median maximum 
concentration Cmax being 1.47 (IQR) (1.14 – 1.85) µg/ml and AUC0-∞ 5.53 µg.h/ml (3.63 – 9.12 µg.h/ml). 
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Median (IQR) elimination half-life was relatively slow at 2.27 h (1.69 – 3.56 h). We compared these 
isoniazid PK measures to published targets; 98.28% (57/58) failed to attain the minimum 2-hour plasma  
Table 6. NAT2 diplotypes and genotypes and deduced phenotype in the study group. 
Observed Diplotype† n Genotype Phenotype 
-20000 1 5D/5K SLOW 
000020 1 12A/12A RAPID 
001000 1 4/11A RAPID 
001020 6 12A/12C RAPID 
002010 2 11A/12C RAPID 
002020 4 12C/12C RAPID 
01-020 1 5C/12C INTERMEDIATE 
010010 1 5D/12A INTERMEDIATE 
010020 2 5C/12A INTERMEDIATE 
010110 2 5E/12A INTERMEDIATE 
011010 3 5D/12C INTERMEDIATE 
011020 15 5C/12C INTERMEDIATE 
011110 3 5E/12C INTERMEDIATE 
0200-0 1 5C/5D SLOW 
020000 1 5D/5D SLOW 
020010 10 5C/5D SLOW 
020020 3 5C/5C SLOW 
020100 3 5D/5E SLOW 
020110 1 5C/5E SLOW 
110010 1 5K/12A INTERMEDIATE 
110110 1 5K/12C INTERMEDIATE 
111010 5 5K/12C INTERMEDIATE 
111020 1 5T/12C INTERMEDIATE 
111110 6 5J/12C INTERMEDIATE 
120000 7 5D/5K SLOW 
120010 5 5C/5K SLOW 
120011 1 5C/5KA SLOW 
120020 1 5C/5T SLOW 
120100 7 5D/5J SLOW 
120110 8 5C/5J SLOW 
120200 1 5E/5J SLOW 
211020 1 5T/12M INTERMEDIATE 
211110 1 5J/12M INTERMEDIATE 
220001 1 5K/5KA SLOW 
220100 4 5J/5K SLOW 
220110 1 5J/5T SLOW 
2202-0 1 5J/5J SLOW 
220200 6 5J/5J SLOW 
†Observed diplotypes are shown as the number of mutations identified in each individual for each SNP. 0 = wild type, 1 = 




concentration target of 3 µg/ml (56). PK parameters by genotype are shown in table 11A, unexpectedly 
median half-life was slowest, apparent oral clearance lowest and AUC0-∞ highest among genotypically 
rapid acetylators, with the reverse true for genotypically slow acetylators, although none of these 
differences was statistically significant. Similarly, there were no statistically significant differences by 
genotype for N-acetyl-isoniazid Cmax, elimination half-life or AUC0-∞. Median isoniazid and AcINH time-
concentration curves are given in Figure 2 (Left). 






NAT2*4 1 0.4 
NAT2*5 169 70.4 
NAT2*11 3 1.3 
NAT2*12 67 27.9 
Total 240 100 
 






NAT2*4 1 0.4 
NAT2*5C 51 21.3 
NAT2*5D 35 14.6 
NAT2*5E 10 4.2 
NAT2*5J 42 17.5 
NAT2*5K 25 10.4 
NAT2*5KA 2 0.8 
NAT2*5T 4 1.7 
NAT2*11A 3 1.3 
NAT2*12A 14 5.8 
NAT2*12C 51 21.2 
NAT2*12M 2 0.8 






Table 9: Frequency distribution of NAT2 genotypes and deduced phenotype in the study group. 











NAT2*5/*12 43 35.8 INTERMEDIATE 
NAT2*5/*5 63 52.5 SLOW 
Total 120 100  
 
 
Absorption was rapid in study 2, with a median INH Tmax being 2 hrs. INH exposure was also variable 
amongst individuals with median (IQR) Cmax 3.14 µg/ml (2.39 – 4.34 µg/ml) and the median AUC0-∞ 
10.76 µg.hr/ml (8.24 – 28.96 µg/ml). The median elimination half-life was 2.62h (2.26 – 4.07h). Again, 
we compared these INH PK measures to published PK targets; 47.5% (19/40) failed to attain the minimum 
2-h plasma concentration target of 3 µg/ml. 
 
Table 10: Overall isoniazid and N-acetyl-isoniazid PK 
 Study 1 Study 2 
 Isoniazid  N-acetylisoniazid Isoniazid N-acetylisoniazid 
AUC0-∞ 
(µg/mL/hr) 
5.53 (3.63 – 9.12) 5.49 (3.18 – 9.26) 10.76 (8.24 – 28.96) 27.67 (23.20 -34.67) 
Cmax (µg/mL) 1.47 (1.14 – 1.89) 0.90 (0.46 – 1.398) 3.14 (2.39 – 4.34) 2.91 (1.73 – 3.70) 
Tmax (hr) 1 (1 – 2) 4 (2 – 6) 2 (2 - 2) 3 (3 – 4) 
CL/F (L/hr) 47.64 (35.36 – 74.11) NA 27.34 (10.83 – 32.00) NA 
t1/2 (hr) 4.61 (3.64 – 8.32) 10.64 (6.62 – 17.07) 6.02 (5.37 – 8.66) 8.03 (6.18 – 12.86) 
All values medians (inter-quartile ranges) 
AUC0--ꚙ = Area under the time – concentration curve  
Cmax = Maximum concentration  
CL/F = Clearance 
t1/2 = Elimination half life 
NA = not applicable  
 
PK parameters by genotype are shown in Table 11 B. For both isoniazid and AcINH and across the PK 
parameters; Cmax, AUC0-∞ and elimination half-life, variability (both range and IQR) was increased 
amongst those genotyped as SAs. Again, however, there were no statistically significant differences 
between these PK parameters by genotype. Median isoniazid and AcINH time-concentration curves are 





Table 11A: Study 1 PK parameters by genotype 






































1.47 (0.97 – 1.89) 1.54 (1.25 – 1.76) 1.41.42 (1.20 -2.05) 0.94 (0.63 – 1.68) 1.07 (0.49 – 1.70) 0.38 (0.90 – 
0.90) 
Tmax (hr) 1 (1 -2) 1 (1 – 2) 2 (2 – 2) 4 (2 – 4) 4 (4 – 7) 6 (4 -6) 
CL/F 
(L/hr) 
57.05 (37.84 – 103.56) 43.53 (32.05 – 
64.33) 
37.75 (31.27 – 
47.92) 
NA NA NA 
t1/2 (hr) 4.67 (3.64 – 8.32) 4.00 (3.35 – 5.19) 8.56 (5.69 – 
14.44) 




All values medians (inter-quartile ranges) 
AUC0--ꚙ = Area under the time – concentration curve  
Cmax = Maximum concentration  
CL/F = Clearance 
t1/2 = Elimination half life 
NA = not applicable 
 
 
For both studies we calculated the log AcINH concentration/log isoniazid concentration ratio, as a measure 
of acetylation, at 2 and 4 hours postdose and analysed this ratio by genotype (Figure 3 and 4). In both 
studies we saw no statistically significant difference in ratios between genotypes at either 2 or 4 hours. In 
study 2 we again saw increased variability in this metric amongst those genotyped as SAs.  
Table 11B: Study 2 PK parameters by genotype 
 Isoniazid  N-acetyl-Isoniazid 
 Slow Intermediate Rapid Slow Intermediate Rapid 
AUC0-∞ 
(µg/mL/hr) 
10.76 (9.73 -31.21) 9.09 (7.3 -18.75) 26.99 26.04 (22.99 -32.76) 6.28 (5.25 -10.01) 28.53 
Cmax (µg/mL) 3.47 (2.49 - 4.49) 2.96 (2.33 - 4.02) 3.94 2.85 (1.52 - 3.68) 3.28 (2.53 - 4.01) 1.91 
Tmax (hr) 2 (2 – 2) 2 (2 – 2) 2 3 (3-4) 3 (3 – 3) 4 
CL/F (L/hr) 27.87 (9.66 -30.83) 33.33 (16.01 - 41.17) 11.12 NA NA NA 
t1/2 (hr) 4.61 (3.9 -5.34) 4.46 (3.9 - 7.88) 8.28 5.81 (4.9 - 7.25) 6.28 (5.25 -10.01) 10.97 
All values medians (inter-quartile ranges) 
AUC0--ꚙ = Area under the time – concentration curve  
Cmax = Maximum concentration  
CL/F = Clearance  
t1/2 = Elimination half life 
NA = not applicable 
 
Hepatic adverse events 
There were no grade 3 and 4 hepatic adverse events in study 1 and only 1 grade 4 hepatic event was 
reported from the only participant with rapid genotype in study 2.  Although there were more hepatic 
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adverse events among the slow genotype participants, the difference was not statistically significant 
between genotypes; p=0.203 in study 1, and 0.276 in study 2.  
 




We investigated the NAT2 genotype and the PKs of isoniazid and AcINH in black Zulu South Africans 
living with HIV from Durban and surrounding areas. We found that most individuals were of SA (52.5%) 
or IA (35.8%) genotype, with only a small number of RA genotype (11.7%). The proportions of the 
deduced acetylator phenotypes in our population was broadly similar to other African and Caucasian 
populations (36, 43, 57, 58) but differ from those previously reported from within other black ethnic 
groups within Southern Africa. For example, Werely found that IA genotypes dominated in the Xhosa 
cohort, with SAs only 30% (45). Our results were comparable to a recent study by Naidoo et al. in patients 
from the same geographic area who reported 34% SA, 43% IA and 18% RA (59). 
 
There was a high prevalence of the NAT2*5 allelic group, accounting for the slow acetylator genotype, 
in our population. In well studied Caucasian and Asian populations, four variants; NAT2*4 (wild type, 
rapid acetylators), NAT2*5B, NAT2*6A, and NAT2*7B (all slow acetylators), account for most NAT2 
alleles. In Asian populations there are generally a higher proportion of wild type NAT2*4 alleles and few 
NAT2*5B alleles, and this difference largely accounts for the much lower prevalence of RAs in non-Asian 
populations. Consistent with other studies in Sub-Saharan African populations, the wild-type NAT*4 allele 
was far less prevalent and variant alleles were far more diverse in our study. In our population, the 
NAT2*5B allele was relatively rare in comparison to its occurrence in two studies in the black population 
from Western Cape and North West Province in South Africa (45, 60).  
 
However, in contrast to these South African populations, there were a diversity of other NAT2*5 alleles, 
including a much higher prevalence of the rare NAT2*5J allele (17.5%) and the poorly characterised 
 Study 1  Study 2  
















1 7  9  25  41 0 5 10 15 
2 2 0 0 2 0 1 1 2 
3 0 0 0 0 0 2 1 3 
4 0 0 0 0 1 0 0 1 
Total 9 (20.9) 9 (20.9) 25 (61) 43 (100) 1(4.8) 8(30.1) 12(57.1) 21(100) 
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NAT2*5K allele (10.4%). The NAT2*6A and NAT2*7B alleles, common in Caucasian and Asian 
populations, were not seen in our cohort. In Caucasian and Asian populations, rapid acetylator NAT2*12 
alleles are rarely seen, whereas in populations in sub-Saharan Africa the NAT2*12A allele is reported at 
much higher frequencies (35). In our study, the NAT2*12A allele did indeed comprise 5.8% of alleles 
seen, but we saw a much higher frequency of the NAT2*12C allele (21.2%), in contrast to other Southern 
African cohorts (10, 45, 60, 61). 
 
Figure 2  (Left) Study 1 median INH and AcINH concentrations over time for INH and AcINH for 58 patients. 
(Right) Study 2 median INH and AcINH concentrations over time for INH and AcINH for 34 patients. The shaded 
areas indicate the IQR. 
 
 
The isoniazid Cmax and AUC0-∞ demonstrated considerable variability between individuals in both 
studies, and almost all participants in study 1 and almost half of the participants in study 2 had a Cmax 
below the lower limit of the target range (56). Low isoniazid concentrations during TB treatment are 
concerning because it is postulated they may lead to poorer treatment outcomes, or the generation of 
isoniazid resistance, the likely first step in the evolution of multi-drug resistant TB (MDR TB). However, 
the evidence for either of these concerns is mixed and in this setting the prevalence of INH mono-
resistance is relatively low.  
 
There was a marked difference in PK measures between the two studies analysed, with Study 1 having 
much lower measures than Study 2.  There are several reasons that could have contributed to this 
difference. The difference in isoniazid dosing could explain the lower PK measures, where Study 1 used 
the FDC dosing as per WHO recommended weight bands, leading to almost half the participants receiving 
doses <300 mg, as previously reported (49). All participants in Study 2 received 300 mg doses of isoniazid 
irrespective of weight. Although the samples of Study 1 did not appear to deteriorate during the 5 years 
between first analysis and subsequent analyses for this study, differences in processing and storage 
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between the studies cannot be excluded. Figure 4 shows the INH and AcINH at different time points. 
Based on those findings, the phenotype of the study participants is generally more intermediate/rapid than 
what the predominant slow genotype suggests, which is in contrast to other studies reporting HIV-infected 
patients have a tendency towards slow acetylator phenotype (62). 
 
 
Figure 3 Box plots for study 1:  
Representing median (solid line), interquartile range (box) and range (whiskers) for the pharmacokinetic parameters; log maximum concentration (Cmax), 
log area under the time-concentration curve (AUC0-∞), and half-life for isoniazid (INH) and N-acetyl-isoniazid (AcINH) stratified by acetylator status and 




We identified no statistically significant difference by NAT2 genotype in a variety of PK measures, hence, 
in this cohort we found poor correlation between NAT2 genotype and phenotypic acetylation of isoniazid. 
Previous studies in other populations have shown a good correlation between NAT2 genotype and 
isoniazid PK, suggesting that NAT2 genotyping could be used as a parsimonious way to risk stratify 
patients and personalise dosing of isoniazid in an attempt to maximise efficacy whilst minimising toxicity. 
There are significant practical difficulties to implementing these approaches in this setting, but our data 
suggest that in this population NAT2 genotyping will not be helpful in guiding TB therapy. A lack of 
concordance between genotypic and phenotypic measures of INH acetylation has been reported previously 
in HIV-positive cohorts (63, 64). It is likely that in this cohort, as in others, that other non-genetic factors 
are more or equally important than NAT2 genotype. Jones et al found that infection with HIV or stage of 
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HIV infection may alter Phase I and II drug-metabolising enzyme (DME) activity in their study on 17 
HIV-infected participants at different levels of immunosuppression (65). They found that HIV infection 
was related to an increase in variability of these DMEs. Whilst additional pathways, aside from NAT2 
genotype, have been implicated in hepatotoxicity of isoniazid-containing TB treatment regimens, it is not 
clear that these pathways alter isoniazid PK and thus could account for the lack of genotypic and 
phenotypic concordance in this study.  
 
 
Figure 4 Box plots for study 2:  
Representing median (solid line), interquartile range (box) and range (whiskers) for the pharmacokinetic parameters; log maximum concentration (Cmax), log 
area under the time-concentration curve (AUC0-∞), and half-life for isoniazid (INH) and N-acetyl-isoniazid (AcINH) stratified by acetylator status and 
logAcINH concentration to logINH concentration ratio at 2 and 4 hours stratified by acetylator genotype,  R,I,  and S, rapid, intermediate and slow acetylator 
genotypes, respectively. 
 
Although there were more hepatic adverse events among the SA, there was no statistical association 
between genotype and hepatotoxicity in the two studies, with only 1 patient who was a RA having a grade 
4 hepatic adverse event and 2 others who were IA having  grade 3 hepatic adverse events.  
 
In our study, the participants received pyridoxine and cotrimoxazole with the ATT in study 2, but not in 
study 1 as we used the samples collected on day 1 for this analysis when only ATT was given. As both 
INH and sulfamethoxazole are inhibitors of CYP2C9, this could be one of the reasons for the variations 
noted. INH also inhibits CYP3A4, which is induced by rifampicin, but this interaction has not proven 
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significant except when it relates to hepatotoxicity (66, 67). That the combination of INH and rifampicin 
leads to an increased risk of hepatotoxicity, has been reported in other studies. In our study 2, isoniazid 
was given with Rifabutin which is a less potent hepatic enzyme inducer, which therefore should have less 
interaction with INH (68). Considering the limited effect on hepatotoxicity, the effect of CYP2E1 was not 
evident in our study. We cannot confirm or exclude the effect of these CYP450 enzymes on INH 
metabolism in these participants. 
 
In our study, samples were stored at -800 Celsius and loss of compound due to storage would have been 
minimal (69), although studies have not reported on plasma samples stored longer than 5 weeks, nor have 
they reported on sample integrity for the metabolite, AcINH. 
 
Conclusion 
Amongst black Zulu TB-HIV-co-infected South African patients, most had slow or intermediate acetylator 
NAT2 genotype. There was a diversity of specific NAT2 alleles, with the pattern differing from previously 
studied cohorts in other settings. Despite the rarity of rapid acetylator genotypes, INH PK were variable 
and a substantial proportion of individuals failed to attain minimum efficacy targets. Importantly, NAT2 
genotype did not explain PK variability in this cohort or the low Cmax, which suggests that other factors 
could be influencing isoniazid bioavailability and metabolism, and which require further elucidation.  
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Impact of tuberculosis treatment and antiretroviral therapy on serial RD-1-specific quantitative 
T-cell readouts (QuantiFERON®-TB-Gold-in-Tube), and relationship to treatment-related 
outcomes and bacterial burden  
 
Treatment monitoring of TB is commonly done using sputum microscopy. This is dependent on 
patients’ ability to produce sputum. In TB and HIV co-infected patients often cannot produce sputum. 
Studies on the usefulness of IGRAs as treatment monitoring tools have been conducted in TB patients 
and very few were conducted in co-infected patients. 
 
Objective 2 - To determine the kinetics of mycobacterial cellular immune responses in patients treated 
with HAART and TB drugs using an INF-γ release assay. 
 
The manuscript below reports on the kinetics of INF-γ using QuantiFERON®-TB-Gold-in-Tube in TB 
and HIV co-infected patients receiving combined treatment. All patients recruited were ART naïve 
before the study. This was a longitudinal study with a twelve month follow up; enrolment started in 
2007 and follow up ended in 2010. The samples for QFT-GIT were processed without first being 
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Background: The impact on anti-TB treatment with and without antiretroviral therapy (ART) on 
standardised interferon-γ release assay (IGRA) readouts has been inadequately studied in high burden 
countries.  
Methods:  The QuantiFERON®-TB-Gold-in-Tube (QFT-GIT) test was used to evaluate (IFN-γ) responses 
longitudinally (0, 3, 6 and 12 months post initiation of tuberculosis  (TB)-HIV co-treatment or ART alone) 
in 82 HIV-infected patients.  
Results: Of the 65 evaluable participants 30 were co-infected on ART, 17 co-infected but not on ART, 
and 18 were HIV-infected alone but on ART. In HIV-infected and HIV-TB-infected patients on ART IFN-
γ responses increased, whilst they decreased in those not on ART. However, baseline, month 3, and month 
6 IFN-γ responses, irrespective of ART, did not differ in TB-HIV co-infected patients who culture-
converted compared to those who did not (1.25 vs. 1.05, p=0.5 at baseline; 3.76 vs. 1.15, p=0.2 for month 
3; and 0.06 vs. 0.7, p= 0.3 for month 6, respectively). IFN-γ levels did not correlate with the magnitude 
of sputum bacillary load, smear status, or liquid culture time-to-positivity.  
Conclusion: As IGRAs do not correlate with 2 or 6-month culture conversion and markers of bacillary 
burden, they are unlikely to be useful for the prognostication of treatment outcome in co-infected patients.  
 








There is a desperate need for new tuberculosis (TB) diagnostics and biomarkers to assist in new drug and 
vaccine development. Presently phase III clinical trials are conducted over a period of 30 to 60 months 
because it must be shown that a drug or drug combination prevents or reduces treatment failure and relapse 
(which requires a 24 month follow-up period) (1). Recently it has been suggested that a shorter follow 
may be possible, as studies have shown that if patients were to relapse, they would do so within 12 months 
of completion of anti-TB treatment (ATT) (2, 3). Similarly, vaccine studies suffer from a lack of 
biomarkers that can predict a favorable response. Monitoring TB treatment response using sputum smear 
and culture poses problems as human immunodeficiency virus (HIV)-infected patients are frequently 
smear-negative (4) and these tests themselves are suboptimal predictors of outcome (5). More recently 
interferon gamma release assays (IGRAs) have become available and have been investigated for use as 
diagnostics and biomarkers of TB treatment response and prognosis (6-27).  
 
Some studies have reported that IGRAs may be useful in monitoring TB treatment response (23, 28), 
while others have reported that most patients remain IGRA-positive after completion of ATT, in spite of 
sputum smear and culture conversion (12, 29). These studies have examined the utility of measuring 
longitudinal IFN-γ responses during the course of TB treatment. They have mostly been conducted in pre-
dominantly HIV-uninfected individuals (12, 21, 30-32) and mainly in countries with low TB and HIV 
burdens (11, 33-35). Only two studies have used the commercially available standardised 
QuantiFERON®-TB Gold in Tube (QFT-GIT) assay in a setting with a high burden of TB and HIV (24, 
36). However, to our knowledge, no study has hitherto reported effects of ART and/ or ATT on 
quantitative IFN-ᵧ responses in HIV-TB co-infected patients. There are also hardly any data about the 
effect of ART alone on such responses. A further limitation is that several published studies, even from 
Africa, have used non-standardised in-house IGRAs in an enzyme-linked immunosorbent assay format 
(16, 37). Although there have been reports that IGRAs may correlate with bacterial load in low burden 
settings (38, 39), this was not the case in the only published report in patients from a high burden setting 
(40). There is therefore a need for more data from high burden settings, such as South Africa, where TB 
prevalence was estimated to be between 0.4 million and 0.6 million cases in 2012 (41).  
 
To address the deficiency in our knowledge about how T-cell responses change during the course of 
therapy we investigated the usefulness of QFT-GIT in monitoring TB treatment responses over a one year 




Durban, South Africa. The inclusion of patients on ART makes this study important in addressing this gap 




As part of a parent pharmacokinetic study, we recruited HIV-infected patients aged 18 years through 65 
years between March 2007 and April 2008 after written informed consent was obtained. This included 62 
newly diagnosed TB patients with smear-positive disease who fall into three subgroups: (i) with a CD4 
count <200 cells/mm3 and initiated on ART as per national guidelines (n=20; henceforth referred to as 
TB-ART-<200); (ii) with a CD4 count  >200 cells/mm3 and initiated on ART (n=21; henceforth referred 
to as  TB-ART->200); and (iii) with a CD4 T-cell count >200 cells/mm3, not initiated on ART (n=21; 
henceforth referred to as TB-no-ART->200). We also enrolled patients without active TB disease (culture-
negative) with CD4 T-cell count < 200 cells/mm3 and who were initiated on ART (n=20; henceforth 
referred to as non-TB-ART-<200). The different patient groups are shown in Figure 7. Inclusion and 
exclusion criteria as reported previously (42).  The study was approved by the Biomedical Research Ethics 
Committee of the University of KwaZulu Natal (E294/05) and was conducted according to ICH and South 
African Good Clinical Practice. All subjects signed informed consent. This study is registered with 
controlled-trials.com, ISRCTN77861053. 
 
Recruitment and specimen collection 
TB patients were enrolled if they were smear- and culture-positive, as well as smear- and culture-negative 
non-TB patients. Blood samples were drawn for the QFT-GIT (Cellestis Ltd., Carnegie, Australia) assay 
at 0, 3, 6 and 12 months from all enrolled participants. Sputum specimens were collected for smear and 
culture at month 0, 2, 5 and 6 during TB treatment, and at every follow up visit (month 9, 12, 15, 18 and 
24) if they showed signs and symptoms of TB.  
 
Laboratory procedures 
Sputum samples were processed using NALC/NaOH. Smear microscopy using both auramine and Ziehl-
Neelsen staining (43), and culture using Middlebrook 7H11 selective agar (Difco) and Mycobacteria 
Growth Indicator Tube (MGIT) liquid medium (Becton Dickenson Biosciences Division, Sparks, 
Maryland, USA). Time to obtain a positive result was recorded as the growth was observed, or negative 




niacin and nitrate biochemical testing and tested for susceptibility to antimicrobial agents using the 
proportion method on Middlebrook 7H10 agar (Difco).  
 
The QFT-GIT assay was performed according to manufacturer’s instructions (44). QFT-GIT blood 
collection tubes, which include a Nil Control tube, TB Antigen tube and an optional Mitogen tube were 
incubated at 37°C as soon as possible and within 16 hours of collection. Following a 16 – 24 hour 
incubation period, the tubes were centrifuged, the plasma removed and the amount of interferon gamma 
(IFN-γ) measured by enzyme linked immunosorbant assay (ELISA). The results were interpreted using 
software supplied by the manufacturer and was considered positive if the response to the specific antigens 
was ≥0.35 IU/ml; negative if the response to the specific antigen was <0.35 IU/ml; the IFN-γ level of the 
positive control was ≥0.5 IU/ml and indeterminate if the value of both antigen stimulated samples were 
<0.35 IU/ml and the positive control was <0.5 IU/ml.  
 
Data management and statistical analysis 
The sample size was that of convenience. All data were entered using double data entry into an Epidata 
database and transferred to Stata version 11 (StataCorp. 2009, College Station, TX) for statistical analysis.  
TB and non-TB patient characteristics were compared using chi square tests for categorical and t-test for 
continuous variables.  Median quantitative responses of QFT-GIT were compared across subgroups at 
baseline using the Wilcoxon Rank sum test. Differences between baseline and 3 and 6 months were tested 
using a paired t-test and differences between the subgroups tested using unpaired t-tests. There were 17 
participants that withdrew or were withdrawn from the study for different reasons. The TB-ART CD4 > 
200 group (n=10) and the TB-ART CD4 < 200 group did not differ in their QFT responses at baseline and 





Figure 5 Study participants flow chart 
Of the 82 participants recruited, 11 participants [9 in the TB arms (8 in TB-ART and 1 in the TB-no-ART group) and 2 in the non TB-ART group)] either 
withdrew consent or suffered a serious adverse event and had to be withdrawn from the study after recruitment. Six were excluded for incomplete tests; 
either missing month 3, 6 or both QFT-GIT results.  
CD4 unit = cells/mm3, TB = tuberculosis, QFT-GIT = QuantiFERON®-TB Gold In-tube, ART = antiretroviral therapy  
 
Results:  
Participant characteristics  
One thousand and thirty-four patients were pre-screened and 82 were enrolled into the study. Eighteen 
were excluded because of World Health Organization (WHO) clinical stage 4 disease. Only 20 TB-HIV 
patients and 20 HIV-only patients with a CD4 count below 200 cells/mm3 were recruited and the rest had 
to have CD4 count above 200 cells/mm3. Most exclusions were as a result of failing to fulfill the CD4 
count criterion. Of the 82 participants, 65 had at least three of the 4 time point-specific QFT-GIT results 
and were therefore analysed. There were no significant differences in the demographic and baseline 
characteristics between the three groups (Table 13) in age, sex, weight, height, body mass index (BMI) 







Table 13: Demographics of patients included in the analysis  
           
Demographic   TB-ART  TB-no-ART no-TB-ART 
 or clinical CD4 < 200 cells/mm3 CD4 > 200 cells/mm3 
 
P-value CD4 > 200 cells/mm3 
CD4 < 200 
cells/mm3 
characteristics (n = 20) (n = 10)  (n = 17) (n = 18) 
Age Mean years (SD) 36.2 (7.04) 29.4 (7.85) 0.02 29.6 (5.40) 35.5 (6.73) 
Sex, n (%)      
Male  7 (35) 4 (40) 0.8 11 (65) 8 (44) 
Female 13 (65) 6 (60)  6 (35) 10(56) 
Weight (kg), mean (SD) 56.1 (12.69) 54.5 (7.12) 0.8 57 (11.94) 62.8 (11.58) 
Height (m), mean (SD) 1.6 (0.09) 1.6 (0.11) 0.9 1.6 (0.11) 1.6 (0.11) 
BMI (kg/m2), mean (SD) 22.0 (4.52) 21.7 (3.73) 0.9 22.4 (5.34) 25.3 (6.13) 
BMI category, n(%)      
Underweight 4 (20) 3 (30)  2 (0.12) 2 (0.11) 
Healthy 12 (60) 6 (60)  13 (0.76) 8 (0.44) 
Overweight 3 (15) 1 (10) 0.9 0 (0) 3 (0.17) 
Obese 1 (5) 0 (0)  2 (0.12) 5 (0.28) 
Haemoglobin, g/l), mean (SD) 10.1 (1.37) 11.2 (2.12) 0.3 11.1 (1.52) 11.0 (1.66) 
CD4 count*, Mean (SD) 113.6  (54.39) 304 (75.05) <0.001 331.9 (78.76) 120.3 (51.66) 
Viral Load (log10) 5.2 (1.04) 4.9 (0.83) 0.2 4.7 (1.08)   
 
Eight participants in arm 1 withdrew, three of whom completed the pharmacokinetic study (PK), two were 
not ready to start ART, two refused to provide a blood sample and one had a grade 4 amylase.  Three 
patients in arm 3 were withdrawn, one for grade 4 anaemia, one refused to provide a blood sample and 
the last had a repeat CD4 count above the enrolment threshold. In arm 2, four participants were withdrawn: 
one refused to provide a blood sample and three completed PK but had missing QFT-GIT results on two 
or three visits.  Two participants in arm 6 died before month 6. 
 
Baseline QFT-GIT results  
From the 82 participants enrolled, only four had indeterminate results and only 65 had at least 3 sets of 
results; of these, only one had an indeterminate result which was regarded as negative. There were no 
significant differences in mean baseline IFN-γ levels between the TB-ART and TB-no-ART groups (2.12 
vs. 2.95 IU/ml, p=0.2) (Figure 5). There was a significant difference between the non-TB-ART and the 
TB-ART groups (0.95 vs. 2.12 IU/ml, p<0.001) and non-TB-ART vs. the TB-no-ART group (0.95 vs. 
2.95 IU/ml, p<0.001). IFN-γ levels were significantly higher in the TB groups (TB-ART and TB-no-ART) 
when compared to the non-TB-ART group, (1.15 vs. 0.24 IU/ml; p<0.001). The correlation between IFN-
γ levels and CD4 count for all groups (TB and non-TB) was positive, rs=0.26, p=0.02. The median baseline 
IFN-γ levels also differed significantly when stratified by CD4 count group (CD4 <200: 0.7 (IQR: 0.05–




correlation between IFN-γ and CD4 count was still positive, rs=0.15 but no longer reaches statistical 
significance, p=0.30. The subsequent comparison of median QFT responses stratified by CD4 count in 
the TB group only (CD4< 200: 1.1 (IQR: 0.7 – 2.5) IU/ml vs. > 200: 2 (IQR: 0.7-4.4) IU/ml, p = 0.40) 
was not significant. Because there was no difference in the baseline IFN-γ in the two TB-ART groups, the 
results were pooled. 
 
IFN-γ levels and bacillary load correlates at diagnosis 
There was no correlation between IFN-γ levels and time to positivity [rs=0.09, p=0.90 (Figure 7 Panel 
A)]. The association between sputum bacillary load as measured by smear grade and IFN-γ levels was not 




Figure 6. Baseline interferon gamma (IFN-γ) levels    Figure 7. Panel A: Relationship between interferon gamma 
(IFN- γ) responses and bacillary load and time to positivity at baseline. Panel B: There were no scanty results. +, 





Proportion QFT-GIT positive at different time points per group (Figure 8) 
The percentage of QFT-GIT-positive patients in the TB-no-ART group between month 0 (81%) and 3 
(56%), 6 (50%) and 12 (46%) was not significantly different (p=0.10, 0.07 and 0.06, respectively, for 
comparisons for each time point relative to the baseline). The pattern was similar in the TB-ART group 
between month 0 (80%), 3 (73%), p = 0.50; however significant differences were detected when month 0 
was compared to month 6 (54%) and 12 (50%), (p=values of 0.04 and 0.02 respectively). When the 
proportion of QFT-GIT-positive in the no-TB-ART group at baseline (26%), was compared to month 3 
(68%), 6 (67%) and 12(76%), an increased proportion of individuals were positive, p = 0.01; 0.02; and 
0.004 respectively.  
 
 
Figure 8. Proportion of patients with a QuantiFERON-TB Gold In-Tube result >0.35 IU/ml by group. 
 
The effect of ART on IFN-γ responses (Figure 9 and Figure 10) 
Change between month 0 and month 3 
With regard to changes in median IFN-γ responses depending on ART or not, irrespective of TB culture 
status at baseline (Figure 11 and 12); TB-ART participants, n=30, had an IFN-γ median response at month 
0 and 3, of 1.05 vs. 3.76 IU/ml, a per patient median increase of 0.015; IQR -0.22:2.4, p=0.07. In TB-no-
ART participants (n=17), IFN-γ median responses were 2.1 and 0.895 IU/ml for these time-points and 
there was a per patient median decrease, -0.27 (IQR -2.4:2.4, p=0.50). In Non-TB-ART participants 
(n=18), IFN-γ median response was 0.14 vs. 1.7 IU/ml and there was a median increase was 0.98; IQR 0-
7, p=0.004.  Figure 12 shows a per patient variation in QFT-GIT changes, with the participants receiving 





Change between month 0 and month 6 
There was no change in median IFN-γ responses from month 0 to month 6 in TB-ART group, IFN-γ 
responses were 1.05 vs. 0.7 IU/ml, and there was a median per patient decrease of 0.11 (IQR -0.65:0.19), 
p=0.30. In TB-no-ART group, IFN-γ median response was 2.1 vs. 0.47 IU/ml and there was a median per 
patient decrease was -0.27 (IQR -2.2:0.75), p=0.20. In the Non-TB-ART group, the IFN-γ median 
response was 0.15 vs. 1.5 IU/ml and there was a median per patient increase was 0.63; IQR 0:2.6, p=0.008.  
 
 
Figure 9 Longitudinal IFN-γ responses are shown for patients undergoing ATT (n=17) and those undergoing TB 
treatment and ART (n=30) at 0, 3, 6 and 12 months, as well as for non-TB patients on ART (n=18). 
 
Change between month 0 and month 12 
The only significant changes were in No-TB-ART group, with a median IFN-γ 0.14 vs. 1.25 IU/ml and  a 
median per patient increase of  0.95 (IQR 0-7, p=0.03). The rest of the changes were similar to those 
between month 0 and 6. 
 
Longitudinal changes in IFN-γ responses  
The change in IFN-γ responses from baseline through to month 12 varied extensively, although in general 
there was a decline from month 6 to 12. In the groups receiving ART, for participants with high baseline 




2), there was a sharp increase of IFN-γ levels at month 3, followed by a sharp decline at month 6 and a 
steadier decline to month 12, which was seen less in the group not receiving ART. 
 
 
Figure 10 Longitudinal changes in QFT-GIT: TB patients on ART, n=30; TB patients not receiving ART, n= 17 and 
Non-TB patients on ART, n=18 between 0 and 3 months and between 0, 3, 6 and 12 months. 
  
Longitudinal changes in sputum culture status and QFT-GIT responses 
Median IFN-γ responses from month 0, 3 and 6 irrespective of ART did not differ between TB participants 
who culture converted at month 2 and those who did not; 1.25 vs.1.05, 3.76 vs. 1.15 and 0.06 vs. 0.7 
respectively. Median IFN-γ responses from month 0, 3 and 6 did not differ significantly between the non-
TB-ART participants who remained culture negative versus those who converted to positive: 0.15 vs. 
0.47, 1.73 vs. 1.6, and 2 vs. 0, respectively. Only three participants remained culture positive (either solid 
or liquid) at month 6, (reduction from 1.12 to 0.06IU/ml; p=0. 02). All other participants in the TB and 
No-TB-ART groups were culture-negative at month 6. Four previously smear and culture negative 
participants (no-TB group) converted to culture (MGIT or 7H11) positive at month 2, median IFN-γ 
increase from 0.47 to 1.6 IU/ml, p=0.08, three received ATT. Two participants were culture positive at 
month 6, both received ATT, IFN-γ declined from 0.15 to 0IU/ml. When the “grey zone” criteria (0.2-0.7 
IU/ml) was applied (45), of the 18 non-TB-ART participants, 9 had baseline QFT < 0.2, of whom three 
remained below 0.2 at month 3, and six increased to above 0.7. Two remained below 0.2 at month 6; two 




increased to > 0.7 by month 3 and were treated (culture positive); three remained in the “grey zone” (not 
treated). Four participants were > 0.7 at baseline and remained > 0.7 at month 3 and 6 (one treated from 















 Figure 11 Median change with 
error bars for 3 groups: no-TB-
ART, TB-ART and TB-no-ART. 
 
Discussion: 
There are limited or no data related to how quantitative RD-1-specific T-cell responses change during the 
course of treatment (ART or TB treatment) in HIV-TB co-infected persons. There are also hardly any data 
about how such responses correlate with microbiological readouts in patients on TB treatment, whether 
HIV-infected or not. The key findings of this paper are that: (i) overall, although T-cell responses generally 
declined with ATT, IFN-γ responses (magnitude or reversion) did not correlate with studies of bacterial 
load at diagnosis or with culture-conversion at 2 to 3 months post treatment initiation; (ii) in contrast to 
TB treatment alone, ART in HIV-TB co-infected persons, caused a transient increase in T-cell responses 
which then fell over time to levels similar in patients not receiving ART; and (iii) ART alone in HIV-
infected persons without TB resulted in a gradual increase in T-cell responses over several months. Thus, 
ART must be taken into account when evaluating T-cell responses (e.g. IGRA and by inference TST) in 
HIV-infected persons irrespective of whether they are on TB treatment, and although such responses 
generally decline with ATT there is no correlation with 2-month culture conversion readouts. 
 
This study confirmed the findings of Theron et al. and that of Oni et al. studies from a high burden setting 
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Thus, with the exception of this report and the findings reported here, studies from either low- or high-
burden settings have not previously reported the correlation of IGRA responses with measures of 
mycobacterial burden (8, 12, 13, 16, 18, 20-23, 26, 28, 32, 37, 47, 48). Although culture conversion in 
itself has sub-optimal predictive value for a favorable treatment response, the lack of any correlation, and 
no difference in the magnitude of IGRA responses in microbiologically positive or negative persons, 
makes it unlikely that IGRAs will be useful as treatment monitoring tools or prognostic markers in HIV-
TB co-infected persons (or uninfected persons with TB for that matter). The lack of correlation is not 
surprising because antigen-specific memory T-cell readouts cannot distinguish between exposure, latent 
infection, and active TB(14, 49).  
 
In contrast to TB treatment alone, ART in TB-HIV co-infected persons caused a transient spike in T-cell 
responses followed by a declining response thereafter, and this pattern was independent of CD4 count 
(though ostensibly more robust in those with a CD4 count of less than 200 cells/ml). This is, to our 
knowledge, the first report of how serial IGRA responses change in HIV-TB co-infected patients on ART 
versus no ART.  The cause for the transient increase in responses is unclear but factors likely to be 
important include: (i) immune reconstitution due to the treatment of TB itself (down-regulation of an anti-
inflammatory response driven by cytokines such as interleukin 10 and cell types including regulatory T-
cells (49-51), (ii) the immune reconstitution effect of ART, which causes the redistribution of effector 
memory T-cells to the blood compartment, and (iii) release of TB antigen consequent upon treatment 
which may augment T-cell responses. Given the lack of this spike-like response in the HIV-TB without 
ART group suggests that ART is the major driver of this phenomenon. TB immune reconstitution 
inflammatory syndrome (TB-IRIS) is also associated with exaggerated cytokine responses including 
antigen-specific Th1 responses, although there was no difference in participants on TB treatment and ART 
who had TB-IRIS versus those that did not (52).  These observations have important implications for the 
interpretation of serial IGRA responses in HIV-infected persons. The treatment of presumed latent TB-
infection in children resulted in a similar transient exaggerated response (34).  
 
ART alone (without active TB) resulted in a significant increase in IGRA responses by month 3. This is 
likely due to ART-related immune reconstitution and redistribution of effector memory T-cells back into 
the blood compartment (53). Similarly, ART can cause apparent conversion of the TST whereby TST-




interpretation of immunodiagnostic tests in the context of IPT provision in high burden settings as current 
data suggest that only TST+ve persons are likely to benefit from IPT (56, 57).  
 
There are several limitations to this work, including the small number of patients and the fact that QFT-
GIT is not the most suitable test for measuring IFN-γ. However, although there was a decline in evaluable 
participants due to deaths and withdrawals, and the number of participants without complete results for 
all time points decreased, there was still sufficient data to show interesting information on the effects of 
concomitant TB-HIV treatment, and much needed data related to its impact on serial IGRA responses are 
provided. This study further sheds light on the impact of the CD4 count in this context, (although the study 
was conducted during a time when newer and more effective ART was unavailable within the national 
treatment programme). However, even with this limited dataset that had limited power, no trend or 
relationship between bacillary load at diagnosis and IFN-γ reversion (0 to 3 months) or sputum culture 
conversion could be shown. It should be borne in mind that the predictive value of culture conversion 
itself for a long-term favorable outcome (failure or relapse at 2 years) is sub-optimal (58). However, the 
lack of correlation of initial and serial IGRAs with bacterial load and high proportion of HIV-TB cases 
remaining IGRA positive at 6 and 12 months post treatment makes it unlikely that it would make a good 
marker of treatment response. Chiappini et al. concluded that monitoring IGRA changes over time seems 
to have only speculative value in adults (59). This meta-analysis however did not differentiate between 
those who were on concurrent ART or no ART. 
 
In conclusion, these preliminary data suggest that although QFT-GIT readouts decreased with time during 
ATT, irrespective of whether participants were on ART, they did not correlate with 2- or 6-month culture-
conversion and markers of bacillary burden. Therefore, IGRAs do not appear to be useful for the 
prognostication of treatment outcome in co-infected patients on concurrent therapy. 
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Longitudinal assessment of health-related quality of life of HIV-infected patients treated for 
tuberculosis and HIV in a high burden setting 
 
Introduction 
Treatment monitoring of TB and HIV is necessary but the most used method is biomedical. Since TB 
affects the psychosocial aspects of patients, it is important to use a biopsychosocial model when assessing 
treatment response. Quality of life assessments add the psychosocial aspects to this evaluation. Very few 
studies have evaluated their use in co-infected patients especially in high TB burden areas.  
 
This section addresses objective 3 of this thesis.  
 
Objective 3 - To evaluate HRQOL in TB-HIV co-infected patients receiving combined treatment.  
Sub-objective 3.1 - To examine changes in the HRQOL of patients receiving TB-HIV co-
treatment.  
Sub-objective 3.2 - To evaluate whether HRQOL differs in patients receiving TB treatment alone 
or together with ARV therapy. 
Sub-objective 3.3 - To compare changes in the HRQOL of co-infected patients receiving TB-HIV 
co-treatment with those receiving TB treatment alone. 
 
The manuscript below addresses the above objective. The present study assessed HRQOL of patients co-
infected with TB and HIV at different levels of immunosuppression as well as in HIV-infected patients 
without TB with CD4 count below or equal to 200 cells/mm3. The manuscript details the HRQOL from 
baseline to 12 months after start of treatment. The analysis shows whether patients in combined 
treatment tolerate treatment. Reversed items were adjusted such that the higher the score the better the 
HRQOL was for all subscales. AEs and SAEs reported by patients (and not laboratory AEs and SAEs) 
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Introduction: Assessment of patients receiving treatment for human immunodeficiency virus (HIV) and  
tuberculosis (TB) using a Health Related Quality of Life (HRQOL)  instrument is important to get the 
subjective view of the patients’ wellbeing.  
Methods: We used the Functional Assessment of HIV Infection (FAHI) HRQOL instrument to collect 
perceived wellness information at baseline, month 3, 6 and 12 from patients enrolled in a pharmacokinetic 
study between March 2007 and April 2008. Composite domain scores at each time point and their relationship 
with the rate of adverse events(AEs) and serious adverse events (SAEs) were compared between treatment 
arms.  
Results: Out of the 82 patients enrolled, 76 were analysed. There was a significant increase in total score in all 
groups between baseline, month 3, 6 and 12 (all p-values<0.0001), and over time (p<0.001). Adjusting for 
baseline total score, baseline CD4 count had a significant effect on the total score (p= 0.002) and the rate of 
change in total score over time, that is; interaction effect (p<0.001). There was no difference in each domain 
scores between participants that received ART with TB treatment and those that received TB treatment only. 
Respiratory AEs had a significant effect on HRQOL. 
 
Conclusion: We found that assessment of HRQOL of participants in TB-HIV treatment using the FAHI 
instrument was useful in evaluating treatment responses. It showed improvement consistent with decrease in 
adverse events and signs and symptoms of TB. Number and type of AEs was related to lower HRQOL in spite 
of TB cure. 
 








Quality of life (QOL) evaluation has been conducted for decades especially in cancer research. There is an 
increasing trend to include QOL in clinical trials, but this is still lacking in TB-HIV research. QOL has 
been defined as how well people are able to perform activities of daily living and their well-being (1), the 
health effects of QOL led to the introduction of the term Health Related Quality of Life (HRQOL) by 
Kaplan and Bush (2).Different studies have investigated HRQOL in participants receiving treatment for 
TB (3-9) or participants receiving therapy for HIV(10-17), but studies investigating the HRQOL of patients 
co infected with TB and HIV and receiving concomitant therapy are limited (1, 18-20), and are mostly cross 
sectional studies. Of the 22 high burden TB countries listed by the World Health Organization (WHO), 
South Africa is ranked third globally. TB incidence  estimates reported in 2013 shows a  slight decrease 
from 430 000-630 000  in 2012 (21) to 410 000-520 000 (22). South African estimates for HIV-infected 
incident cases decreased from 270 000-390 000 in 2012 to240 000–310 000 in 2013. More than 70% of 
patients with TB in South Africa are also HIV-infected (23), and TB is the leading cause of HIV related 
morbidity (24). It is well established that Highly Active Antiretroviral Therapy (HAART) reduces 
opportunistic infections as well as reducing morbidity and mortality (25, 26). In order to evaluate the benefit 
of ART in TB-HIV patients, HRQOL could be used. 
 
The probability of problems related to side effects when receiving TB may be worsened by concomitant 
HIV therapy, thereby affecting QOL treatment (27). Patient-reported QOL may help clinicians decide how 
to proceed with the patient’s treatment if  assessed using a valid and reliable instrument. It is recommended 
by Dhuria et al. that a multidimensional instrument is used (9). 
 
The aim of the study was to compare the HRQOL of TB and HIV co infected patients receiving TB 
treatment alone and those receiving treatment for both conditions at the same time. We also evaluated 
HRQOL of HIV-infected patients without TB receiving ART. The current study was undertaken to examine 
changes in HRQOL after initiating TB treatment and ARVs, TB treatment alone and ARVs alone over a 








This study was conducted in Durban, South Africa. All patients were HIV positive or co- infected with TB 
and recruited from clinics around Durban between March 2007 and April 2008. 
 
Study design 
This was a sub-study to a randomised control trial (RCT), where patients were randomised into early 
HAART or no HAART depending on their baseline CD4 count. 
 
Participants and inclusion criteria 
HIV positive patients aged 18 to 65 years, with and without TB, who provided written informed consent, 
were included in the study (28).  Patients were excluded if they had a history of drug resistant tuberculosis 
or TB treatment in the past 2 years, an indication for medication that might interact with study treatment, 
treatment dependent diabetes mellitus, epilepsy, a history of excessive alcohol consumption or drug abuse, 
pregnant women and women of childbearing age refusing to use standard barrier contraceptive measures 
or intra uterine device (IUD) for the duration of the study. Patients with severe illness, weighing <30 kg, 
with hepatic transaminases >2.5 times the upper limit of normal (ULN), serum creatinine >1.5 times ULN, 
neutrophils <1200/mm3 or haemoglobin <8 g/dL were also excluded. 
 
Participants were enrolled when they had TB/HIV co-infection and their CD4 count was above the 
threshold for commencement of ARVs according to the national programme (above 200 during the study 
period). Also, TB patients co infected with HIV with CD4 count below 200 were enrolled and commenced 
on early ARVs (within two weeks of starting TB treatment). HIV-infected patients without TB, with CD4 
count below 200 were also included in the study. Four groups were recruited: high CD4 count on TB 
treatment and ART(CD>200TH); high CD4 count on TB treatment alone (CD>200T); low CD4 count on 
TB and  HIV therapy (CD≤200TH) and low CD4 on non-TB on HIV therapy (CD≤200H).  
 
Procedures 
All patients were asked to choose a directly observed therapy (DOT) supporter before starting treatment. 
TB was diagnosed by sputum smear to confirm TB-HIV co-infection. Assessments were conducted at 
baseline and repeated monthly for the first six months. They included a physical examination, full blood 
count, urea and electrolytes, liver transaminase assays (aspartate transaminase [AST] and alamine 
aminotransferase [ALT]). After 6 months these assessments were conducted every 3 months until 24 




Clinical and abnormal laboratory AEs were graded according to the Division of AIDS Table for Grading 
the Severity of adult and paediatric Adverse Events (DAIDS AE Grading Table), grade 3 and 4 adverse 
events were reported as serious adverse events (SAEs).  
 
Treatment 
All TB patients received fixed dose combination standard anti-TB treatment (ATT) comprising of isoniazid, 
rifampicin, pyrazinamide and ethambutol for two months and fixed dose combination treatment comprising 
isoniazid and rifampicin for 4 months. All participants with CD4 count below 200 without TB were started 
on ART immediately after enrolment, efavirenz and combivir (lamivudine and zidovudine) and on the 14th 
day of enrolment for the CD4≤200 TB-HIV group. The CD4>200 group with TB-HIV was randomized 
into group that received ART on 14th day post randomization or no ART. 
 
Patients completed the Functional Assessment of HIV Infection (FAHI) before treatment commencement, 
at month 3 (after end of intensive phase), at month 6 (at the end of TB treatment), and at month 12. The 
core of the instrument is a general HRQOL instrument with an additional subscale for mental wellbeing. 
The domains of FAHI include physical (score 0-40), functional (score 0-52), social (score 0-32), emotional 
(score 0-40) and cognitive wellbeing (score 0-12), with a maximal total score of 176 (29), obtained by 
totaling all subscale scores. Lay counselors were trained on how to administer the FAHI Zulu language 
questionnaire by interviewing patients and filling the responses. Professional nurses were trained on the 
administration and checking the filled questionnaires for completeness. Where there were errors, they were 
sent back to the counselor who did the correction. If clarification was needed from the patient this was 
sought as the patient was admitted for the day and was available to answer questions. The questionnaires 
were then double entered into Epidata. Data cleaning was conducted by query generation by data capturers 
and where there were discrepancies, these were sent to the professional nurse who ensured that they were 
resolved. 
 
We included 10 additional questions on: waking up during sleep, abnormal dreams, feeling sleepy during 
the day, alcohol consumption, balance, dizziness, hearing, painful feet, numbness of feet, and body shape 
changes. These ten questions were scored from 0-4 therefore the score total ranged from 0-40. We selected 
these questions based on the known side effects of efavirenz and piloted them on 10 patients receiving 




correlations were examined to determine whether an item in the scale needed to be reversed or not. 
 
Statistical analysis 
The Cronbach’s alpha was used to measure internal consistency of the individual score components for 
each domain. Demographic characteristics were presented as frequencies and percentages for categorical 
variables, and as means with standard deviations for continuous variables.  Skewed variables were 
presented as medians with interquartile ranges (IQRs). Comparisons between treatment arms at baseline 
were performed using the Chi-squared test and Fishers exact test for nominal variables, and non-parametric 
trend tests for ordinal variables. T-tests were used to compare means and the Wilcoxon rank sum test was 
used to compare the distribution of skewed variables between groups.  
 
All analysis was done in accordance with intention to treat (ITT) principles. The individual domain scores 
and total score at each time point (Baseline, month 3, 6 and 12) were compared between 1) CD>200TH 
and CD>200T 2) CD≤200TH and CD≤200H and 3) CD>200 and CD<=200 using unpaired t-tests, unless 
otherwise stated. To test the aforementioned differences after adjusting for baseline scores, ANCOVA 
(analysis of covariance) was used.  All comparisons were planned and no adjustment was made for multiple 
comparisons.  To compare the overall trend of quality of life scores over time, linear mixed models with 
random  intercepts and slopes were fitted.(30) Nested models were compared using the likelihood ratio test 
and information criteria were used to select the model which provided the best fit to the data. The number 
of adverse events was compared between the four groups using the Kruskal-Wallis test, and pairwise 
comparisons were performed using the Wilcoxon rank sum test. The association between HRQOL scores 
and the type of adverse event experienced in the preceding period was assessed separately at each time 
point using median quartile regression. We used the standard error of measurement (SEM) to define 
important change in the total quality of life score (31, 32).All analysis was performed in Stata version 




A total of 82 participants were enrolled, Figure 12 is the flow chart showing the number of patients analysed 
from baseline to month 12. Seventy-six participants were analysed, and their baseline characteristics are 
presented in Table 14. Age and night sweats were significantly different between the CD4>200 and ≤200 




no statistical significance noted. Age was statistically significant between CD4 count >200 and CD4 count 
≤200 groups. 
 
Figure 12. Patient flow chart 
 
 
ATT anti tuberculosis treatment, ART antiretroviral therapy 
 
Treatment outcomes 
Six participants had been withdrawn by month 3, and refused follow up, 70 remained. Three participants 
died before month 6, 67 remained. Two participants died before month 12, 1 MDR-TB and 1 had no 
questionnaire, 63 remained. 
 
There were 7 deaths in the study, 5 before month 12. One of these was in the CD4>200 while 6 were in 
the CD4<=200 group. Two non-TB participants converted to active TB within the first 3 months and were 
started on ATT.  One became multi-drug resistant and was withdrawn and sent for treatment at month 9. 
Only 4 out of six participants were smear or culture positive at month 5 or 6, 4 of which were in the 




















  N=18 N=19  N=19 N=20   
Sex  Female  10 (55.6%) 7 (36.8%) 0.25 12(63.2%) 11(55.0%) 0.61 0.25 
Age (Mean 
(SD)) 
 29.8 (7.5) 31.6 (6.5) 0.46 36.1 (7.2) 35.0 (7.1) 0.62 0.004 
Median CD4 
count (IQR) 
 310  
(274 - 333) 
318  
(242 - 345) 





        
TB symptoms       
Cough Normal 4 (22.2) 6 (31.6) 0.361 3 (15.8) 0.118 
 Mild  9 (50.0) 10 (52.6) 8 (42.1) 
 Moderate 5 (27.8) 3 (15.8) 8 (42.1) 
       
Night sweats Normal 12 (66.7) 6 (31.6) 0.062 4 (21.1) 0.019 
 Mild 4 (22.2) 10 (52.6) 8 (42.1) 
 Moderate 2 (11.1) 3 (15.8) 7 (36.8) 
       
Chest pain Normal 10 (55.6) 13 (68.4) 0.480 9 (47.4) 0.300 
 Mild 6 (33.3) 4 (21.1) 7 (36.8) 
 Moderate 2 (11.1) 2 (10.5) 3 (15.8) 
       
Fever Normal 9 (69.2) 12 (70.6) 0.596 10 (52.6) 0.268 
 Mild  4 (30.8) 3 (17.7) 8 (42.1) 
 Moderate 0 (0.0) 2 (11.8) 1 (5.3) 
       
Haemoptysis Normal 18 (100) 19(100)  18 (94.7) 0.163 
 Mild 0 0 1 (5.3) 
 Moderate 0 0 0 
 
Quality of life outcomes 
Reliability and validity 
The Cronbach’s alpha, used to measure internal consistency, was 0.90 for the physical domain; 0.89 for 
the emotional domain; 0.86 for the functional domain; 0.87 for the social domain; 0.55 for the cognitive 
domain, and 0.79 for the CNS domain. Average value of inter-item correlations were used to assess 
reliability, the value of which was 0.72 for the cognitive and social domains and 0.63, 0.71, 0.68 and 0.58 
for the functional, emotional physical and CNS domains, respectively.  
 
Total HRQOL scores between groups 
Table 15 shows total scores over time for the treatment groups. At baseline there was a significant 
difference in the HRQOL between the four groups (p= 0.005). At month 3 there was a significant difference 





Table 15: Mean domain and total scores of FAHI and CNS at different time points 
 
1 19, 18, 18 and 16 individuals at month 0, 3, 6 and 12 respectively 
218 individuals at month 0 and 13 individuals at time points 3, 6 and 12   
319, 19, 18 and 16 individuals at month 0, 3, 6 and 12 respectively 
420, 20, 18 and 18 individuals at month 0, 3, 6 and 12 respectively 
aTotal score comprised of Physical, emotional, functional, social and cognitive domain scores 
















CD>200,TH: CD4 count > 200, on ATT and ART; CD>200,T: CD4 count > 200 on ATT; 
CD<=200,TH; CD4 count <=200, on ATT and ART; CD<=200,H; CD4 count <=200 on ART 
 
At month 6 and 12, there was no significant difference in HRQOL between the 4 groups; p=0.263 and 
0.375, respectively. After adjusting for baseline, month 3 total scores were still significantly different 
between CD4> and CD4≤200 groups; p=0.01, but not for month 6 and month 12. Baseline scores in the 
CD4>200TH and CD4>200T groups were similar; p-value=0.99). At month 3, 6 and 12 there were no 
significant differences in HRQOL, (p = 0.17,0.45 and 0.82 respectively. Table 15 also shows the baseline 
scores between the CD4≤200,TH and CD4≤200,H groups were not significantly different; p=0.40. Month 
3, month 6 and month 12 scores were not significantly different, p = 0.70, p= 0.43 and p=0.13 respectively. 
 
Since no significant differences were found within the higher CD4 count groups, we combined 
CD4>200TH and CD4>200T to form the CD4>200 group and CD4≤200,TH and CD4≤200,H to form the 
CD4≤200 group. Table 16 shows mean total scores, sd and p-values for CD4> and ≤200.Between the 
CD4>200 and CD4≤200 groups, there was a significant difference in the baseline, p<0.001 and month 3 
total scores, p<0.001and month 6 total scores, p=0.08 between the CD4>200 and CD4≤200 groups, but 
not for month 12, p =0.71.  After adjusting for baseline total score, there was still a significant difference 
in the total score at month 3, p= 0.010. 
 
Quality of life trends over time between treatment groups 
The longitudinal HRQOL score for the four groups is presented in Figure 12. The change from baseline of 
the total scores combined was significant from month0 to month12, p<0.0001. Further statistical analysis 
confirms that the trend is indeed significantly increasing; p<0.0001. Adjusting for baseline total score, 
baseline CD4 count had a significant effect on the total score, p=0.002, and the rate of change in total score 


































Domain scores comparing CD4>200 and CD4≤200 groups 
As seen in Table 15, the baseline physical wellbeing domain scores were not significantly different 
between groups, p=0.08, however for month 3 there was a significant difference, p=009. At month 6 and 
12 the scores were not significantly different, p=0.096 and 0.74, respectively. Baseline and month 3 
emotional, functional and social domain scores were significantly different, but month 6 and 12 were not.  
Baseline, month 3, and month 6 scores were significantly different for the cognitive domain, but not for 
month 12. 
 
Table 15 also shows the apparent difference between time points on the physical wellbeing scores. There 
was significant increase in physical, emotional, functional and social wellbeing scores over time: p<0.001 
for each domain. However, the mean cognitive wellbeing score did not differ significantly between 
baseline and month 3 (p=0.86). The largest change in cognitive wellbeing score occurred between month 
3 and month 6 (mean difference 0.81, p <0.002). 
 
Table 16: Total score at month 0, 3, 6, 12 expressed as mean(sd) 
Month CD4<=200 CD4>200 p-value  
   
0 99.65 (29.68) 124.46 (29.02) <0.001 
3 121.57 (28.40) 144.94 (21.30) <0.001 
6 139.48 (23.043) 149.30 (21.78) 0.08 
























The CNS domain was similar to the other domains, showing no significant difference between 
CD4>200TH and CD4>200T as well as between CD4≤200TH and CD4≤H, but significant difference 
between the CD4>200 and CD4≤200 at baseline, month 3 and month 6 and similar to the cognitive 
wellbeing domain, was not significantly different at month 12. 
 
Serious adverse events (SAEs), adverse events (AEs) and quality of life  
We assessed the presence of SAEs between the following intervals; 0-3, 3-6 and 6-12 months. Twenty-
one (28%) patients experienced at least one SAE between 0 and 3 months. There were 11 (15.28%) and 8 
(12.7%) patients who experienced an SAE between 3-6 or 6-12 months, respectively. In the above figures, 
the denominator was all patients in the study at the end of the relevant interval. The number of AEs are 
shown in Table 17. There was a significant difference in the total number of AEs (SAEs included) between 
month 3 and month 6 in all groups. For all groups, the median HRQOL total score increased sharply while 
the median number of AEs decreased sharply from month 3 to month 6 (Figure 15).  There was a slight 
increase in the number of AEs between month 6 and month 12 in the higher CD4 groups.  
 
Table 17.  Median (IQR) number of AEs per period by arm  
  ARM Time 0-3 Time 3-6 Time 6-12 
CD>200,TH 3 (2-5) 2 (0-2) 4 (0-5) 
CD>200,T 4 (3-7) 2 (1-3) 4 (1-7) 
CD<=200,TH 7 (5-12) 3 (1-3) 2 (1-3) 
CD<=200,H 4.5 (2.5-7) 2 (1-3.5) 1 (0.5-3) 
p-value 0.47 0.04 0.20 
TB therapy + ART=TH; TB therapy only=T; ART only=H; adverse event=ae;  
 
Since the majority of patients had TB we checked the effect of anaemia and respiratory adverse events on 
HRQoL, as anaemia is one of the common AEs in TB patients (33).The presence of anaemia in the 
previous period did not have an effect on the mean HRQOL total score in the follow up period, p=0.63, 






Figure 15   The relationship between HRQOL and number of AEs in the previous three months 
 
 
When analysing  respiratory AEs we found that individuals who had a respiratory AE between baseline 
and month 3, month 3 and month 6 and month 6 and month12, had a significantly lower quality of life at 
the next follow up period; month 3; p=0.0085, month 6; p=0.019 and month 12; p=0.017 respectively. 
 
Figure 16 Adverse events and quality of life between month 3 and 6. 
 
 
Meaningful decline in HRQOL scores 
Minimal important change as defined in the method section, was a change larger than the SEM. For the 
total score, taking all components into account, Cronbach’s alpha was 0.908. The standard deviation at 




change in total score was hence defined as a change greater than 9.6 between visits. Changes between 
scores were calculated as follows: Change from baseline to month three, change from month 3 to month 6 
and change from month 6 to month 12. Twenty two patients (28.9%) had decline in HRQOL scores at any 
time. There were no significant differences between CD4≤ and CD4>200; p=0.51, or between CD4>200TH 
and CD4>200T, 5(27.8%) and 7(36.8%) patients had decline in HRQOL respectively; p=0.72. There were 
no significant differences between CD4≤200,TH and CD4≤200H, 4(21.1%) and 6(30%) patients had 
decline in HRQOL respectively; p=0.72. 
 
Discussion 
This study assessed the HRQOL lower in TB/HIV co-infected patients with CD4 count ≤200, as well as in 
HIV non-TB patients with CD4 count ≤200, this is consistent with available literature (14, 34, 35). The 
similarity between the CD4≤200 with and without TB is in agreement with the study by Dowdy et al., who 
found that participants with HIV alone had similar HRQOL as those with TB and HIV co-infection (20). 
The total score at baseline divided the groups in two, high CD4 count and low CD4 count groups. This 
showed that participants with lower CD4 counts had significantly decreased baseline total HRQOL scores 
when compared to the higher CD4 count groups, irrespective of TB, this was similar to the findings of 
Akimoro et al. (36). In addition, physical, emotional and functional wellbeing scores were also significantly 
different between the two groups (CD4>200 and CD4≤200), as would be expected. However, in the study 
by Deribew et al., the effect of CD4 count could not be determined (37).Dowdy et al. found that cross-
sectional studies in TB-HIV co-infected patients had similar findings. Dowdy et al. found that physical 
domain was decreased in TB and HIV co-infected patients at start of treatment, while Venter et al. found 
that CD4 count had an effect on the physical domain (20, 38). In our study, the CD4 count was significantly 
lower in older patients, which we assumed was related to the length of time since the HIV diagnosis, which 
would be the result of the length of time since diagnosis and delay in starting ART(the government ARV 
programme had not started at this time).   The difference in the experience of night sweats could not be 
explained. 
 
For all scores combined, there was a highly significant change from baseline through month 12. Change in 
HRQOL scores over time showed that by the third month of treatment  participants in all groups had 
improved significantly and at six months were almost similar, while at twelve months all participants had 




of treatment there was significant improvement in HRQOL in patients with TB and HIV and those with 
HIV alone (18).  
 
Participants with CD4>200 improved the same whether they were on ARVs or not. As shown by Ralph et 
al., standard TB treatment was very successful in improving the HRQOL of patients with CD4 count > 200 
not receiving ART(40). Those with CD4 count below 200 were started on ARVs within two weeks of 
starting anti-Tuberculosis treatment (ATT) and showed very quick response to treatment. The largest 
improvement was from baseline to month 3 in all groups, the lower the baseline CD4 count, the higher the 
rate of change observed.  The experience of AEs was highest in the lower CD4 count group with TB 
followed by the non-TB lower CD4 count group. Low CD4 count and number of AEs were the main 
predictors of HRQOL. The study by Call et al. found similar significant differences in  physical wellbeing 
between the CD4 count below and above 200 (34). 
 
Almost all participants were smear-negative by end of two months and improvement in CD4 count was 
significant. The improvement could be the result of close monitoring that was done during the study. All 
patients had their own self-selected DOT supporter who was called before each visit to verify adherence. It 
was noticeable, however, that participants who took TB treatment only had slightly more SAEs at 6 months 
than others, however, by 12 months this had resolved.  Four patients in the CD4>200 TB group were 
positive at month 5 or 6, while two patients in the CD4≤200TH group were positive during the same period.  
Decline in minimal important change in HRQOL was seen in patients who had decline in CD4 count and 
or had hepatic adverse events. According to Cella et al., patients can endure rather large negative changes 
in their QOL for the purpose of potential gains in the future (41). 
 
The choice of timing and frequency of assessments was determined by the TB treatment outcomes, which 
are after the intensive phase of treatment at 2 months, and after treatment completion at 6 months. The 
HRQOL interview was conducted at month 3 to allow for all patients to complete the intensive phase. The 
next interview was at 6 months (TB treatment completion), and lastly at 12 months to evaluate full recovery. 
Despite lack of specific questions relating to TB specific symptoms, the FAHI questionnaire was able to 
effectively evaluate the HRQOL of TB and HIV co-infected patients.  It was able to assess the differences 
between groups receiving combined TB and HIV therapy, from those receiving TB treatment only and non-




patients reporting respiratory signs and symptoms within the three months prior to the HRQOL evaluation, 
had lower scores at the next evaluation 
 
The first limitation of the study was the small sample size as a sample of convenience was used. Also there 
were patients who did not have all the domains filled, and some patients withdrew before month 3. 
However, the observed changes in HRQOL are consistent with what would be expected for patients on 
treatment. When considering the number of AEs and SAEs over time, the results of the HRQOL make 
sense. 
 
Another limitation of the study is that the questionnaire was not applied frequently enough. Although we 
were able to find the differences between groups, it may have been better if we evaluated the HRQOL more 
frequently in the first two months. As the questions from the FAHI questionnaire are based on the past 
seven days, there is the possibility that adverse effects could have been underreported. In addition, the CNS 
questionnaire was formulated to evaluate the side effects from Efavirenz, since these are more prominent 
during the first couple of weeks of starting treatment, the effects of Efavirenz may have been missed by 
this questionnaire. The score obtained for the cognitive domain, implies that the items of this domain did 
not form a good overall score. Also, during the three months preceding the application of the questionnaire, 
the participant may have had and resolved an adverse event before the past seven days.  
 
In spite of the limitations listed, the data collected was able to show the differences between groups and 
was consistent with other findings in similar cohorts. Minimal important changes in HRQOL showing 
improvement in groups, as well as those showing worsening of condition, were related to the number of 
AEs and SAEs experienced in each group. 
 
Conclusion 
In this study we found that evaluating HRQOL in TB-HIV co-infected patients is useful as it gives the 
patients’ subjective report on their treatment response. We found that respiratory signs and symptoms had 
an effect on HRQOL even after cure of TB (6 months), this means patients may need continued care even 
after completion of treatment. Evaluating HRQOL adds value to the monitoring of TB/HIV outcomes and 
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Urine lipoarabinomannan (LAM) and antimicrobial usage in seriously ill HIV-infected patients 
with sputum smear-negative pulmonary tuberculosis  
 
Diagnosis of TB is commonly made when the patient presents with signs and symptoms of TB. The most 
common diagnostic algorithm involves testing of sputum for mycobacterium TB using smear microscopy 
or Gene Xpert MTB/RIF and sputum culture. In smear-negative TB or sputum scarce patients, such as 
those with HIV, diagnosis using a biological fluid either than sputum is needed. Urine is an easy to get 
fluid and a urine LAM test has been investigated in these populations. We investigated the usefulness of 
urine LAM to diagnose TB in seriously-ill smear-negative patients.  
 
Thesis Objective 4 - To determine the utility of urine LAM in diagnosis of TB in seriously-ill HIV-
infected patients with TB. 
Sub-objective 4.1- To determine the utility of urine LAM for the diagnosis of smear-negative TB.  
Sub-objective 4.2- To evaluate the potential utility of urine LAM to reduce antibiotic usage. 
 
The manuscript below reported on urine LAM and antimicrobial usage in seriously-ill HIV-infected with 







Background: Based on current WHO guidelines, hospitalized tuberculosis (TB) and HIV co-infected 
patients with CD4 count <100 cells/mm3 who are urine lipoarabinomannan (LAM) positive should be 
initiated on TB treatment. This recommendation is conditional, and data are limited in sputum smear-
negative patients from TB endemic countries where the LAM test is largely inaccessible. Other potential 
benefits of LAM, including reduction in antibiotic usage have, hitherto, not been explored.  
Methods: We consecutively enrolled newly-admitted seriously-ill HIV-infected patients (n= 187) with 
suspected TB from three hospitals in KwaZulu-Natal, South Africa. All patients were empirically treated 
for TB as per the WHO 2007 smear-negative TB algorithm (patients untreated for TB were not recruited). 
Bio-banked urine, donated prior to anti-TB treatment, was tested for TB-infection using a commercially 
available LAM-ELISA test. TB sputum and blood cultures were performed.  
Results: Data from 156 patients containing CD4 count, urine-LAM, sputum- and blood-culture results 
were analysed. Mean age was 37 years, median CD4-count was 75 cells/mm3 (IQR [34–169 cells/mm3]), 
54/156 (34.6%) were sputum culture-positive, 12/54 (22.2%) blood-culture positive, and 53/156 (34.6%) 
LAM-positive. Thus, LAM sensitivity was 55.6% (30/54. The study design did not allow for calculation 
of specificity. Urine-LAM positivity was associated with low CD4 count (p=0.002). Ninety percent 
(48/53) of LAM-positive patients received antibiotics [15/48 (31.3%), 23/48 (47.9%) and 10/48 (20.8%) 
received one, two or three different antibiotics respectively], while the duration of antibiotic therapy was 
more than 5 days in 26 of 46 (56.5%) patients.  
Conclusion: Urine LAM testing in sputum smear-negative severely-ill hospitalized patients with TB-HIV 
co-infection and advanced immunosuppression, offered an immediate rule-in diagnosis in one-third of 
empirically treated patients. Moreover, LAM, by providing a rapid alternative diagnosis, could potentially 
reduce antibiotic overusage in such patients thereby reducing health-care costs and facilitating antibiotic 
stewardship.  
 








The urine lipoarabinomannan (LAM) test has been shown not to be useful in untargeted patients with 
suspected tuberculosis (TB) in a primary health care setting (1), but it is useful for the diagnosis of 
hospitalized HIV-infected TB patients with a CD4 count <200 cells/mm3, who would otherwise have 
required further investigation. This is a test based on detection of mycobacterial LAM antigen, a 
polysaccharide present in mycobacterial cell walls, which is excreted in the urine (2), now available as a 
point of care urine strip test. Given that between 24% and 62% of HIV-infected patients with TB present 
with sputum smear-negative findings (3), and that Xpert Mycobacterium tuberculosis (MTB)/ rifampicin 
(RIF) has limited availability in many countries, TB in patients living with advanced stage HIV is often 
difficult to diagnose. This category of patients frequently have difficulty in producing sputum (4, 5), and 
when combined with low sensitivity of sputum smear microscopy (6, 7), leads to delays in diagnosis (8) 
and treatment. Sputum microbiological culture is the only other definitive tool for the diagnosis of active 
TB (9), but it is labour intensive and the time to result is prolonged. The difficulty in the diagnosis of 
sputum smear-negative TB adds to the causes of failure to halt transmission and control the epidemic, 
especially in high burden countries. Diagnosis is therefore often made on clinical and radiological 
grounds, which is often atypical (10). Therefore, there is a need for tests that do not require sputum and 
are more sensitive to ensure early diagnosis.  
 
Urine LAM has been investigated with varying results, but more so in sputum smear-positive patients (1, 
11-32). There are few studies that have investigated the usefulness of urine LAM in diagnosing sputum 
smear-negative TB (33-35), but none have investigated the use of LAM in reducing antibiotic use. The 
use of antibiotics to treat suspected TB while waiting for confirmation of diagnosis in hospital is common, 
although in HIV-infected patients a response to antibiotics may not exclude TB (36). Considering the 
need to prevent antibiotics resistance, optimal and prudent use of antibiotics is necessary in line with 
antibiotic stewardship (37, 38). In this study, we investigated the diagnostic performance of LAM-ELISA 
in seriously-ill hospitalized HIV-infected patients with sputum smear-negative pulmonary TB (PTB) and 
its potential impact on antibiotic usage. The LAM-ELISA, since completion of this study, has been 







Design and setting 
This sub-study was conducted as part of a prospective cohort study evaluating the use of a WHO-
recommended algorithm to reduce mortality in seriously-ill HIV-infected patients with sputum smear-
negative PTB in South Africa (36). Participants were recruited from three hospitals around Durban 
between March and December 2009. 
 
Participants 
Patients with advanced immune suppression and symptoms of TB requiring hospitalization, and with 
smear-negative sputum, were consecutively enrolled once informed consent was obtained. At one time 
point on admission, before commencement of antibiotics or anti-TB therapy (ATT), the following samples 
were collected from consenting participants: spot expectorated sputum and blood for culture, and 
midstream urine for LAM test. Participants were excluded if they were 1) currently being treated for latent 
TB infection (LTBI); 2) treated for TB disease; or 3) were found not to be HIV-infected based on lack of 
“strong clinical HIV evidence” or an HIV test at either screening, admission or during hospitalization. The 
study was approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal 
(KZN) and an Institutional Review Board at the U.S. Centers for Disease Control and Prevention (CDC). 
 
Patients were started on TB treatment based on criteria defined in the parent study (36): 1) had at least 2 
negative specimens for acid fast bacilli; 2) radiographic abnormalities consistent with active TB 
(according to the treating medical practitioner); 3) laboratory evidence of HIV-infected or strong clinical 
evidence of HIV infection, later confirmed by a laboratory test and 4) a decision by a clinician to treat 
with a full course of anti-TB treatment (ATT) or sputum smear-negative for acid fast bacilli but culture 
positive for Mycobacterium tuberculosis (MTB). 
 
Sputum and blood processing 
All sputum samples were processed using NALC/NaOH and microscopy smear using both Auramine and 
Ziehl-Neelsen staining and were cultured on Middlebrook 7H11 selective agar (Difco) and MGIT liquid 
medium (Becton Dickenson, Sparks, USA). Positive Mtb cultures were confirmed with niacin and nitrate 
biochemical testing. All blood samples were collected by venipuncture and cultured into aearobic and 







Urine samples were processed according to the manufacturer’s instructions (Clearview TB ELISA, 
Inverness Medical Innovations, Inc., Waltham, U.S.A.); within 24 hours of collection urines were boiled 
at 95–100°C for 30 minutes, centrifuged for 15 min at 10000 rpm and aliquots of 1 ml of the supernatant 
stored at -70ºC. The assay was performed on the stored aliquots once a week.  
 
From each frozen aliquot, 100 µl sample was incubated for 60 min at ambient temperature, and washed 
with Phosphate Buffered Saline pH 7.4/Tween-20 (PBST). Subsequently, 100 µl of undiluted conjugate 
solution (HRP-conjugated LAM-specific rabbit polyclonal antibody) was added. After a 60 min 
incubation and washing with PBST, 100 µl of the colour developer tetramethylbenzidine (TMB) was 
administered to each well. The substrate was again incubated for 15 min at ambient temperature, and the 
reaction was stopped by adding 100 µl of stop solution (1 M H2SO4). The colour development was 
measured at 450 nm on an automated ELISA plate reader. Samples and negative and positive controls 
were run in duplicate. 
 
Prior to interpretation of the urine LAM-ELISA results, the validity of each run was confirmed as per the 
manufacturer’s package insert as: i) negative control mean optical density (OD) was >0.1 OD and <0.3 
OD and ii) positive control mean OD was >0.3 and ≤0.5 above the negative control. Differences for each 
sample between the two runs were examined to see if their difference were not >15.0%. If the mean OD 
of the sample aliquots were ≥0.1 above the mean OD of the negative controls, the sample was considered 
urine LAM-positive. LAM-ELISA and the LAM strip test have been found not to be significantly different 
in studies comparing these two versions (39, 40). 
 
Chest radiograph 
Chest radiographs (X-rays) were initially read by the treating medical practitioner and then sent to an 
independent radiologist for reading. The results were then sent to the hospital concerned for the benefit of 
the medical practitioner. The external radiology results did not directly affect the start of treatment. 
 
Statistical methods 
Sample size was not calculated for this sub-study but we used the second cohort of the main study (36). 
Descriptive statistics were used to summarize the data.   Comparisons of categorical data between 




such as CD4 and time to event were compared using Mann-Whitney “U” test, while t-test was used for 
age.  Standard measures of diagnostic efficacy are reported where culture is considered the gold standard.  
Data were entered in Epidata and analysed in Stata V13.1. Kaplan Meier was used to analyse time to death 
or discharge and a log rank test used to compare subgroups. Median time to death or discharge were 





We enrolled a total of 187 patients, (Figure 17), out of which 168 had sputum and urine LAM-ELISA 
results and 156 had all results including CD4 count and were analysed. Table 18 shows the demographic 
characteristics; 87 (55.8%)  patients were male and 154 (98.7%) were black, 81 in WHO stage 3 (51.9%) 
and 75 (48.1%) in WHO stage 4 (41). Twenty-four (15.4%) were on ART and 43 (27.6%) had a history 
of prior TB treatment. Median CD4 count was 75 cells/mm3, IQR (34.5–169). 50/156 (32.1%) of patients 
had a CD4 count <50 cells/mm3; 42/156 (26.9%) had CD4 count between 50 cells/mm3 and 100 
cells/mm3; 35/156 (22.4%) had CD4 count between 100 and 200 cells/mm3; and 29/156 (18.6%) had CD4 











Figure 17: Participant flow diagram of seriously-ill HIV-infected hospitalized patients with sputum smear-
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Out of the 156 patients analysed, 54/156 were sputum culture-positive (34.6%),  53/156 (34.0%) were 
urine LAM-positive. Thirty urine LAM-positive patients were culture-positive, therefore, the overall test 
sensitivity was 55.6%. Of the 30 urine LAM-positive/culture positive patients, 21 70.0%) had CD4 count 
<100 cells/mm3. Urine LAM sensitivity for patients with CD4 count <100 cells/mm3 was 63.6% (21/33). 
Urine LAM sensitivity for patients with CD4 count 100–200 cells/mm3 was 57.1% (9/14) and among 
those with CD4 count >200 cells/mm3, it was 14.3% (1/7). Among the culture negative patients, 23 
(22.5%) were urine LAM-positive, as seen in Figure 18.  
 
Sputum, chest radiograph, urine LAM and blood culture  
Figure 18 shows culture positivity, with 54/156 (34.6%) sputum culture positive patients with at least one 
sputum sample. Although all patients’ diagnosis included chest radiography, only 120/156 (76.9%) 
patients had their chest X-rays read by an independent radiologist. Of the 53 urine LAM-positive patients 
35/53 (66.0%) had a chest X-ray read by the radiologist and 20/35 (57.1%) were consistent with PTB. 
The majority, 52/53 (98.1%), of the urine LAM-positive patients had blood culture ordered, 11/52 (21.2%) 
of whom were sputum and blood culture positive and 32/52 (61.5%) blood culture negative, with 7/52 
(13.5%) contaminated and 2/52 (3.8%) not done. Only 1/54 (1.8%) culture positive patient was urine 
LAM-negative and 8/11 (72.7%) blood culture positive patients had a CD4 ≤100 cells/mm3.  
 
Figure 18: LAM, sputum and blood culture, in seriously-ill, HIV-infected patients with sputum smear-negative 





As shown in Table 20, of the 12 blood-culture positive patients, 6 (50.0%) were confirmed as not PTB 
by the radiologist.  
 
Table 18: Demographic characteristics of seriously-ill HIV-infected patients (n=156) 
†, comparison done using fisher's exact test. LAM, lipoarabinomannan; ART, antiretroviral therapy; ATT, anti-TB therapy; TB, tuberculosis. 
 
 
      Culture & LAM       
Characteristics 
Total Pos Neg p value 
n=156 Culture: n=54 LAM: n=53 Culture: n=102 LAM: n=103 Culture LAM 
N   % N   % N % N   % N %     
Sex                       
     Male 87 55.8% 36 66.7% 34 64.2% 51 50.0% 53 51.5% 0.04646 0.131 
Female 69 44.2% 18 33.3% 19 35.8% 51 50.0% 50 48.5% .   
Race                      
     Black 154 98.7% 54 100% 53 100% 100 98.0% 101 98.0% 1.000† 1.000† 
Indian 1 0.6% 0 0% 0 0% 1 1.0% 1 1.0%     
White 1 0.6% 0 0% 0 0% 1 1.0% 1 1.0%     
Clinical Stage                      
     Stage 3 81 51.9% 32 59.3% 28 52.8% 49 48.0% 53 51.5% 0.182 0.873 
Stage 4 75 48.1% 22 40.7% 25 47.2% 53 52.0% 50 48.5%     
On ARV                      
    Yes 24 15.4% 7 13.0% 7 13.2% 17 16.7% 17 16.5% 0.542 0.589 
No 132 84.6% 47 87.0% 46 86.8% 85 83.3% 86 83.5%     
Prior ATT                      
    Yes 43 27.6% 9 16.7% 8 15.1% 34 33.3% 35 34.0% 0.027 0.012 
No 113 72.4% 45 83.3% 45 84.9% 68 66.7% 68 66.0%     
CD4 group           
 
          
    < 50 50 32.1% 15 27.8% 18 34.0% 35 34.3% 32 31.1% 0.310† 0.016† 
    50-<100 42 26.9% 18 33.3% 18 34.0% 24 23.5% 24 23.3%   
100-200 35 22.4% 14 25.9% 14 26.4% 21 20.6% 21 20.4%     
> 200 29 18.6% 7 13.0% 3 5.6% 22 21.6% 26 25.2%     
X-ray           
 
          
Not TB 38 24.4% 17 31.5% 15 28.3% 21 20.6% 23 22.3%     
    TB 57 36.5% 19 35.2% 18 33.9% 38 37.3% 39 37.9%     
Atypical TB 7 4.5% 1 1.9% 1 1.9% 6 5.9% 6 5.8%     
Pleural 
effusion 
1 0.6% 1 1.9% 1 1.9% 0 0% 0 0% 
    
signed out 1 0.6% 0 0% 1 1.9% 1 1% 0 0%     
Transfer 3 1.9% 2 3.7% 2 3.8% 1 1% 1 1.0%     
Missing 49 31.4% 14 25.9% 15 28.3% 35 34.3% 34 33.0%     
Anti TB 
treatment 
started           
 
          
0-5 days 121 77.6% 44 81.5% 42 79.3% 77 75.5% 79 76.7% 0.393 0.718 




Factors associated with a positive urine LAM result  
Prior ATT was associated with a negative urine LAM result at the univariate level, 8 (15.1%) of urine-
LAM-positive patients had prior ATT compared to 35 (34.0%) of urine-LAM-negative patients (OR: 2.6; 
95%CI: 1.2-5.9, p=0.02.).  A positive urine LAM result was also  associated with a CD4 count <200,  
(50/127) 39.4%; compared to 10.3% (3/29) patients with CD4 count >200 (OR: 5.6; 95%CI: 1.6-19.6, p 
= 0.007.  In a multivariable model containing variables significant at the univariate level, both remained 
independently associated with a positive LAM result: (ORadj:3.2; 95%CI: 1.3-7.6, p=0.009). (ORadj:6.2; 
95%CI: 1.821.8, p=0.005) respectively. 
 
Antibiotic use and ATT 
The majority 48/53 (90.6%) of the urine LAM-positive patients received antibiotics and 18/46 (39.1%) 
with recorded time, were on antibiotics for a median time of 5 days (Table 19). Of the 48/53 (90.6%) 
LAM -positive patients that received antibiotics, 10 (20.8%) received three types or more while 23/48 
(47.9%) received two types and 15/48 (31.3%) received one type of antibiotics. All patients received 
ATT, of the 53 urine LAM-positive patients, 32 (60.4%) received ATT within 3 days of admission as per 
protocol, and the rest within 4–22 days.  
Table 19 Potential benefits of early diagnosis with LAM in seriously-ill HIV-infected patients with 
sputum smear-negative pulmonary tuberculosis (n=53)  
Treatment and length of stay  LAM positive (n=53)  
Antibiotics given, n (%)  
Yes  48 (90.6)  
No  5 (9.4)  
Time on antibiotics (n=46, 2 
patients missing time), median 
[IQR] (days)  
5 [3–7]  
Time on antibiotics (n=46), n (%)  26 (56.5)  
<5 days  20 (43.5)  
≥5 days  
Number of antibiotics (n=48), n (%)  
1  15 (31.3)  
2  23 (47.9)  
3 or more  10 (20.8)  
Start of TB treatment (n=53), 
median time of start of TB 
treatment, median [IQR] (days)  
3 [2–4]  
0–3 days, n (%)  33 (63.3)  
4–22 days, n (%)  20 (37.7)  
Length of stay (n=53), n (%)  
0–3 days  12 (22.6)  
4–6 days  25 (47.2)  






Treatment outcomes - time to discharge and time to death 
Median time to discharge, excluding deaths was 5 days, (IQR 4–6) for the urine LAM-positive (n=48) 
and 6 days (IQR 4–8) for the urine LAM-negatives (n=99), and was statistically significantly different, 
(p=0.03). Median time to death was 12 days (IQR 11–13) for the urine LAM-positive (n=5) and 7 days 
(IQR 7–8), for the urine LAM-negative (n=4) but was not significantly different (p=0.11).  
 
Discussion: 
We evaluated the use of urine LAM for the diagnosis of smear-negative TB and found that more than 52% 
of culture-positive patients were urine LAM-positive. Moreover, nearly 20% of sputum smear- and 
culture-negative presumptive TB patients were urine LAM-positive.  
 
Almost all the patients in this study received empiric antibiotics. With the availability of LAM results, in 
at least one third of the patients, antibiotic usage could have been obviated or curtailed. Although all 
patients in this study should have been started on ATT within 3 days, (as per 2007 WHO guidelines for 
treatment of smear-negative TB and study protocol), and all were found to have chest X-ray abnormality 
consistent with TB by their treating clinician, we found that at least 10 LAM-positive patients were given 
three or more types of antibiotics with or without ATT for more than 5 days (42.2%). This was probably 
to cover the patients for other bacterial infections should TB not be confirmed, although there were no 
confirmed bacterial infection tested on these patients. In addition, nearly 40% of the 53 urine-LAM-
positive patients received ATT within 4-22 days, and the delay may have been due to the need to allow 
antibiotics time to act while waiting for sputum-culture results. 
 
It is reasonable to assume that fewer antibiotics could have been used had the urine LAM results been 
available on the day of admission. Peter et al suggested that the urine LAM assay may be used as a “rule 
in” test for smear-negative HIV-infected patients (42). Using LAM as a rule in test, in conjunction with 
clinical signs and symptoms and radiographic findings, urine LAM-positive patients could receive ATT within 
hours of admission, saving excessive use of antibiotics. This would be in line with current country-specific 
and antibiotic stewardship guidelines. Indeed, Padayatchi et al have advocated for ensuring that patients 
receive appropriate treatment with specific attention to dosing and duration as the first goal of antibiotic 
stewardship preventing drug overuse and abuse as the second goal, and minimizing TB drug resistance at 




strongly on antibiotic trials for smear-negative TB (44). There are recent studies investigating the use of 
trial of antibiotics as a diagnostic tool for smear-negative TB (45) indicating that the practice is ongoing. 
A study by Walusimbi et al (46) recommends that it is useful to start HIV-infected smear-negative patients 
on an initial course of antibiotics and in South Africa, four of the five patients given antibiotics while 
waiting for culture results, (patients were smear and Xpert negative) could not be started on ATT as they 
were lost to follow up by the time the results were available, and recommended to start HIV-infected 
sputum smear-negative patients on an initial course of antibiotics (47). In this setting, a positive urine 
LAM test is likely to reduce antibiotic usage. 
 
Table 20: Seriously-ill HIV-infected patients with sputum smear-negative pulmonary tuberculosis and 













We found that a positive blood culture was one of the factors associated with a positive urine LAM, 
consistent with findings of Shah and colleagues (20). More than 80% of patients with positive blood 
culture were positive for urine LAM, and 58% of them had chest X-rays not consistent with TB by a 
radiologist (Table 19). Thus, urine LAM, being of much lower cost and a point of care assay, could replace 
blood culture as a screening investigation in HIV-infected hospitalised patients with fever and advanced 
HIV disease.  
 
Our study had several limitations. We did not enroll a control group, and since all the patients were either 
culture-confirmed TB or clinically diagnosed TB, we could not calculate the specificity. A limited autopsy 



























1334 0 Not TB 1 1 1 97 1 6 
1376 0 TB 1 1 1 63.1 1 5 
1543 0 Not TB 1 1 0 79.4 1 17 
2466 0 Not TB 1 1 1 88 1 8 
3247 0 Not TB 1 1 1 65 1 24 
3284 0 NA 1 1 1 26 0 NA 
3317 0 NA 1 1 1 74 1 NA 
3372 0 TB 1 1 1 68 0 8 
3404 0 NA 1 1 1 106 1 9 
3406 1 Not TB 1 1 1 68 1 9 
3434 0 Not TB 1 1 1 128 1 11 
3508 0 NA 1 1 1 176 0 31 




TB at the time of death (48). More than half were not on TB treatment, and based on this information from 
the same geographical area as our study, we could not confirm that the culture negative patients did not 
have TB disease. The LAM-ELISA, since completion of this study, has been superseded by the LAM 
lateral flow assay but equivalence between the assays has been demonstrated (18, 39). Fujifilm SILVAMP 
TB LAM assay was assessed in comparison to AlereLAM by Broger et al, and the findings were that 
FujiLAM offers superior diagnostic sensitivity, while maintaining specificity, and has the potential to 
transform rapid point-of-care tuberculosis diagnosis for hospitalized PLHIV (49).  
 
We did not directly demonstrate a reduction in antibiotic usage though it is likely this could have been 
substantially curtailed in urine LAM-positive patients. This will need to be evaluated in a future 
prospective study using LAM and remains an important question to be answered. 
 
In summary, urine LAM testing in sputum smear-negative severely ill HIV-infected hospitalized patients 
with suspected TB and advanced immunosuppression offers the potential to start ATT early and to 
decrease the number and duration of antibiotics used.  
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Discussion and conclusions 
In this thesis we report four different types of biomarkers. We evaluated the relationship of NAT2 
acetylation genotype and phenotype, QFT-GIT’s usefulness in monitoring TB-HIV treatment response, 
HRQOL for monitoring of TB-HIV treatment using the subjective view from patients, and urine LAM for 
diagnosis of smear-negative TB.  
 
The first analysis, reported in Chapter 3 of this thesis  investigated the NAT2 genotype of predominantly 
IsiZulu speaking black South Africans from Durban and surrounding areas. We used six of the seven most 
frequent SNPs (NAT2 nomenclature) in the human population. Suarez-Kurtz et al found 100% agreement 
between the inferred acetylator phenotypes using either seven- or four-SNP genotype panels in six study 
groups including admixed populations (1). Their study included blacks, although these were not South 
Africans.  We found that: 1) the slow acetylator genotype was the most prevalent, (52.5%), compared to 
intermediate (35.8%) and rapid (11.7%). 2). There was a high prevalence of NAT2*5 and NAT2*6 in our 
population, contributing to the slow acetylator genotype. The pharmacokinetics analysis conducted in a 
subset of participants, study 2, showed an increased variability INH pharmacokinetics and its metabolite, 
AcINH, but was not statistically different. There was a high level of discordance between the deduced 
phenotype, and actual phenotype (derived from the ratio of the 3-hour and 6-hour concentrations of the 
mean log Ac-INH/mean log INH), and the molar (metabolic) ratio, derived from parent drug over the 
metabolite, from the PK results.  
 
We reported the effects of NAT2 genetic polymorphisms on the pharmacokinetics of isoniazid and its 
effect on hepatotoxicity in two studies.  Research has shown that response to treatment is not uniform, 
with some people responding better than others (2, 3). Research has also shown that there are people who 
are genetically more prone to certain diseases than others (4). When evaluating treatment experiences we 
should also understand the influence of genetic interactions involved. 
 
There have been conflicting reports on whether slow or rapid acetylators are more prone to hepatotoxicity. 




Our analysis did not show conclusively which acetylator phenotype was more prone to hepatotoxicity. We 
found that the genetic and phenotypic picture was discordant at most.  
 
Genetic studies have been used to determine similarities and difference between individuals. Different 
population groups have been found to have certain predisposition to certain conditions that other race 
groups don’t have. We report the findings on NAT2 polymorphisms among Zulu speaking black South 
Africans, which differ from other black South Africans. We found that although NAT2 genotype indicated 
higher frequencies of slow and intermediate acetylator genotypes, isoniazid PK suggested a higher 
frequency of rapid acetylator phenotypes. This was different from other findings in HIV-infected 
individuals which suggest a tendency to slow phenotype. There was a diversity of specific NAT2 alleles 
of a pattern differing from previously studied cohorts in other settings. Investigation of the contribution 
of other factors including further genetic variants,  in this population, is warranted, this was beyond the 
scope of this project. 
 
One disturbing finding was the low concentration of INH, with Cmax below the lower limit of target range 
in 98.3% patients in study 1 and 47.5% patients in study 2 because multidrug resistant TB is high in the 
region of the studies and this may contribute to its prevalence. Importantly NAT2 genotype did not explain 
PK variability in this cohort or the low Cmax, which suggests that other factors could be influencing 
isoniazid bioavailability and metabolism, which require further elucidation.Another study conducted in 
the same population found reduced isoniazid levels (7). There may be value in re-evaluating the dose 
ranges for patients in this population. 
 
Adverse events to isoniazid, such as hepatotoxicity and peripheral neuropathy are expected to be higher 
in slow acetylators. In our study we found no peripheral neuropathy, all patients were on pyridoxine, 
which may have prevented the peripheral neuropathy. Only one patient, who was a rapid acetylator, had 
grade 4 hepatotoxicity and the rest had grade 1 and 2 elevation in liver enzymes. It is possible that the 
dose range was responsible for the reduction in liver toxicity, which was less than the expected 2 – 28% 
(8). All our patients were less than 55 years old, this could have contributed to the low rate of 
hepatotoxicity. 
 
The phenotype determination using the pharmacokinetics of isoniazid was not comparable to the 




C in the haplotype, there is a possibility of misclassification as detailed by Agundez et al. in their study 
(9). They indicated that an individual with a slow haplotype in combination 12A, B, C, D and 13, may be 
misclassified as slow. For our interpretation, our participants with this combination were classified as 
intermediate, but it is possible that that the rapid allele was more dominant. Based on this assumption, the 
behaviour of the pharmacokinetics parameters, leaning more towards rapid than slow could be influenced 
by this misclassification. In this group, NAT2*5 occurred in combination with *12A or *12C. While this 
might explain the intermediate acetylator genotypes mimicking the rapid acetylators, it does not explain 
the slow genotypes that were all *5/*5 showing rapid acetylation profile. The only participant  with rapid 
genotype in this group was homozygous *12C/*12C. This participant was the only participant with drug 
induced hepatitis in this group. The rest of the adverse events in this group were almost evenly distributed 
between the slow and the intermediate groups. 
 
When predicting phenotype, there was no clear differentiation at two hours. Using a 4-hour post-dose cut-
off time for the  acINH:INH ratio (10), the separation between slow and intermediate/rapid acetylators 
was not obvious for study 1, while for study 2, a clear separation of the acetylator phenotypes was 
apparent. Using PK analysis alone, there were 6% rapid, 27% intermediate and 60% slow phenotypes in 
study 1, and 9% rapid, 52% intermediate and 39% slow in study 2, respectively, which is in agreement 
with the NAT2 data. 
 
Study 1                                                                           Study 2 
 
Using different phenotype classification methods, there was notable discordance between genotype and 




concentration ratio of AcINH/INH and the molar ratio of INH/AcINH but the intermediate and rapid 
phenotypes were very different. The distribution of adverse events experienced did not follow the trend 
as both the slow and intermediate genotype had similar rates of adverse events. Although there were 
increased liver enzymes, only one participant, who happened to be rapid genotype experienced grade 4 
drug induced hepatotoxicity. There was no difference in the distribution of grade 1  and 2 liver enzymes 
among the groups.  
 
The study limitations included the small sample size and the lack of an HIV-uninfected comparator group.  
 
In chapter 4 we reported on the kinetics of IGRA. QFT-GIT test was conducted at baseline, month three, 
month six of ATT and at month twelve, six months after completion of ATT. QFT-GIT readouts generally 
decreased with time during anti-TB treatment, irrespective of whether patients were on ART. We also 
found that IGRA responses did not correlate with 2 or 6-month culture-conversion and markers of 
bacillary burden. ART alone (without active TB) resulted in a significant increase in IGRA responses by 
month 3. This is likely due to ART-related immune reconstitution and redistribution of effector memory 
T-cells back into the blood compartment(11). Similarly, ART can cause apparent conversion of the TST 
whereby TST negative persons become TST positive on ART (12, 13). These data have important 
implications for interpretation of immunodiagnostic tests in the context of TPT provision in high burden 
settings as current data suggest that only TST positive persons are likely to benefit from TPT (14, 15).  
 
Very few studies were conducted in TB and HIV co-infected patients to evaluate QFT-GIT usefulness in 
monitoring treatment and all agree that it cannot be used. Based on this, the WHO has issued guidelines 
that IGRAs should not be used to diagnose TB especially in high burden areas (16). In low burden areas 
IGRAS have been used successfully to diagnose latent TB. In this study participants continued to have 
positive QFT-GIT six months after completion of ATT, although there were no signs and symptoms of 
relapse or reinfection. The latest test, QFT-Plus showed similar sensitivity to QFT-GIT but there are no 
studies that have evaluated it longitudinally in active TB patients. Had the QFT test worked to diagnose 
and monitor TB, the cost would be unaffordable for most TB programs.   
 
Limitations of this study include the small sample size and the use of QFT-GIT, which is not the most 




reversion of IGRA in most patients support the findings that this test should not be used to monitor 
treatment and is in line with findings of other researchers.  
 
Chapter 5 reported on HRQOL for monitoring TB-HIV therapy. When evaluating HRQOL, we found that 
HRQOL is useful in assessing tolerability and safety of TB-HIV treatment in co-infected patients. The 
improvement in HRQOL was not related to the treatment type as patients improved the same whether they 
were on ATT alone or with ART. This is important as participants taking ATT only were those with CD4 
count above 200 cells/mm3. HRQOL at baseline was associated with baseline CD4 count, and the number 
and type of adverse events experienced by participants during follow up was associated with reduced 
HRQOL. It was expected that participants with CD4 count below 200 cells/mm3 would be worse off than 
those with higher CD4 counts, as has been reported in other studies (17). The disease progression for these 
participants would also contribute to the decline in HRQOL. Although we found that CD4 count was the 
main risk factor for reduction in HRQOL, the lower the CD4 count the lower the HRQOL scores, it was 
this group that showed the most improvement is HRQOL scores. This is encouraging as in our setting we 
found that most people delay testing and thereby delaying in start of ART. In South Africa all TB patients 
are offered an HIV test and started on ART as soon as possible while on ATT, this is in line with the 
current WHO guidelines (18).  
 
When evaluating meaningful decline in HRQOL we found that not taking ART with TB treatment is a 
risk factor for decline in CD4 count and HRQOL. This was relevant for the participants on the ATT only 
arm as the commencement of ART was delayed. At the time of the study, only people with CD4 count 
below 200 cells/mm3 were eligible for ART. These findings are in line with current literature on this 
subject. The total score at baseline divided the groups in two, high CD4 count and low CD4 count groups. 
This showed that participants with lower CD4 counts had significantly decreased baseline total HRQOL 
scores when compared to the higher CD4 count groups, irrespective of TB, this was similar to the findings 
of Akimoro et al. (19). In addition, physical, emotional and functional wellbeing were also significantly 
different between the two groups (CD4>200 cells/mm3 and CD4≤200 cells/mm3), as would be expected. 
However, in the study by Deribew et al., the effect of CD4 count could not be determined (20).  Dowdy 
et al. measured QOL among individuals receiving HIV therapy, active TB treatment and therapy for both 
TB and HIV. Since this was a cross sectional study, adverse effects of treatment were not analysed. They 
found that cross-sectional studies in TB-HIV co-infected patients had similar findings. They also found 




et al. found that CD4 count had an effect on the physical domain (21, 22). In our study, the CD4 count 
was significantly lower in older patients, which would be expected since they had not started ARVs by 
the time of the study. The addition of the 10 items on central nervous system to the HRQOL investigation 
did not add much value. The CNS domain behaved the same as the cognitive domain, with differences 
seen only between high and low CD4 count groups. The explanation for this would be that the application 
of the questionnaires was sparsely spaced. The efavirenz side effect are expected immediately after 
commencement of therapy and at most very few people experience these after two weeks of therapy (23, 
24).   
In order to be user friendly, an instrument should be of short to medium length of between 10 – 20 
minutes as patients may not want to be held up in the clinic for long and the clinic staff may be 
overwhelmed with routine work. If the instrument is in local language, it can be handed to patients to fill 
as they are waiting to be seen by clinic staff.  The clinic staff can then check it for completion and only 
help those patients who are unable to fill it themselves. An instrument with these features would help the 
TB program understand the subjective view of the patients’ quality of life during combined TB and HIV 
treatment. 
 
This study had the same  limitations as the other two studies i.e. the small sample size and the lack of an 
HIV-uninfected comparator group. 
  
The study reported in chapter 6 investigated the diagnostic performance of LAM-ELISA in seriously-ill 
hospitalized HIV-infected patients with sputum smear-negative pulmonary TB (PTB) and its potential 
impact on antibiotic usage. Urine LAM as a diagnostic biomarker in patients with smear-negative TB was 
investigated. We found that urine LAM was useful for the diagnosis of TB in seriously-ill smear-negative 
patients and in that it could potentially reduce antibiotic overuse. We used culture as a gold standard, but 
since all patients were diagnosed clinically and by chest X-ray, culture-/LAM+ patients, 23 of 53 (53%) 
urine LAM positive patients, is the group that urine LAM had added value (those who would  not have 
been diagnosed by sputum culture). 
 
The sensitivity was similar to other studies, with higher sensitivity in lower CD4 count groups. This was 
similar to a study by Dheda et al. (25, 26) and others, sensitivity was highest in patients with CD4 count 
below 100 cells/mm3. Since this study, the LAM-ELISA, has been superseded by the LAM lateral flow 




has been included in the guidelines for diagnosis of TB in HIV co-infected patients with CD4 count less 
than 100 cells/mm3 (29). The global TB report for 2019 has a statement on updating the 2015  guidelines 
to strengthen “indication for the use of LF-LAM among hospitalized HIV-positive patients with signs and 
symptoms of TB (pulmonary and extrapulmonary); the test is now recommended for all such patients, 
irrespective of their CD4 count. If the CD4 count is below 100, LF-LAM is recommended even in the 
absence of TB symptoms.”(30). 
 
The findings of our study support the use of urine LAM for diagnosis of TB in this population as it includes 
the HIV-infected smear-negative individuals, as indicated in Chapter 3. Additional investigations would 
still be needed for susceptibility testing to ensure that correct treatment is prescribed. Although the 
sensitivity was not high in sputum culture positive patients, urine LAM was positive for all blood culture 
positive patients. This finding is important in that TB treatment can be commenced. We also know that 
culture does not diagnose all pulmonary TB, either because of low bacterial load or poor sputum sample. 
Since LAM will diagnose some of these patients with culture negative TB, they can also be commenced 
on TB treatment early. This may potentially help reduce the number of antibiotics used in empiric 
treatment thereby improving antibiotic stewardship. The use of urine LAM in TB diagnosis is the step in 
the right direction, but the search for a better TB diagnostic continues.  
 
The limitations of this study were that we did not extensively explore extra pulmonary TB findings. We 
also followed patients up after 8 weeks to ask about treatment outcomes but did not follow up to treatment 
completion. Although all patients received treatment for TB, we could not confirm whether they all 
continued TB treatment after discharge from hospital. Another limitation of the urine LAM test is its low 
sensitivity in patients with high CD4 counts, its failure to detect drug resistant-TB, and its failure to 
diagnose TB in HIV-uninfected patients.  
 
We concluded that urine LAM testing in sputum smear-negative severely-ill hospitalized patients with 
TB-HIV co-infection and advanced immunosuppression, offered an immediate rule-in diagnosis in one-
third of empirically treated patients. Also, urine LAM, by providing a rapid alternative diagnosis, could 







With the current difficulties in diagnosis of all forms of TB and monitoring of its treatment response, it 
would be beneficial to find biomarkers that would fulfil this unmet need. Although the biomarkers 
discussed here have some limitations and benefits, we still have not found one biomarker optimal for both 
diagnosis and monitoring, the search continues.  There were interesting results showing that genotype may 
not be a useful biomarker for prediction of treatment effects, including adverse events. The knowledge of 
acetylator genotype  was not necessarily interchangeable with phenotype in this cohort. Until more studies 
show high levels of genotype-phenotype concordance, knowing the genotype would not help the TB 
program and therefore it is not recommended that it be used to plan treatment of TB-HIV co infected 
patients. In addition, this study did not suggest acetylator genotype had an influence in the experience of 
adverse events. 
IGRAs do not appear to be useful for the prognostication of treatment outcome in co-infected patients on 
concurrent therapy. As already recommended by the WHO, the QFT-GIT test should not be used in 
monitoring TB-HIV therapy. 
 
In addition to existing knowledge, this report brings important information to use when planning future 
studies. More work needs to be done in new diagnostics development as well as TB-HIV monitoring tools 
to cut down the time to diagnosis and to ensure rapid intervention in patients failing treatment. Also, the 
existing monitoring tools need improvement to ensure their availability at point of care. There is limited 
research available on HRQOL of TB and TB-HIV co infected patients in our country. Because South 
Africa is multi-lingual, multi-cultural country, the existing instruments need to be translated to local 
languages and validated or tested on local patients. It would be useful to ensure that more HRQOL 
instruments are made available and their use encouraged.  
 
Our recommendations are that HRQOL would benefit the program if included as a tool to monitor effect 
of treatment. The choice of an instrument should consider shorter and disease specific instruments that 
can be easily included without taking too much of the clinic staff or patients’ time. In order to be user 
friendly, an instrument should be of short to medium length of between 10 – 20 minutes as patients may 
not want to be held up in the clinic for a long time and the clinic staff may be overwhelmed with routine 
work. If the instrument is in a local language, it can be handed to patients to fill in as they are waiting to 
be seen by clinic staff.  The clinic staff can then check it for completion and only help those patients who 
are unable to fill it themselves. An instrument with these features would help the TB program understand 





We also concluded that the use of urine LAM for diagnosis of smear-negative TB in HIV-infected patients 
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ALLELE 1 ALLELE 2   ALLELE 1 ALLELE 2 PHASE P 
GS20000 154 TT TT CC AG AA GG 220100 282/341/590 282/341 5J/5K 282/341/590 282/341 5J/5K 
1.00
0 
GS20001 213 CC CT CT GG GG GG 011020 341/481/803 803 5H/12A 341/803 481/803 5C/12C 
0.99
9 
GS20002 214 CC CT CT GG GG GG 011020 341/481/803 803 5H/12A 341/803 481/803 5C/12C 
0.99
9 
GS20003 128 CC TT CC GG AG GG 020010 341/803 341 5C/5D 341 341/803 5D/5C 
1.00
0 
GS20004 245 CC TT CC AG AA GG 020100 341/590 341 5E/5D 341/590 341 5E/5D 
1.00
0 
GS20005 200 CC CT CT GG GG GG 011020 341/481/803 803 5H/12A 341/803 481/803 5C/12C 
0.99
9 
GS20006 199 CT TT CC GG AA GG 120000 282/341 341 5K/5D 282/341 341 5K/5D 
1.00
0 
GS20007 182 CT TT CC GG AA GG 120000 282/341 341 5K/5D 282/341 341 5K/5D 
1.00
0 
GS20008 110 CC CT CT GG GG GG 011020 341/481/803 803 5H/12A 341/803 481/803 5C/12C 
0.99
9 
GS20009 257 CC TT CC GG GG GG 020020 341/803 341/803 5C/5C 341/803 341/803 5C/5C 
1.00
0 
GS20010 274 CT TT CC AG AA GG 120100 282/341/590 341 5J/5D 282/341/590 341 5J/5D 
0.83
0 
GS20011 215 CT CT CT GG AG GG 111010 
282/341/481/80
3 
  5G/4 282/341 481/803 5K/12C 
0.88
3 
GS20012 137 TT TT CC AG AA GG 220100 282/341/590 282/341 5J/5K 282/341/590 282/341 5J/5K 
1.00
0 
GS20013 157 CC TT CC AG AG GG 020110 341/803 341/590 5C/5E 341/803 341/590 5E/5C 
0.93
8 
GS20014 162 CT CT CT GG GG GG 111020 
282/341/481/80
3 
803 5G/12A 282/341/803 481/803 5T/12C 
0.60
7 
GS20015 210 CC TT CC GG AG GG 020010 341/803 341 5C/5D 341 341/803 5D/5C 
1.00
0 
GS20016 204 TT TT CC AG AA GG 220100 282/341/590 282/341 5J/5K 282/341/590 282/341 5J/5K 
1.00
0 
GS20017 250 CT CT CT AG AG GG 111110 282/341/590 481/803 5J/12C 282/341/590 481/803 5J/12C 
0.97
5 
GS20018 205 CT TT CC GG AG GG 120010 282/341/803 341 5J/5D 282/341 341/803 5K/5C 
0.85
6 


















ALLELE 1 ALLELE 2   ALLELE 1 ALLELE 2 PHASE P 
GS20020 218 CT TT CC GG AA GG 120000 282/341 341 5K/5D 282/341 341 5K/5D 
1.00
0 
GS20021 109 CT TT CC AG AG GG 120110 282/341/590 341/803 5J/5C 282/341/590 341/803 5J/5C 
0.95
6 














GS20024 167 CT TT CC AG AG GG 120110 282/341/590 341/803 5J/5C 282/341/590 341/803 5J/5C 
0.95
5 
GS20025 153 CC TT CC GG AG GG 020010 341/803 341 5C/5D 341 341/803 5D/5C 
1.00
0 
GS20026 219 CC CT CT GG GG GG 011020 341/481/803 803 5H/12A 341 803 5D/12A 
0.87
4 
GS20027 134 TT TT CC AG AA GG 220100 282/341/590 282/341 5J/5K 282/341/590 282/341 5J/5K 
1.00
0 
GS20028 241 CT TT CC AG AA GG 120100 282/341/590 341 5J/5D 282/341/590 341 5J/5D 
0.83
0 
GS20029 201 CT CT CC GG AG GG 110010 282/341/803   5T/4 282/341 803 5K/12A 
0.96
2 
GS20030 148 CT CT CT GG AG GG 111010 
282/341/481/80
3 
  5G/4 282/341 481/803 5K/12C 
0.88
1 
GS20031 168 CT TT CC GG AA GG 120000 282/341 341 5K/5D 282/341 341 5K/5D 
1.00
0 
GS20032 103 CT CT CT GG AG GG 111010 
282/341/481/80
3 
  5G/4 282/341 481/803 5K/12C 
0.88
2 
GS20033 188 CT TT CC AG AA GG 120100 282/341/590 341 5J/5D 282/341/590 341 5J/5D 
0.83
0 
GS20034 122 CT TT CC AG AA GG 120100 282/341/590 341 5J/5D 282/341/590 341 5J/5D 
0.82
4 
GS20035 242 CC CT CT GG GG GG 011020 341/481/803 803 5H/12A 341/803 481/803 5C/12C 
0.99
8 






GS20037 141 CT CT CT AG AG GG 111110 282/341/590 481/803 5J/12C 282/341/590 481/803 5J/12C 
0.97
5 
GS20038 171 CT TT CC AG AA GG 120100 282/341/590 341 5J/5D 282/341/590 341 5J/5D 
0.83
0 


















ALLELE 1 ALLELE 2   ALLELE 1 ALLELE 2 PHASE P 
GS20041 32006 CT CT CT AG AG GG 111110 282/341/590 481/803 5J/12C 282/341/590 481/803 5J/12C 
0.97
5 
GS20042 32062 CC TT CC GG AG GG 020010 341/803 341 5C/5D 341 341/803 5D/5C 
1.00
0 
GS20043 32112 CT TT CC GG AG GG 120010 282/341/803 341 5K/5D 282/341 341/803 5K/5C 
0.85
7 
GS20044 32103 CT TT CC AG AG GG 120110 282/341/590 341/803 5J/5C 282/341/590 341/803 5J/5C 
0.95
5 
GS20045 32117 CC CT CC GG GG GG 010020 341/803 803 5C/12A 341/803 803 5C/12A 
1.00
0 
GS20046 32047 CC CT CT GG GG GG 011020 341/481/803 803 5H/12A 341/803 481/803 5C/12C 
0.99
8 




















GS20050 32004 CC CT CT GG AG GG 011010 341/481/803   5H/4 341 481/803 5D/12C 
0.98
3 
GS20053 32045 CT TT CC AA AA GG 120200 282/341/590 341/590 5J/5E 282/341/590 341/590 5J/5E 
1.00
0 
GS20054 32005 CC TT CC GG AG GG 020010 341/803 341 5C/5D 341 341/803 5D/5C 
1.00
0 
GS20055 32064 CC TT CC AG AA GG 021100 341/590 341 5E/5D 341/590 341 5E/5D 
1.00
0 
GS20056 32069 CC TT CC GG AG GG 020010 341/803 341 5C/5D 341 341/803 5D/5C 
1.00
0 
GS20057 32053 CT TT CC AG AG GG 120110 282/341/590 341/803 5J/5C 282/341/590 341/803 5J/5C 
0.95
5 








GS20059 32038 CC CT CC GG AG GG 010010 341/803   5C/4 341 803 5D/12A 
0.87
4 
GS20060 32033 CC CT CT AG AG GG 011110 341/803 481/590 5C/6E 341/590 481/803 5E/12C 
0.97
3 
GS20061 32074 CC CT CT GG GG GG 010020 341/803 803 5C/12A 341/803 481/803 5C/12C 
0.99
8 
GS20062 32059 CC CT CT AG AG GG 011110 481/803 341/590 12C/5E 341/590 481/803 5E/12C 
0.97
6 


















ALLELE 1 ALLELE 2   ALLELE 1 ALLELE 2 PHASE P 
GS20064 32100 CC TT CC GG AG GG 020010 341/803 341 5C/5D 341 341/803 5D/5C 
1.00
0 














GS20067 32009 CC CT CT GG GG GG 011020 341/481/803 803 5H/12A 341/803 481/803 5C/12C 
0.99
8 
GS20068 32096 CC TT CC GG AG GG 020010 341/803 341 5C/5D 341 341/803 5D/5C 
1.00
0 
GS20069 32025 CC CT CT GG GG GG 011020 341/481/803 803 5B/12A 341/803 481/803 5C/12C 
0.99
8 
GS20070 32031 CT TT CC GG AA GG 120000 282/341 341 5K/5D 282/341 341 5K/5D 
1.00
0 
GS20071 32089 CT TT CC GG AG GG 120010 282/341/803 341 5T/5D 282/341 341/803 5K/5C 
0.87
4 
















GS20074 32042 CT CT CT AG AG GG 111110 282/341/590 481/803 5J/12C 282/341/590 481/803 5J/12C 
0.97
5 
GS20075 32054 CT TT CC GG AA GG 120000 282/341 341 5K/5D 282/341 341 5K/5D 
1.00
0 
GS20076 32057 CC CT CT GG GG GG 011020 341/481/803 803 5B/12A 341/803 481/803 5C/12C 
0.99
8 
GS20077 32061 CC CT CT GG AG GG 011010 341/481/803   5H/4 341 481/803 5D/12C 
0.89
3 
GS20078 32060 CC CT CC GG GG GG 010020 341/803 803 5C/12A 341/803 803 5C/12A 
1.00
0 






GS20080 32101 CC TT CC AG AA GG 020100 341 341/590 5D/5E 341/590 341 5E/5D 
1.00
0 
GS20081 32084 CT TT CC AG AG GG 120110 282/341/590 341/803 5J/5C 282/341/590 341/803 5J/5C 
0.95
5 
GS20082 32093 CT TT CC AG AA GG 120100 282/341/590 341 5J/5D 282/341/590 341 5J/5D 
0.82
9 
GS20083 32108 CT TT CC GG AG GG 120010 282/341/803 341 5T/5D 282/341 341/803 5K/5C 
0.85
3 


















ALLELE 1 ALLELE 2   ALLELE 1 ALLELE 2 PHASE P 
GS20085 32113 CC TT CC GG GG GG 020020 341/803 341/803 5C/5C 341/803 341/803 5C/5C 
1.00
0 
GS20086 32019 CT CT CT AG AG GG 111110 282/341/590 481/803 5J/12C 282/341/590 481/803 5J/12C 
0.97
5 








GS20088 32026 CT TT CC GG GG GG 120020 282/341/803 341/803 5T/5C 282/341/803 341/803 5T/5C 
1.00
0 
GS20089 32011 CC CT CT AG AG GG 011110 341/481/803 590 5H/6B 341/590 481/803 5E/12C 
0.97
7 
GS20090 32032 CC TT CC GG BLANK GG 0200-0 341 341 5D/5D 341 341/803 5D/5C 
0.48
6 
GS20091 32036 CC CT CT GG AG GG 011010 341/481/803   5H/4 341 481/803 5D/12C 
0.89
4 








GS20093 32018 CT TT CC AG AG GG 120110 282/341/590 341/803 5J/5C 282/341/590 341/803 5J/5C 
0.95
5 














GS20096 32040 CT CT CT AG AG GG 111110 282/341/590 481/803 5J/12C 282/341/590 481/803 5J/12C 
0.97
6 
GS20097 32016 CC TT CC GG AG GG 020010 341/803 341 5C/5D 341 341/803 5D/5C 
1.00
0 
GS20098 32116 CC CT CT GG GG GG 011020 341/481/803 803 5H/12A 341/803 481/803 5C/12C 
0.99
8 
GS20099 32043 CT TT CC GG AG AG 120011 282/341/803 341/857 5KA/5S 282/341/857 341/803 5KA/5C 
0.97
2 
GS20100 32044 CC CC CT GG AA GG 001000 481   11A/4   481 4/11A 
1.00
0 
GS20101 32049 CC CT CC AG AG GG 010110 341/803 590 5C/6B 341/590 803 5E/12A 
0.93
9 
GS20102 32027 CT TT CC GG AG GG 120010 282/341/803 341 5J/5D 282/341 341/803 5K/5C 
0.85
5 
































ALLELE 1 ALLELE 2   ALLELE 1 ALLELE 2 PHASE P 








GS20107 32079 CT TT CC AG AG GG 120110 282/341/590 341/803 5J/5C 282/341/590 341/803 5J/5C 
0.95
5 








GS20109 32023 CT CT CC AG AG GG 110110 282/341/590 803 5J/12A 282/341 481/803 5K/12C 
0.88
1 
GS20110 32098 CT CT CT GG AG GG 111010 
282/341/481/80
3 
  5G/4 341 341/803 5D/5C 
1.00
0 
GS20111 32088 CC TT CC GG AG GG 020010 341/803 341 5C/5D 341 341/803 5D/5C 
1.00
0 
GS20112 32002 CT CT CT GG AG GG 111010 
282/341/481/80
3 
  5G/4 281/341 481/803 5K/12C 
0.88
2 
GS20113 32007 TT CT CT GG GG GG 211020 
282/341/481/80
3 






GS20114 32015 CT TT CC AG AG GG 120110 282/341/590 341/803 5J/5C 282/341/590 341/803 5J/5C 
0.95
5 
GS20115 32021 CC CT CC AG AG GG 010110 341/803 590 5C/6B 341/590 803 5E/12A 
0.93
6 
GS20116 32001 CC TT CC GG GG GG 020020 341/803 341/803 5C/5C 341/803 341/803 5C/5C 
1.00
0 
GS20117 32029 CC CT BLANK GG GG GG 01-020 341/803 803 5C/12A 341/803 481/803 5C/12C 
0.75
4 
GS20118 32058 TT CT CT AG AG GG 211110 
282/341/481/80
3 






GS20119 32091 CC CT CT GG GG GG 011020 341/481/803 803 5H/12A 341/803 481/803 5C/12C 
0.99
8 






GS20121 32090 CC TT CC GG AA GG 020000 341 341 5D/5D 341 341 5D/5D 
1.00
0 













Appendix B  
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